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Closed-Loop Controlled Total Intravenous Anaesthesia 
By 
Chao Dong 
Anaesthesia is important for both surgery and intensive care and intravenous anaesthetics are 
widely used to provide rapid onset, stable maintenance, and rapid recovery compared with 
inhaled anaesthetics. The aim of the project on which this thesis is based was to investigate a 
reliable and safe methodology for delivering total intravenous anaesthesia using closed-loop 
control technology and bispectral analysis of human electroencephalogram (EEG) waveform. 
In comparison with Target Controlled Infusion (TCI), drug effect is measured during drug 
infusion in closed loop anaesthesia (CLAN). This may provide superior safety, better patient 
care, and better quality of anaesthesia whilst relieving the clinician of the need to make 
recurrent and minor alterations to drug administration. 
However, the development of a CLAN system has been hindered by the Jack of a 'gold 
standard' for anaesthetic states and difficulties with patient variability in pharmacokinetic and 
pharmacodynamic modelling, and a new and generic mathematical model of a closed-loop 
anaesthesia system was developed for this investigation. By using this CLAN model, 
investigations on pharmacokinetic and phannacodynamic variability existing in patients were 
carried out. A new control strategy that combines a Proportional, Integral, Derivative (PID) 
controller, bispectral analysis of EEG waveform and pharmacokinetic/ pharmacodynamic 
models was investigated. 
Based on the mathematical model, a prototype CLAN system, the first CLAN system capable 
of delivering both hypnotics and analgesics simultaneously for total intravenous anaesthesia, 
was developed. A Bispectral Index (BIS), derived from power spectral and bispectral analysis 
on EEG waveform, is used to measure depth of anaesthesia. A supervision system with built-
in digital signal processing techniques was developed to compensate the non-linear 
characteristics inherent in the system while providing a comprehensive protection mechanism 
for patient safety. The CLAN system was tested in 78125 virtual patients modelled using 
published data. Investigations on intravenous anaesthesia induction and maintenance with the 
CLAN system were carried out in various clinical settings on 21 healthy volunteers and 15 
patients undergoing surgery. Anaesthesia targets were achieved quickly and well maintained 
in all volunteers/patients except for 2 patients with clinically satisfactory anaesthesia quality. 
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1. Introduction 
Depth of anaesthesia monitoring is an important part of patient care. Anaesthesia is used in 
many areas such as dental surgery, surgical operation with incision, and intensive care. One of 
the aims of anaesthesia is to allow the patients to feel no pain and get into an unconscious 
state without memory in surgical operations. 
However, it is harmful or even dangerous to patients if an excessive amount of drug is given. 
In order to control intravenous drug delivery, the depth of anaesthesia needs to be assessed. 
One critical problem often faced by anaesthetists in clinical practice is how to assess 
accurately the depth of anaesthesia in patients during surgery, and another is how much drug 
should be infused to achieve the desired depth of anaesthesia. It is desirable that the depth of 
anaesthesia could be assessed together with drug administration automatically and 
interactively with little human intervention as can be seen in many industrial processes. 
At present, many anaesthetists are still delivering anaesthetic drugs manually using clinical 
signs (such as sweating, pupil size, etc.) to assess depth of anaesthesia. A primary aim of this 
project is to investigate the technology that provides automated intravenous drug 
administration and depth of anaesthesia assessment. 
1.1. Background of Intravenous Drug Administration 
The development of technology for intravenous drug delivery has evolved from manual 
delivery, automated model driven target controlled infusion (TCI) that is also known as 
computer assisted continuous infusion (CACI) (Aivis et al., 1985; Jacobs, 1990, 1995; Bailey 
and Shafer, 1991; Shafer and Gregg, 1992; Jacobs and Williams, 1993; Gray and Kenny, 
1998), to today's closed-loop anaesthesia (CLAN) (Schwilden, Schuttler and Stoeckel, 1987; 
Kenny et al., 1992; Linkens, Shieh and Peacock, 1996; Webb, Alien and Smith, 1996; Roy 
and Huang, 1997; Linkens, Abbod and Backory, 1997; Mortier et al., 1998; Epstein, 1998; 
Morley et al., 2000; Absalom, Sutcliffe and Kenny, 2002; Wang and Wang, 2002). Although 
manual control of drug delivery is still the main method used in clinical practice, automated 
TCI has become more popular, while the CLAN system, though potentially the ultimate goal 
of intravenous anaesthetic drug administration, is still in early stages of research and 
development. 
In manual control of anaesthesia, the clinician delivers anaesthesia by choosing a standard 
dose or dosage scheme of an anaesthetic agent and guessing the degree to which a specific 
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patient IS sensitive or tolerant using information gathered by pre-operative history 
examination and clinical experience. The dosage scheme is then adjusted by trial and error 
with the objective of optimizing anaesthesia and avoiding toxicity. An anaesthesia syringe 
pump is commonly used for the manual infusion scheme, and anaesthetists usually pre-
program the pump by using pharmacokinetics (PK), which characterizes mathematically the 
drug absorption, distribution, metabolism, and excretion. Usually, a bolus dose and a fixed 
maintenance infusion rate would be calculated from the mathematical PK model before the 
infusion. The bolus dose is for anaesthesia induction so that the desired drug concentration is 
achieved, while the maintenance infusion rate is to compensate for drug clearance over time. 
Following advances in computer technology and the improvement in pump accuracy, the 
concept of using pharmacokinetics in manual delivery of an intravenous drug was combined 
with computer control technology. This resulted in the development of automated CACI 
(Computer Assisted Continuous Infusion) now widely known as TCI (Target Control 
Infusion). Research on CACI or TCI intravenous drug delivery has been active since the early 
1980's, and resulted in the commercial TCI device "Diprifusor" (Glen, 1998). 
A TCI system is an open loop system with the drug infusion rate controlled by a mathematical 
pharmacokinetic model of the drug. With a typical TCI system, the clinician simply sets a 
target concentration (either in plasma or at effect site) corresponding to the desired depth of 
sedation/anaesthesia for a specific patient, then the anaesthetic drug is infused automatically 
through an anaesthesia pump. The drug infusion rate is given by the PK model based on the 
difference between the desired and estimated concentrations (Jacobs, 1990, 1995; Bailey and 
Shafer, 1991; Shafer and Gregg, 1992; Jacobs and Williams, 1993). Manual calculation of 
induction bolus and the maintenance infusion rate is not needed if a TCI device is used, and 
the intervention from clinicians on drug administration is only required if adjustment on depth 
of sedation/anaesthesia is required. 
The use of a TCI system relieves the anaesthetist of frequently making alterations on infusion 
rate, and the anaesthesia maintained by a TCI system is more stable than that maintained 
manually and less overshoot or undershoot were observed (Russell et al., 1995; Russell, 
1998), hence it improves the quality of anaesthesia. However, an open loop control system 
requires a mathematical model with sufficient precision in describing the dynamic 
characteristics of the patients, and the PK model used in current TCI systems is far from exact 
with median absolute performance error (MDAPE) or median performance error (MDPE) of 
around 26% or 24% (Vuyk et al., 1995a), respectively. Pharmacokinetic parameters vary from 
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patient to patient (inter-patient variability) or even within a single patient over time (intra-
patient variability), and this variability is not fully modelled. This implies that there is no set 
of pharmacokinetic parameters that apply to all patients in a population. In fact, the 
pharmacokinetic parameters used in a TCI system are the average values in a population. The 
anaesthetist needs to set a lower (or higher) target concentration for a specific patient who is 
judged as more (or less) sensitive to the drug than the population average based on clinical 
experience. Without feedback of measurement on drug effect, a TCI system is unable to 
adjust automatically the target concentration due to patient variability and intervention from 
the anaesthetist is required to do it manually. 
The idea to provide the TCI system with a measurement of drug effect so that the target 
concentration is adjusted automatically leads to the development of closed loop control of 
intravenous anaesthesia. In a closed loop anaesthesia (CLAN) system, drug effect or depth of 
anaesthesia (DOA) is measured in real time and is compared with the target DOA to get an 
error signal. Then the CLAN system generates a drug infusion rate according to the error. 
A CLAN system is potentially superior to an open-loop TCI system in many aspects. For a 
TCI system, the performance depends on the precision of patient model, while that of a 
CLAN system largely depends on the precision of drug effect measurement. A TCI system 
controls the drug concentration and ignores the pharmacodynamic characteristics in patients 
while a CLAN system controls the drug effect or depth of anaesthesia. As TCI is an open loop 
control system, any perturbation will not be addressed automatically. When anaesthesia is 
insufficient due to surgical stimulation or any other reason a CLAN system will respond by 
infusing more drug, and on the other hand, if the depth of anaesthesia is deeper than desired it 
will stop drug infusion. By using a CLAN system, the effect from patient variability would be 
minimized, and a better quality of anaesthesia maintained. In comparison with the use of a 
TCI system, intervention from a clinician during the drug infusion controlled by a CLAN 
system could be further reduced. 
Closed loop control, also known as feedback control, is widely used in industry because of its 
superior control quality regardless of the type of object under control, in linear or nonlinear, 
time invariant or time varying. Even in the area of intravenous drug administration, closed 
loop control has been successful for regulating, for example, sodium nitroprusside(Behbehani 
and Cross, 1991) and muscle relaxant (Link ens and Hasnain, 1991) etc. In anaesthesia, 
although closed loop control systems delivering inhalational anaesthetic agents have already 
been built (Vishnoi and Roy, 1991; Jee and Roy, 1992), the development of closed loop 
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control system for intravenous anaesthesia has been slow and cautious due to vanous 
problems. 
1.2. Problems in Depth of Anaesthesia Monitoring 
The most common problem, faced by both clinicians and researchers in the area of depth of 
anaesthesia monitoring, is the lack of a 'gold standard' to define the anaesthetic states. This is 
a fundamental problem bringing difficulties for depth of anaesthesia measurement. Other 
problems in depth of anaesthesia monitoring are described below. 
• Pharmacokinetic/dynamic modelling. The modelling of dose-effect relationship is 
known as pharmacokinetic and pharmacodynamic modelling that characterizes the 
drug distribution process up to the site of drug action. However the modelling error is 
still a significant concern. Median absolute performance error (MDAPE) or median 
performance error (MDPE) of 26% or 24% were reported (Vuyk et al., 1995a) on a 
population of patients in a propofol infusion study (Gepts et al., 1987). 
• Drug effect assessment. It is extremely difficult for clinicians to assess quantitatively 
the depth of anaesthesia during surgery due to the lack of technology supporting on-
line and objective assessment. Measurement of drug concentration from blood 
samples is only available off-line. In clinical practice, clinical signs (blood pressure, 
heart rate, pupil size, sweat etc.) and experience are still widely used. EEG monitors 
that calculate various spectral variables such as median frequency and beta power 
from the EEG waveform are helpful. However these EEG derivatives are not linearly 
correlated with drug concentration, and as such are of limited use. Recently, an EEG 
monitor that calculates the Bispectral Index (BIS) from EEG has been commercially 
available. Though some clinical researchers reported that this drug effect index is 
linearly correlated with propofol drug concentration (Leslie et al., 1995; Doi and 
Gajraj, 1997), it has not received universal acceptance from anaesthetists, and the 
linear relationship between this index and drug concentration is only valid in a 
statistical sense. 
• Patient variability. Patient variability is part of the modelling problem and is caused 
by the incomplete modelling of the drug distribution process. In terms of drug 
distribution, every patient is unique and therefore the pharmacokinetic model and 
pharmacodynamic model of any patient are different from those of others, this is 
known as inter-patient variability. On the other hand, the pharmacokinetic model and 
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phannacodynamic model change over time in a single patient, which is the so-called 
intra-patient variability. Patient variability comes from the different characteristics in 
patients such as sex, age, weight, height, drug history, fitness, etc. (Maitre et al., 1987; 
Stanski and Maitre, 1990; Minto et al., 1997; Schnider et al., 1999). Some of these 
factors are already modelled in phannacokinetics albeit with modelling errors, but 
most of them are still unknown. 
• Hysteresis. Though the plasma drug concentration peaks shortly after drug has been 
infused, it takes time for the drug to arrive at the site of drug action or effect site, this 
time is known as drug effect peak time (Schnider et al., 1999). The peak time varies 
from patient to patient, and could be changed even in a single patient over time. 
• Drug interaction. In clinical practice, more than one drug is usually used m 
combination with other drugs, and some drugs interact with each other. This has been 
seen in general anaesthesia using propofol and alfentanil (Plummer and Short, 1992; 
Stanski and Shafer, 1995; Vuyk et al., 1995b; Vuyk, 1997, 1998; Rosow, 1997), for 
instance. Drug interaction is still a research topic. 
• EEG data quality. At present, electroencephalogram (EEG) wavefonn is the only 
drug effect measurement available for on-line assessment of depth of anaesthesia 
(DOA). However, the measurement error of the EEG wavefonn has added uncertainty 
to the EEG variables. Bad epochs and artefacts in the EEG wavefom1 could cause data 
rejection in EEG variable calculation. The impedance maintained between the skin 
and the electrodes could cause poor quality of EEG wavefonn. Interference may be 
increased by body movement. 
1. 3. Current State of the Art 
As the site of action of anaesthetics is the central nervous system, the EEG signal, which is a 
record of brain activity, is important for the detennination of depth of anaesthesia, and has 
been used as the only source to evaluate analytically the DOA in real time. However, the EEG 
signal itself is difficult to understand or interpret, and vulnerable to noise. It is necessary for 
the EEG signal to be processed with signal processing techniques in order to get meaningful 
interpretation. Various EEG derivatives or variables, for example, median frequency, 
Bispectral Index and auditory evoked response, have been derived from an EEG signal in this 
way and serve as the measure ofDOA in CLAN systems. 
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The research on closed loop anaesthesia or CLAN systems started in early 1950s when 
Bickford and colleagues introduced the "servo-anesthetizer" (Bickford, 1950, 1951; Bellville, 
1957) which regulates ether using integrated and rectified amplitude of the EEG signal. The 
system was tested on several animal species and humans, and promising results were 
obtained. However, the servo-anesthetizer was not widely accepted for it was difficult to 
determine which EEG derivative could be used as the measure of the DOA. Schwilden, 
Schuttler and their colleagues started research on CLAN systems from late 1980's 
(Schwilden, Schuttler and Stoeckel, 1987; Schuttler et al., 1995; Albrecht et al., 1997), and 
developed a system using the EEG median frequency (MF) as the measure of DO A. In the 
latest version of the system, a two-compartment PK model was incorporated into the control 
system, and an adaptive controller used to update part of the PK model parameters according 
to the error between the measured MF and the target MF. The system has been tested on 
several anaesthetic drugs including propofol and satisfactory results were reported 
(Schwilden, Schuttler and Stoeckel, 1987; Schwilden, Stoeckel and Schuttler 1989; 
Schwilden and Stoeckell993; Schuttler et al., 1995). 
In the 1990s, more research groups became active in the research of CLAN system. Kenny et 
al. (1992) developed an anaesthetic index called AEP (Auditory Evoked Potentials) index, 
formerly known as LAS (Level of Arousal Score). As a measure of DOA, the AEP index is 
derived from the analysis of auditory evoked potential (AEP) of a human EEG signal and 
served as the feedback signal of their CLAN system. Functionally, the CLAN system consists 
of a proportional-integral (PI) controller and a standard TCI system with three-compartment 
pharrnacokinetic model. The PI controller regulates the target concentration of the TCI system 
that generates infusion rates for the pump to maintain the target concentration. The system 
was tested for propofol infusion with patients breathing spontaneously and with those who 
received paralysing drugs during surgery. Satisfactory anaesthesia was reported (Kenny et al., 
1993). 
Advanced signal processing technologies have been introduced into this area. Roy and Hwang 
( 1997) and Linkens et al. ( 1997) and their colleagues applied a wavelet transformation on the 
EEG derived auditory evoked potentials for feature extraction, and the extracted features are 
then fed into an artificial neural network for depth of anaesthesia classification. A fuzzy logic 
controller was used in Linkens' system to regulate directly the infusion rate, while in Roy's 
system, the infusion pump is controlled by ST ANPUMP, a research TCI system, and the 
target concentration of ST ANPUMP was regulated by a fuzzy logic controller. Webb et al. 
( 1996) have done similar work by directly applying a neural network techniques to AEP 
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latency to determine the DOA and using a fuzzy logic controller to regulate the infusion rate. 
Satisfactory system performance was achieved in animal tests with Roy's system. However, 
no clinical testing on humans has been reported for these systems. 
Due to the importance of clinical signs in determining the depth of anaesthesia in clinical 
practice, Linkens et al. ( 1996) developed a fuzzy logic controlled CLAN system using clinical 
signs. The numeric clinical signs (i.e. systolic arterial pressure and heart rate) are used to 
assess the primary DOA, and the anaesthetist's observations of sweating, lacrimation and 
pupil response are used to assess the degree of lightness of anaesthesia. Also the bolus drug 
effects are analysed to provide the patient sensitivity to the drug. Then the drug infusion rate 
is regulated by a rule base and a self-organising fuzzy logic controller, which take the primary 
DOA, degree of lightness and patient sensitivity as the inputs. The system has been tested in 
clinical trials as an intelligent adviser. 
The investigation of an adviser (Epstein, 1998) on DOA monitoring and maintenance by an 
expert system approach is also reported. The system incorporates the measurements of BIS, 
BIS variability, heart rate, blood pressure, end tidal anaesthetic gas concentrations, predicted 
effect site drug concentrations, and anticipated events. 
More recently, bispectral analysis, another advanced signal processmg technique that 
identifies the inter-frequency relationship of an arbitrary waveform, was introduced to the 
analysis of EEG signals. Consequently, by combining the results from bispectral analysis and 
traditional power spectral analysis of the EEG signal, a more reliable index for depth of 
anaesthesia, Bispectral Index (BIS), was commercially developed and evaluated (Billard et 
al., 1994; Leslie et al., 1995; Pearson et al., 1996; Liu, Singh and White, 1996; Sebel and 
Lowdon, 1997). Using the Bispectral Index as the measure ofDOA and the feedback signal of 
the closed loop system, Morley and colleagues (Morley et al., 2000) designed and tested their 
simple PID (Proportional, Integral, Derivative) control system. The PID controller directly 
regulates the drug infusion rate according to the error, the integration error and the derivative 
error between the BIS target and the measured BIS, no pharmacokinetic/dynamic model was 
used in this system. Clinical experiments on patients (Morley et al., 2000) show that it was 
effective in maintaining a constant level of anaesthesia. 
Mortier and colleagues developed their CLAN system using BIS (Mortier et al., 1998). An 
adaptive controller and a pharrnacokinetic model are used in the system to adapt to the inter-
patient variability, and the model parameters are updated according to the BIS measurement 
from the patient. Clinically satisfactory results have been obtained from their experiments on 
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patients (Mortier et al., 1998; Struys et al., 2001) with this system. 
At the time of writing in 2003, two other CLAN systems were reported. Wang and Wang 
(2002) developed a system using BIS feedback plus a predictive control technique, while 
Kenny's group (Absalom, Sutcliffe and Kenny, 2002) employed a PID contro11er and a 
commercial TCI device, Diprifusor, in their CLAN system. In Wang's system, the drug 
infusion rate is controlled directly by a proportional (P) controller with compensation from a 
predictive controller that anticipates in advance the major surgical stimulations such as 
incision and closing. This control strategy resulted in a much better control performance than 
using a proportional controller alone. In Absalom's system, the drug infusion is controlled by 
a Diprifusor TCI device whose target plasma drug concentration is updated every 30 seconds 
by a PID controller based on the measured BIS and the BIS target. It was reported that 
clinically adequate level of anaesthesia was maintained in patients undergoing surgery by 
using this CLAN system. 
1.4. Aims and Objectives of the Project 
The aim of this project was to investigate closed-loop anaesthesia for total intravenous 
anaesthesia or general anaesthesia. As drug effect is measured during the drug infusion, 
closed loop control of anaesthesia and sedation may provide superior safety and better quality 
of anaesthesia while relieving the clinician of a need to make recurrent and minor alterations 
to drug administration. Potentially, closed loop controlled drug delivery could lead to better 
patient care by minimizing the possibility of excessive dosing and allowing prompt 
identification of and response to perturbations which might go unnoticed by a clinician or be 
deemed too small to merit manual alterations of drug administration. On the other hand, a 
CLAN system for total intravenous anaesthesia would provide an efficient way to deliver two 
drugs simultaneously and would also provide a valuable tool for clinical research, such as on 
drug interaction. 
To achieve this aim, it requires the investigation of pharmacokinetic and pharmacodynamic 
variability in population patients, the development of the control system, and a number of 
clinical experiments on human volunteers and patients. The CLAN system would consist of a 
CLAN sub-system delivering intravenous hypnotic agent propofol, and a TCI sub-system 
delivering intravenous analgesic agent alfentanil. 
The key objectives identified from this aim are to: 
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• develop a mathematical model for closed-loop anaesthesia system; 
• investigate the pharmacokinetic and pharmacodynamic variability in patients; 
• investigate the control strategy of drug administration; 
• develop techniques to ensure patient safety in clinical experiments; 
• develop signal-processing techniques to overcome the non-linear characteristics of the 
closed-loop system; 
• develop a CLAN system with user interface delivering both hypnotics and analgesics 
simultaneously; 
• develop techniques to online collect, store, and display clinical data and clinical 
events/comments; 
• evaluate the CLAN system on human subjects. 
1. 5. Outline of the thesis 
The thesis consists of eight chapters including an introduction to the research, medical and 
teclmological background, mathematical model development, investigation of key issues in 
closed-loop anaesthesia, and design and clinical evaluation of a prototype system. 
Following the general introduction in this chapter, Chapter 2 gives the necessary background 
in intravenous anaesthesia. To help understand the choice of feedback signal for the closed-
loop anaesthesia, various methods for depth of anaesthesia monitoring are introduced. 
Pharmacokinetics and pharmacodynamics, which are the theoretical basis for intravenous 
drug delivery, are summarised. Then the anaesthetic drugs, propofol and alfentanil that are 
chosen for evaluating the system are introduced. Also, the concepts of manual control, open 
loop control, and closed loop control of intravenous drug delivery are introduced and their 
advantages and disadvantages discussed. Finally, a brief introduction to the Aspect A-1000 
EEG monitor and the Graseby 3400 anaesthesia pump are given. 
Chapter 3 summarizes the principle of closed-loop control with special focus on PID control. 
It also introduces power spectral, bispectral analysis, and their application on EEG signal. 
Chapter 4 gives details of the development of a generic mathematical model of closed-loop 
anaesthesia. 
Chapter 5 presents the investigation of key issues of closed-loop anaesthesia, such as inter-
patient variability and control strategy. The performance of the closed-loop anaesthesia 
control is also investigated. A journal paper was published on this work (Sneyd et al., 2001 ). 
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Chapter 6 presents the design of a CLAN system based upon the mathematical model. The 
CLAN system uses Bispectral Index, which is derived from the EEG signal measured by the 
Aspect EEG monitor, to measure and control the depth of anaesthesia. The CLAN system is 
capable of delivering total intravenous anaesthesia for the chosen drugs. 
Chapter 7 describes the evaluation of the CLAN system on volunteers, and patients 
undergoing surgery. This work resulted in three publications (Dong et al., 1999a, 1999b, 
1998). 
Chapter 8 presents discussion and conclusion on this investigation and gives suggestions to 
future research. 
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2. Intravenous Anaesthesia 
2. 1. Introduction 
The definition of depth of anaesthesia (DOA) is extremely varied, ranging from scientific 
discussions of the minimum alveolar concentration (MAC) for inhalational anaesthetics or 
plasma drug concentration for intravenous anaestheiics to clinical descriptions of "light", 
"moderate", or "deep" anaesthesia (Stanski, 1994). Currently, there is no accepted "gold 
standard" defining the state of anaesthesia. In fact, the definitions of anaesthesia depth have 
evolved with the drugs used in clinical practice. Consequently, the use of potent inhaled 
anaesthetics, opioids, and intravenous anaesthetics in modem clinical practice has precluded 
the unifying definitions of anaesthetic depth. Generally, there are at least four components to 
"anaesthetic depth": sedation/hypnosis, analgesia, amnesia, and blockade of reflexes, and 
different drugs could be used to achieve each effect. In intravenous anaesthesia, there are 
some ways available to assess the DOA among which are clinical signs based on the clinical 
observations, plasma drug concentration by assaying the blood samples taken from the 
patient, and EEG variables derived from the patient's EEG signal using signal processing 
techniques. The clinical signs and EEG derivatives can be observed or obtained in real time, 
whereas a significant delay is needed for the assaying of a blood sample and the assays are 
not generally available. In clinical practice, the assessment of DOA by clinical signs varies 
from anaesthetist to anaesthetist due to different experiences in anaesthetists. To achieve the 
desired anaesthetic depth, either inhaled anaesthetics or intravenous anaesthetics can be used. 
However, completely different methods are required to administer them. For intravenous drug 
delivery, manual delivery or automated target control infusion (TCI) is currently used in 
routine practice in operating theatre and intensive care unit (ICU). Pharmacokinetics and 
pharmacodynamics are essential concepts with which the intravenous drugs may be given to 
their best advantage. The use of pharmacokinetics and pharmacodynamics in the drug 
infusion using TCI technique leads to continuous infusion techniques. An anaesthesia pump is 
needed to drive the syringe in both methods. A variety of intravenous drugs are available to 
induce and maintain anaesthesia. Propofol is popular for sedation/hypnosis, and alfentanil is 
widely used for analgesia. The use of intravenous drugs provides a rapid onset and a quick 
recovery as well. 
In the following sections, the basic background on depth of anaesthesia monitoring, 
intravenous drug delivery, and intravenous drugs to be used in this investigation is introduced. 
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2.2. Monitoring Depth of Anaesthesia 
2.2.1. Clinical Signs 
Clinical signs of anaesthetic depth include blood pressure (BP), heart rate (HR), HR 
variability, sweating, pupil size, lacrimation, (isolated arm and eye) movement and respiratory 
patterns etc. However, the use of muscle relaxants eliminates the rate and volume of 
respiration as the clinical signs of DOA (Stanski, 1994), it also makes interpretation of 
movement both difficult and imprecise in most clinical circumstances. Of the clinical signs 
blood pressure and heart rate are numerical signs, and all the others are not. In clinical 
practice, clinical signs are important for anaesthetists to assess the depth of anaesthesia and 
have been routinely monitored. However, it has not been possible to use clinical signs to 
generate uniform measures of depth of anaesthesia. The usefulness of the clinical signs may 
be changing over time, and the clinical signs may correlate with DOA for certain anaesthetics 
and may not for some others. Surgical stimulation may interfere with some of the clinical 
signs such as blood pressure, and many factors have influence on pulse rate. 
2.2.2. Drug Concentration 
Another way to assess depth of anaesthesia is to determine the anaesthetic drug concentration 
from assaying blood samples. After being administered intravenously, the drug is transferred 
with hysteresis to the rest of the body by blood circulation, and only part of the drug will 
reach its effect site or its site of action, i.e., the brain. The drug concentration in plasma peaks 
almost instantly then declines due to the elimination or distribution of the drug from the body 
or to the rest of the body, whereas the drug concentration at effect site increases gradually 
until the drug concentrations in plasma and at effect site equilibrate. The relationship between 
the dose of drug administered and the drug concentration in plasma is characterized by 
pharmacokinetics, while pharmacodynamics characterizes the relationship between the drug 
concentration in plasma and the drug concentration at effect site. However, the drug 
concentration at effect site is only a measure of pharmacological effect, and the depth of 
anaesthesia is a measure of drug effect. To estimate approximately the drug effect from the 
effect site drug concentration, a sigmoid model is available. 
Ideally, the depth of anaesthesia could be estimated from the measure of drug concentration at 
effect site. However the effect site is not accessible, and instead, the plasma drug 
concentration is measured from blood samples. Pharmacokinetics and pharmacodynamics 
make the estimate of effect site concentration possible. As significant time is required in 
assaying a blood sample, the measurement of depth of anaesthesia from drug concentration is 
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usually reserved for clinical experiments where the drug concentrations are analysed and/or 
processed after the experiments. 
2.2.3. Human Electroencephalogram (EEG) Signal 
The human EEG signal represents the cortical electrical activity derived from summated 
excitatory and inhibitory postsynaptic activity, which are controlled and paced by subcortical 
thalamic nuclei. This electrical activity has direct physiologic correlates relevant to depth of 
anaesthesia. Cerebral blood flow and cerebral metabolism are related to the degree of EEG 
activity. The EEG is a valuable tool because it reflects cerebral physiology, and is a 
continuous and non-invasive measure, its pattern changes markedly on administration of 
anaesthetic drugs, and also it is not affected by neuromuscular blockers (Thornton and 
Newton, 1989). Figure 2-1 shows some sample EEG patterns at different stages of anaesthesia 
with different drugs. EEG generally changes from a low amplitude, high frequency signal 
while awake to a large amplitude, low frequency signal when deeply anaesthetised. These 
changes are traditionally described using the frequency bands shown in Table 2-1. 
Thiopental EEG Fentanyl EEG 
Awake Awake 
Stage 1 Stage 1 
2 2 
3 3 
4 
150 1.1V 1 sec_ 
Figure 2-1 Increasing plasma concentrations of fentanyl or thiopental produce a characteristic 
progression of changes on EEG. In stage 1 (light anaesthesia), the frequency and amplitude of 
waveforms increase. In stage 2 (deeper anaesthesia), for both drugs produce a decrease in 
frequency and an increase in amplitude. In stage 3 (very deep anaesthesia), thiopental 
produces a burst-suppression pattern and finally, an isoelectric EEG. 
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Table 2-1 EEG frequency bands 
EEG Frequency Band Frequency Range (Hz) 
Very low frequencies (Delta) 0-4 
Low frequencies (Theta) 4-8 
Medium frequencies (Alpha) 8-14 
High frequencies (Beta) 14-30 
The EEG signal has been used as an objective measurement of the depth of anaesthesia for a 
long time. However, the raw EEG signals, as seen in Figure 2-1, are difficult to understand, 
and different classes of anaesthetics are known to cause different EEG patterns. Some EEG 
patterns are generally associated with unconsciousness, and there is no EEG pattern that 
proves consciousness is present. In order to assess the depth of anaesthesia, meaningful 
features containing in a raw EEG signal and related to the depth of anaesthesia need to be 
extracted by means of signal processing. 
Traditionally, the EEG signal is processed by Fourier transformation for power spectral 
analysis. Many variables were derived from the EEG by this method. For example, spectral 
edge frequency (SEF) and median frequency (MF) are defined as the frequencies below which 
95% or 50% of the EEG signal power is located, respectively. Processed EEG variables from 
power spectral analysis are single-variable descriptors of depth of anaesthesia, and they are of 
limited use in describing depth of anaesthesia. 
More recently, bispectral analysis was used to analyse the EEG signal, and a depth of 
anaesthesia indicator, Bispectral Index (BIS) (Billard et al., 1994; Leslie et al., 1995; Pearson 
et al., 1996; Sebel et al., 1997) was derived and made commercially available. BIS is a multi-
variable depth of anaesthesia indicator that combines the results from bispectral analysis and 
those from power spectral analysis of the EEG signal. It was reported (Leslie et al., 1995; Doi 
et al., 1997) that BIS is linearly related to the propofol drug concentration over a clinically 
relevant range. 
Another class of depth of anaesthesia descriptors IS derived from the auditory evoked 
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response (AER), also known as the auditory evoked potential (AEP), produced by auditory 
stimulation of peripheral nerves. The AER is a subset of EEG signal and can be separated 
from the EEG signal by means of special signal averaging techniques. The AER can be 
divided into three responses: brain stem response obtained in the first 10ms after the 
stimulation, the early cortical response (15~80ms), and the late cortical response (80~100ms). 
Descriptors of depth of anaesthesia have been developed using AER (Kenny et al., 1992; 
Webb, Allen and Smith, 1996; Roy and Huang, 1997). A computer averaging technique, a 
neural network technique, and a wavelet transform were used for the developments. 
2.2.4. Aspect A-1000 EEG Monitor 
The Aspect Medical Systems A-1000 EEG Monitor is a patient-connected, user-configurable, 
four-channel EEG monitor, designed specifically for intra-operative or intensive care patient 
monitoring. An external analogue to digital signal converter (DSC), which can be placed 
close to the patient, is used to connect a patient to the monitor. With electrodes, the EEG 
signal of the patient can be measured with the DSC in either the bipolar or referential modes 
using up to four channels, then the DSC converts the analogue EEG signal into a digital signal 
and transmits it to the monitor. Subsequently, the digitised EEG signal is analysed within the 
monitor using power spectral and bispectral analysis techniques. A set of variables, including 
the Bispectral Index and median frequency, are derived from the signal processing. The 
update rate of the processed EEG variables is user selectable from 5, 10, and 30 to 60 
seconds. A full list of the processed EEG variables and some relevant specifications are given 
in Appendix A. Either the raw EEG or the numerical value or trend of a processed EEG 
variable can be displayed on the monitor. Raw EEG data and the processed EEG parameters 
are also transmitted, in real time, to two RS-232 serial communication ports (i.e., raw EEG 
port and the processed EEG port), which makes it possible to record or process further the 
EEG data. 
Bispectral Index is one of the key EEG variables provided by an Aspect EEG Monitor. 
Numerous versions of proprietary BIS algorithm have been commercially developed. BIS 
v3.12 was initially used in this project, and then it was updated to BIS v3.3. The latest version 
BIS XP has been optimised for intensive care. 
2.3. Intravenous Drug Delivery 
2.3.1. Pharmacokinetics 
Pharmacokinetics characterises quantitative aspects of drug absorption, distribution, 
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metabolism and excretion, and describes the time course of drug and metabolite concentration 
at their "site of action". The mathematical model or physiological model (Glass et al., 1994) 
describing the distribution of drug in the body can be derived from experiments in which 
plasma drug concentration is measured at intervals after a bolus drug infusion, then non-linear 
regression is used to fit the concentration versus time curve. Linear approximation is applied 
during this modelling process, and the following poly-exponential expression, mathematically 
derived in Section 4.2, describes the drug distribution process in the body: 
(2-1) 
i=-1 
where Dp(t) is the disposition function of the drug in the body after a bolus infusion, 
exponents A; are the inverse of the half-lives(half-life = 0.693/..1), coefficients A; are the 
relative contributions of each half-life to overall drug disposition, and the integer 11 is the 
number of exponentials (Glass et al., 1994). If the infusion rate over time is J(t), then the 
plasma drug concentration over time, CpcALc(t), is: 
CpcALc(t) = I(t) * Dp(t) (2-2) 
where * denotes convolution. Examining the measured plasma concentrations over time 
(Glass et al., 1994), the plasma concentration peaks almost instantly after the bolus infusion 
of drug and then decays exponentially. In the development of the above pharmacokinetic 
model in Section 4.2, several assumptions have been implied. Basically, a PK model is 
assumed to be linear and stationary, i.e., giving a half or a double dose of drugs results in a 
half or a double set of concentrations and responses respectively, and the parameters in a PK 
model do not change over time. Another key assumption of a PK model is that it is valid for 
an individual patient as a representative of a population. The development ofpharmacokinetic 
models provides a way to simulate the process of drug distribution in the body. Theoretically, 
the more exponential terms in Dp(t), the higher precision the pharmacokinetic model provides. 
However in practice, usually two or three exponential terms in the pharmacokinetic model 
give reasonable results for most anaesthetic drugs (Glass et al., 1994), and it is unusual to use 
more than three exponential terms in practice for computational complexity would greatly 
increase. The following equation shows the tri-exponential drug disposition function: 
(2-3) 
From the pharmacological point of view, when a certain dose of drug is given to a patient, the 
drug will be transferred from the plasma to the rest of the body including peripheral tissues, 
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organs, and fat stores, and part of the drug will be eliminated from the body. The drug transfer 
from the plasma to a certain part of the body stops when the drug concentrations at the two 
sites equilibrate. Following the further decline of the plasma concentration, redistribution of 
the drug from that part of the body to plasma would happen until the drug concentrations 
equilibrate again. This equilibration state is maintained dynamically between the plasma and 
the rest of the body. This drug disposition process is very much like a multi-compartment 
hydraulic model upon which the multi-compartment pharmacokinetic model was constructed. 
Figure 2-2 shows the generalized multi-compartment pharmacokinetic model while Figure 
2-3 is a specific three-compartment hydraulic-like pharmacokinetic model. 
(V2) (V3) (Vn) 
Plasma (VI) 
Infusion Rate Elimination 
Figure 2-2 Generalized multi-compartment pharmacokinetic model of intravenous drug 
disposition (Vi denotes the volume of the ith compartment) 
Infusion Rate 
!l(t) 
Rapid Peripheral k21 Plasma kiJ Slow Peripheral 
Compartment 2 CrcALc(t) Compartment 3 
(Vz) kl2 (VI) k31 CV3) 
lkw 
Elimination 
Figure 2-3 Three-compartment pharmacokinetic model of drug disposition following 
administration of intravenous drug. CpcALc(t) (ng·mr1) is the drug concentration in central 
compartment. Vl, V2, and V3 (L} are the volumes of the three compartments, respectively. I(t) 
(J.I.g·kg-1·min-1) is the drug infusion rate, k10 is the elimination rate at which drug is irreversibly 
removed from the plasma, and k12. k11 , k13, k31 are the inter-compartmental drug transfer rates. 
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In Figure 2-2, the central compartment or compartment 1 (V1) denotes the plasma, and the 
peripheral compartments represent different physiological parts of the body. The central 
plasma compartment includes "rapidly mixing portion of the blood and the first-pass of 
pulmonary uptake" (Glass et al., 1994), while the peripheral compartments "are composed of 
those tissues and organs showing a time course and extent of drug accumulation (or 
dissipation) different from that of the central plasma compartment" (Glass et al., 1994). Each 
physiological part is assumed to have the same drug transfer rates to and from the plasma. For 
example, a three-compartment pharmacokinetic model, shown in Figure 2-3, is composed of 
three physiological parts: plasma (compartment 1 or central compartment), a rapid 
equilibration part (compartment 2), and a slow equilibration part (compartment 3). The 
compartment 2 may roughly consist of muscle tissues, while the compartment 3 may 
correspond roughly to the fat stores. During the process of drug distribution and 
redistribution, part of the drug infused would be removed by the distributional clearance, 
metabolic clearance and terminal elimination. 
The three-compartment hydraulic model shown in Figure 2-3 intuitively describes the process 
of drug disposition in the body, and it is easier to understand in comparison with its abstract 
mathematical description by equation (2-2) and (2-3). The parameters in both the 
mathematical model and the multi-compartment model can be mathematically transformed 
from one to another. 
One of the important physiological parts in the human body is the effect site or the site of 
drug action. In definition, the effect site includes membranes, receptors, and enzymes, and 
more importantly the site is not accessible. According to clinical observations, additional time 
is needed for the drug concentration in the brain to rise and induce anaesthesia after a bolus 
infusion. This is so-called hysteresis of drug effect. The hysteresis varies from patient to 
patient and from one drug to another, and it may change intra-operatively within a single 
patient. Due to the transport clearance, the peak drug concentration at effect site or brain is 
lower than that in plasma. After a bolus dose, the drug concentration in plasma peaks almost 
instantaneously then declines, the effect site drug concentration rises slowly and peaks at the 
time when the drug concentrations in plasma and at effect site equilibrate. After the 
equilibration, both the plasma concentration and the effect site concentration decline. 
Although the effect site drug concentration is higher than that in plasma after the 
equilibration, the drug transfer from the plasma to the effect site is assumed irreversible. Part 
of the drug at effect site is also eliminated at a certain rate. This process can be described by 
adding the fourth compartment to the three-compartment model (Figure 2-4): 
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Rapid Peripheral ~ Infusion Rate 
Comp:t2 ~ ll(t) 
Slow Peripheral 
Compartment 3 
(V3) 
kl2~ Plasma 
CpcALC(t) 
(VI) 
lk!O 
Elimination 
k1e Effect Site keo 
Cec&c(t) Elimination 
(V4) 
Figure 2-4 Three-compartment phannacokinetic and one effect site compartment modelling 
for intravenous drug infusion 
In Figure 2-4, keo is the elimination rate of the drug from the effect site to the environment, k1e 
is the drug transfer rate from plasma to effect site, and the effect site volume (V4) is 
negligible. 
2.3.2. Pharmacodynamics 
While pharmacokinetics describes the dose-concentration relationship, phannacodynamics 
characterizes concentration-effect relationship. The concentration is the drug concentration at 
the site of action, i.e., the effect site drug concentration, and the effect could be any 
quantitative measurement of drug effect (or intensity of biological effect), including various 
EEG effects (e.g., Bispectral Index, median frequency or spectral edge frequency and so on). 
In pharmacology, a sigmoid model (Holford and Sheiner, 1981) shown in Figure 2-5 is used 
to show this concentration-effect relationship, and the mathematical expression of this 
relationship is presented in equation (2-4). In Figure 2-5, E is drug effect, C is effect site or 
steady-state plasma drug concentration, Eo is baseline effect, Emax is maximum drug effect, C0 
is steady-state drug concentration when 50% of drug effect has been achieved, and y is the 
steepness of the relationship curve. In Figure 2-5, zero concentration for zero effect is 
implied. 
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E 
100 Emax 
80 
60 
maJ2 
40 
20 
Eo o~--~~--~--~--~e 
0 0.5 1 1.5 2 
Figure 2-5 An example of sigmoid model of concentration-effect relationship (E denotes 
percentage of effect, C denotes steady-state drug concentration; Emax=100,E0=0,;=8,e0=1) 
E = E er Eo 
""'' e/ +er (2-4) 
The sigmoid model is mathematically complex, especially when y is not an integer, and the 
sigmoid model varies in patients with different parameters. In the example sigmoid model 
shown in Figure 2-5, the concentration-effect relationship could be considered as linear within 
a certain range of effect ( 10% - 80% in Figure 2-5). This property makes it possible for linear 
approximation of this model. 
2.3.3. Accuracy of Pharmacokinetic Model and Patient Variability 
At present, the accuracy of drug infusion by use of pharmacokinetic model is significant, the 
evaluation (Swinhoe et al., 1998) of the commercial Diprifusor TCI in patients undergoing 
major surgery shows that the performances of its drug concentration prediction are 16.2% of 
MDPE (Median Performance Error), and 24.1% of MDAPE (Median Absolute Performance 
Error). This evaluation also found that the measured propofol concentrations tended to be 
higher than the calculated concentrations using the PK model, especially after induction or an 
increase in target concentration. 
Due to the physiological differences between patients, each of them has a umque 
phannacokinetic/pharmacodynamic (PKIPD) model. That is, the parameters in the PK/PD 
model vary from patient to patient. Furthermore, the PKIPD parameters could change intra-
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operatively during the process of drug delivery. The patient variability comes from both the 
pharmacokinetic side and the pharmacodynamic side. Usually pharmacodynamic variability 
exceeds pharmacokinetic variability, and inter-patient variability is large, whereas intra-
individual differences are much smaller (Levy, 1998). Inter- and intra-variability in the 
patients cause the loss of accuracy (Ausems, Stanski and Hug, 1985; Maitre et al., 1988; Short 
et al., 1994; Vuyk et al., 1995a; Coetzee et al., 1995) of drug concentration estimation by a 
PK model. Currently, there is insufficient data on the degree of patient variability. The 
existence of patient variability therefore resulted in the development of population PK models 
(Maitre et al., 1987; Stanski and Maitre, 1990; Minto et al., 1997) and physiology based PK 
models (Wada and Ward, 1994, 1995; Cammarota and Onaral, 1998). 
A population PK model would take into consideration the factors which alter the 
pharmacokinetics of a drug, such as height, weight, age, sex, disease state, induction agent, 
duration of anaesthesia, drug history (including the pre-medication) and so on. Although 
many pharmacokinetic models have been developed (Gepts et al., 1987; Cockshott et al., 
I 987; Shafer et al., 1988; Tackley et al., I 989; Marsh et al., 1991), they are all average 
population models. Stanski et a! concluded that the pharmacokinetic mechanism for the 
decreased thiopental dose requirement in the elderly was a decreased rapid inter-compartment 
clearance, and there is no age-related change in brain responsiveness or pharmacodynamics 
when the spectral edge is used as a measure of drug effect (Stanski and Maitre, 1990). Egan et 
al. (1995) obtained the result that gender has no effect on the pharmacokinetics or 
pharmacodynamics of remifentanil. Minto et al (1997) reported that there is an effect of age 
on the pharmacokinetics and pharmacodynamics of remifentanil, and an effect of lean body 
mass on the pharmacokinetic parameters. However, there is no influence of gender on any 
pharmacokinetic or pharmacodynamic parameter. Schnider et al (1999) found that elderly 
patients are more sensitive to the hypnotic and EEG effects of propofol than are younger 
persons. In clinical practice, an average PK model, which is a representative of a population, 
is actually used. 
In order to construct an average population model, three steps are required. Firstly, a 
mathematical model for each of the representatives of the population is built by experiment 
and non-linear regression on the experimental data. Those models are then mathematically 
transfonned into compartment models, and finally the multiple sets of pharmacokinetic 
parameters in the compartment models are averaged to form a single set of parameters 
representing the average PK model. In practical use of the average pharmacokinetic model for 
drug infusion, the average physiological model needs to be transformed back into its 
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mathematical model in favour of computation. 
2.3.4. Manually Controlled Drug Infusion 
Manual delivery of anaesthetic drug is the traditional method to deliver anaesthesia using a 
high precision anaesthesia pump. It involves the calculation of a bolus dose which induces the 
anaesthesia and a maintenance infusion rate to maintain the anaesthesia. 
As drug concentration is defined to be the amount of drug divided by volume (equation (2-5)), 
the induction bolus dose (Bd) can be therefore easily calculated from the target drug 
concentration (Cr) and the volume (V1) of the patient as shown in equation (2-6). 
Amount Concentration = ---
Volume 
(2-5) 
(2-6) 
The bolus dose Bd calculated from equation (2-6) can be used to achieve the target drug 
concentration in plasma without overshoot. However most of the time in this case, the drug 
concentration in plasma is below the target. Alternatively, the central compartment volume V1 
in equation (2-6) can be replaced with the volume of distribution at the time of peak effect (V 4 
in Figure 2-4), so that the drug concentration is equal to the target concentration when the 
plasma and the effect site are in equilibrium after the bolus infusion, although it results in 
overshoot in plasma. 
After the bolus infusion, smaller infusion rates must be maintained to compensate the 
distribution loss and the clearance of drug. As the rate of distribution into peripheral tissues 
decreases over time, the maintenance infusion rate should therefore be changed accordingly. 
The following equation, derived from pharmacokinetic model, can be used for the calculation 
of maintenance infusion rate in a dosing regimen design. 
(2-7) 
However few anaesthetists would mentally use this equation in their clinical practice. 
Average manual infusion dosing schemes, developed from PK/PD model, are available for 
various drugs. Table 2-2 shows the example schemes for the manual administration of 
propofol and alfentanil. 
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Table 2-2 Examples of manual infusion schemes when combined with 66% 
nitrous oxide and oxygen (Glass et al., 1994) 
Anaesthesia Sedation or Analgesia 
Loading Dose Maintenance Loading Dose Maintenance 
ug!kg Infusion ng!kg/min ug!kg Infusion ng/kg/min 
Propofol 1000-2000 80- 150 250-1000 10-50 
Alfentanil 50- 150 0.5-3 10-25 0.25- 1 
2.3.5. Target Controlled Infusion 
Target controlled infusion, also known as computer assisted continuous infusion (CACI), is 
an automated drug infusion method. The physical components in a TCI system include a high 
precision anaesthesia pump which drives a syringe, and a computer or microprocessor system 
controlling the infusion rate of the pump using a pharmacokinetic model. Currently, all TCI 
systems are for research except for the Diprifusor (Glen, 1998) which is commercially 
available. 
From the point of view of a control strategy, target controlled infusion is an open loop control 
system (See Figure 2-6) for there is no measure of drug effect or patient response in the 
system. The system gives the drug according to the difference between the given target 
concentration (either in plasma or at effect site) and the drug concentration at the target site 
predicted by the built-in pharmacokinetic model. ST ANPUMP is one of such TCI systems. 
Computer System ~I Target infusion Rate Anaesthesia Drug Concentration (Pharmacokinetic Model) p Pump Patient I 
Figure 2-6 A Typical target controlled infusion system 
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Convenience, quick induction, less overshoot and less drug consumption are the mam 
advantages of a TCI device over manual control (Russell, 1998), and 93% of the users prefer 
to use the TCI while 89% of the users found it easier to use in accordance with the report 
from Servin ( 1998). 
2.3.6. Closed-loop Controlled Drug Infusion 
The main drawback of a TCI system is the nature of open loop control strategy by which the 
system does not response to drug effect, patient response to the drug infused or depth of 
anaesthesia (DOA). A TCI system cannot automatically choose the pharmacokinetic model 
for a specific patient. In order to keep the anaesthesia at the same level, the anaesthetist needs 
to adjust manually the target concentration during maintenance in the light of clinical 
observations. 
In the contrary, a closed loop anaesthesia (CLAN) system would give the drug to the patient 
according to the target drug effect and the real time measure of the drug effect from the 
patient. If any event happens and results in inadequate anaesthesia, a closed loop controlled 
anaesthesia system would respond to this event readily. Theoretically, a stable closed loop 
system has, inherently, the ability to minimise the error between the desired input and the 
measured output. This implies that a properly designed and implemented closed loop 
anaesthesia system is capable of inducing and maintaining the desired depth of anaesthesia in 
all patients in spite of the existence of patient variability and intra-operative surgical events 
causing inadequate anaesthesia. 
Physically, a basic CLAN system would consist of a high prectston anaesthesia pump 
including a syringe, an equipment measuring the DOA of the patient, a computer or 
microprocessor system incorporating a controller which controls the infusion rate of the 
anaesthesia pump by evaluating the measured DOA and the target. The block diagram of such 
a basic system is shown in Figure 2-7. 
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Computer System Infusion Anaesthesia 
(Controller) Rate .. Pump 
.,. 
Drug Drug Effect 
Equipment ~~ Physiological 
Measuring . Patient 
Drug Effect Signal 
Figure 2-7 A basic closed loop anaesthesia system 
Potentially, quality of anaesthesia control may be superior with a closed loop system. While 
inheriting the advantages from TCI, a CLAN system may provide more stable DOA and less 
overshoot. By reducing the requirement for clinician intervention to make frequent 
adjustments to anaesthesia, their time is spared to give better attention to other necessary 
tasks. One potential use of a CLAN system would be to allow a less skilled practitioner to 
deliver anaesthesia. 
2.3.7. Graseby 3400 Anaesthesia Pump 
Manufactured by Graseby Medical Limited, the Graseby 3400 anaesthesia pump is a clinical 
pump for administration of intravenous drugs by the way of driving a syringe which contains 
drug. When used for manual delivery of intravenous drug, a bolus dose can be specified in the 
pump for the induction, or one can set up a constant infusion rate for the maintenance of drug 
effect. The pump is capable of infusing intravenous drug at a rate from 0.1 ml!hour up to 1200 
ml!hour. Alternatively, an external computer can be used to control remotely the pump 
through the RS232 serial communication port provided with the pump. Infusion rate, pump 
status, total infused volume and error messages can be controlled or inquired by the computer. 
However, the user can not press the "start" button on the pump to start the infusion when the 
pump is under the control of a computer. 
2.4. Anaesthetic Drugs 
2.4.1. Propofol 
Propofol, also known as Diprivan (a trademark and the property of AstraZeneca PLC), is an 
intravenous anaesthetic agent. When infused into a patient, propofol forces the patient into the 
hypnotic state which is required for any surgery. Propofol was found to produce rapid onset of 
anaesthesia, short duration of action, satisfactory maintenance, and rapid recovery with 
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reliable amnestic properties (Sebel and Lowdon, 1989). Propofol can be used for sedation of 
patients in ICUs and has also been used for total intravenous anaesthesia combined with an 
opiate (e.g., alfentanil, fentanyl, or sufentanil etc.). In the elderly patient (Kirkpatrick et al., 
1988), the clearance of propofol was significantly lower than in the younger patient. The 
volume of the central compartment in the elderly patient was also smaller than that in the 
younger patient. There were no differences in the volumes of distribution at steady state or in 
the half-lives of distribution and elimination. Less drug is therefore needed for the induction 
in elderly patients. The time for propofol to produce peak effect (i.e., peak time) after a bolus 
infusion was reported in the range of 1-2.4 minutes (Schnider et al., 1999). Many two- or 
three-compartment pharmacokinetic models have been developed with weight, age, sex, or 
height incorporated in some of these models. Table 2-3 shows a propofol pharmacokinetic 
model developed by Gepts and colleagues (Gepts et al., 1987). 
The Gepts' rate constants were derived from a clinical study on 3 groups of 6 patients each 
undergoing surgery under regional anaesthesia. Propofol was infused in constant infusion 
rates of 3, 6, and 9mg/kg!hr respectively for at least 2 hours. Arterial blood samples were 
collected at selected times during and up to 8 hours after infusion. 
The rate constants shown in the first column of Table 2-3 are the mean±standard deviation 
values among the 18 patients. The median absolute performance error (MDAPE) and the 
median perfom1ance error (MDPE) of this PK model are 26% and 24% (Vuyk et al., 1995a), 
respectively. The evaluation studies for computer controlled infusion of propofol on 5 (Vuyk 
et al., 1995a) and 3 (Coetzee et al., 1995) pharmacokinetic parameter sets show the 
pharmacokinetic parameters derived by Gepts et a! (1987) are equally clinical acceptable with 
those derived by Cockshott et al (1987), Tackley et a! (1989), Shafer et a! (two-
compartments) (1988), and Marsh et a! (1991) while other two are less accurate. 
Table 2-4 lists the good three-compartment pharmacokinetic parameter sets ofpropofol as the 
results of the comparison studies in (Vuyk et al., 1995a) and (Coetzee et al., 1995). In the 
meantime, the evaluation found that the plasma concentration was underestimated with all the 
good parameter sets, and a modified parameter set which is based on the parameters obtained 
by Gepts et al (1987) was recommended by Glass et al. (1989) and they are listed in the 
second column of Table 2-3. The recommended parameters are used in STANPUMP and also 
the CLAN system in this project. 
36 of220 
Table 2-3 Phannacokinetic parameters ofpropofol 
from 18 subjects and the recommended modifications 
PK Mean± SD Values Mean Values 
Parameters Gepts et al. (1987) Glass et al. (1989) 
Kto(min-1) 0.1190 ± 0.0351 0.152 
K12 (min"1) 0.1140±0.1051 0.207 
K21 (min-1) 0.0550 ± 0.0558 0.04 
K13 (min-1) 0.0419 ± 0.0155 0.092 
KJt (min-1) 0.0033 ± 0.0013 0.0048 
Vt{L) 16.924 ± 6.9570 0.159w* 
* w IS the patient wetght m ktlogram 
Table 2-4 Other popular phannacokinetic parameter sets ofpropofol 
PK Variables Marsh et al Tackley et al Cockshott et al 
(1991) (1989) (1987) 
k 10 (min-1) 0.119 0.0827 0.1058 
ktz (min-1) 0.112 0.105 0.1440 
k13 (min-1) 0.0419 0.022 0.0282 
kzt (min-1) 0.055 0.064 0.064 
k31 (min-1) 0.0033 0.0034 0.0034 
Vt (L) 0.228w* 0.32w* or 22.4 17.5 
* w IS the patient wetght m kilogram 
2.4.2. Alfentanil 
Alfentanil is an intravenous analgesic agent which relieves pain. It can be used either in 
surgery or in ICU. Alfentanil can be combined with a hypnotic for a total intravenous 
technique. Alfentanil has a short terminal elimination half-life (80-120 minutes) because of 
the relatively small steady-state distribution volume and a rapid plasma-effect site 
equilibration time (i.e., the drug effect peak time, 1-2 minutes) (Scott, Ponganis and Stanski, 
1985) which results in a rapid onset of narcotic effect. Different surgical/anaesthesia stimuli 
require different alfentanil plasma or effect site concentrations to provide adequate clinical 
anaesthesia. However, if a hypnotic is used with alfentanil to induce anaesthesia, the dose of 
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the hypnotic can usually be markedly reduced. The infusion of alfentanil should be 
discontinued approximately 20 to 30 minutes prior to the expected end of surgery. 
There are some pharrnacokinetic models available for alfentanil. Shown in Table 2-5 is a 
typical population pharmacokinetic model developed by Maitre et al. (1987) based upon a 
clinical study on 45 patients. The PK model incorporates the sex, weight and age of individual 
patient, the mean bias (±SE) (systematic over- or under-prediction) of the model was -
7.9±5.2%, and the mean absolute error (±SE) as a measure of the precision was 22.3±2.9% 
(Maitre et al., 1988). 
Table 2-5 Pharrnacokinetic parameters of alfentanil 
PK Parameters Value or Expressions 
KIO Age> 40yr (0.356- (0.00269 . (Age- 40))) I V 1 
(min-1) Age~Oyr 0.356Nt 
Kt2(min-1) 0.104 
K21 (min-') 0.0673 
K13 (min-') 0.017 
KJI Age> 40yr 0.0126- (0.000113. (Age- 40)) 
(min-1) Age~Oyr 0.0126 
v. Men 0.111 . Weight (in kg) 
(litre) Women 0.111 . 1.15. Weight (in kg) 
tp (min) 1.376 
2.4.3. Drug Interaction between Propofol and Alfentanil 
In clinical practice, inhalational or intravenous anaesthetic agents are combined to reduce the 
dose requirements of the individual agents, to diminish the incidence of side effects during 
induction and maintenance of anaesthesia, or to increase the speed of recovery. As propofol 
and alfentanil are both short action anaesthetic agents, they are frequently used in 
combination. However, there is drug interaction (Piummer and Short, 1992; Stanski and 
Shafer, 1995; Vuyk et al., 1995b; Vuyk, 1997, 1998; Rosow, 1997) for the combination use of 
analgesic and hypnotic agents, and/or the simultaneous use of several sedatives. Propofol will 
reduce the requirements of alfentanil concentration by interfering with its metabolism, and on 
the other hand alfentanil reduces the requirements of propofol concentration by reducing both 
the distribution and clearance of propofol (Vuyk et al., 1995b; Vuyk, 1998), which changes 
the dose-concentration-response relationship. 
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3. Closed-loop Anaesthesia 
3.1. Introduction 
Automatic control has played a very important role in the advance of engineering and science. 
It is extremely important to apply automatic control to auto-piloting systems such as in 
rockets (Choi, Bang and Kim, 1999), robots (Lacroix, Polotski and Cohen, 1999), and 
autonomous underwater vehicles (Craven et al, 1999). Since the advent of automatic control, 
it has become an important and integral part of modem manufacturing and industrial 
processes to improve productivity, replace routine repetitive manual operations, achieve and 
maintain the optimal performance of dynamic systems. Although its use in medical science is 
unusual, automatic control has been successfully used for the automated delivery of some 
types of drug, such as nitroprusside for blood pressure control (Behbehani and Cross, 1991), 
muscle relaxants (Linkens and Hasnain, 1991) and inhalational anaesthetics (Vishnoi and 
Roy, 1991). 
All control systems could basically be classified into two categories: open loop control, and 
closed loop control that is also known as feedback control. While open loop control requires 
an accurate model for the controlled object or plant, the closed loop control needs to measure 
the plant output or states to adjust the input of the plant in order that the plant output 
approaches the desired or tracks the desired if it changes. 
Digital signal processing has been widely used in modem control systems. In anaesthesia, 
power spectral analysis is a fundamental technique to process EEG signal and determine the 
state of anaesthesia. More recently, bispectral analysis, which reveals more hidden 
information carried in the EEG signal, has been used to produce the depth of anaesthesia 
descriptor Bispectral Index. 
In this Chapter, the theoretical background on closed-loop control system with particular 
details on the proportional integral derivative (PID) controller is presented. The principle of 
higher order spectral analysis including power spectral and bispectral analysis is also 
introduced. 
3.1.1. Open loop Control 
Open-loop control systems are defined as those systems in which the output has no effect on 
the control action even if the output is measured or assessed in some way. One practical 
example of an open-loop control system is a washing machine that executes the scheduled 
events on a time basis according to how it is programmed. The accuracy of the open-loop 
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control depends on calibration or the mathematical model that describes the input-output 
relationship of the dynamic system. In any control system, an actuator that performs the 
control actions is needed and is either physically constrained or not. Where a constrained 
actuator is used, some open-loop control systems may be able to adjust the scheduled control 
signals to meet the requirements of the actuator. For example, a target controlled dmg 
infusion system is a model-driven open-loop control system. The actuator of the system 
consists of a medical pump and a syringe which are physically constrained by the maximal 
pump speed, pump precision, syringe diameter and volume. One of the adjustments on the 
scheduled infusion rates in this open-loop control system is to clamp the infusion rate to the 
maximal infusion rate allowed when the scheduled infusion rate is higher than the maximal 
pump speed and also modify the following infusion rates to compensate the clamping. 
Open-loop control systems will not perform the desired task if there is any disturbance or 
system non-linearity, or if there is any parameter that is time-varying or not modelled 
mathematically in the model that is used for the control. All these will affect the performance 
of open-loop control over the dynamic systems and cause an error between the system output 
and the command input (or desired system output). A strong motivation for using feedback 
signal in control systems is to reduce and correct this error. The use of feedback signal makes 
it possible for a control system to adapt those uncertainties. 
3.1.2. Closed-Loop Control 
Closed-loop control is also referred to as feedback control. In a closed-loop control system, 
the error signal that is the difference between the command input and the feedback signal is 
fed to the controller so as to adjust the control action that reduces the error. The feedback 
signal may be the output of the system or a function of the output signal and its derivatives, 
and affects system performance characteristics, such as stability, sensibility, and overall gain. 
The use of feedback makes the system response relatively insensitive to external disturbances 
and internal variations in system parameters, which is the main advantage over open-loop 
control. In order to obtain the same control accuracy, in open-loop control systems, accurate 
system models are required, while it is not necessary in closed-loop or feedback control 
systems because of this advantage. However, in some cases where the system dynamics are 
too complex or our knowledge of them is insufficient, the combination of open-loop control 
and closed-loop control is usually less expensive and will give satisfactory overall system 
performance. Figure 3-1 shows the block diagram of a closed-loop or feedback control system 
where the sensor provides he feedback signal by measuring the system response (y(k)) with 
40 of220 
the presence of disturbance (v(k)), and the controller gives a control signal (u(k)) according to 
the error signal (e(k)) that is the difference between the command input (x(k)) and the 
feedback signal. 
Consider a digital control system that has the block diagram shown in Figure 3-1. The pulse 
transfer function representation of the system is shown in Figure 3-2. 
Command 
Input 
X(z) 
Disturbance v(k) 
x(k) .6:?\ e(k) 
"'<:::- lcontrollerl u(k) ~1 Actuator I 
Sensor 
Figure 3-1 A typical closed-loop control system 
V(z) 
E(z) U(z) l 
Ht(z) 
~ Controlled y(k) I---
Object 
Y(z) 
Figure 3-2 The pulse transfer function representation of the closed-loop control system 
Where Hc(z), Hp(z), and Hj(z) are the pulse transfer functions of the controller, plant (i.e. the 
controlled object), and the sensor in the closed-loop control system, respectively. X(z), E(z), 
U(z), V(z), and Y(z) are the z-transform of the discrete command input, error signal, control 
signal, external disturbances, and the system output or response, respectively. 
Suppose the disturbance of the control system is zero, then the open-loop pulse transfer 
function of the system in Figure 3-2 is defined as the product of all the pulse transfer 
functions in the closed feedback loop: 
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while the overall closed-loop pulse transfer function of the system is defined as: 
The output and the error signal of the closed-loop control system are then 
Y(z) = G(z)X(z) 
E(z) = X(z) 
I+ H(z) 
3.2. Closed-Loop Control Systems 
3.2.1. Introduction 
(3-l) 
(3-2) 
(3-3) 
(3-4) 
For a given control problem, it is important to choose the appropriate control strategy and 
design the proper controller so as to achieve the desired performance of system control. 
Various control strategies have been used in industry and many other areas including 
medicine, there is no such a control strategy that is the best for all control problems. The 
control strategies vary from conventional control (e.g., PID control), model reference control, 
optimal control, stochastic control, H .. control, to neural network control and fuzzy logic 
control. All control strategies could be full adaptive, part adaptive or non-adaptive. For some 
control strategies, one could be used in combination with another to form a new control 
scheme, for example, PID+reference model, PID+fuzzy, or neural-fuzzy. 
Of all the control strategies, PID control might be the most successful control strategy used in 
control engineering in the past due to its simplicity and efficiency. It is especially useful if the 
plant dynamics are unknown or partly known. It is possible to obtain better performance of 
control from other control strategies, however the PID control usually gives satisfactory 
control. 
There are many ways available for the design of a conventional single-input-single-output 
discrete time closed-loop control system. Indirectly, a discrete time control system can be 
designed from the equivalent continuous time control system via transform method. Also it 
can be designed directly using root locus method, frequency response method, or analytical 
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method. Where there is deficiency in the root locations or frequency response of the plant, 
compensation would be needed to obtain the desired root locations or frequency response. 
The indirect design method via transfom1 requires the design of a conventional continuous 
time control system first and then translates it into discrete time form. The methods available 
for the translation include pole-zero mapping, impulse invariance method and numerical 
integration such as and bilinear transformation method. The root locus method is based on the 
pole-zero configuration in the z-plane. By adding new poles or zeros to compensate or cancel 
the undesirable plant poles or zeros, the desired transient and steady state performance of the 
control system would therefore be achieved. While the frequency response method gives 
opportunity to design a control system whose specifications are given in frequency domain. 
However, the analytical method is quite different from the above elementary methods, it is 
based on the idea that all aspects of the performance of a closed-loop control system might be 
measured by a single, suitably defined, performance criterion. Essentially, a performance 
index is used in this design method to measure the performance of the system control. The 
analytical method is widely used in optimal control and stochastic control. 
In design of a control system, in order to obtain a control system that meets all the given 
specifications, it is quite common for us to finish the design via trial-and-error approach. The 
general procedure of designing a discrete time control system via this approach involves 
choosing an appropriate control strategy, designing the controller, setting up the mathematical 
model of the closed-loop system, constructing a prototype and simulating the system. Once 
the satisfactory performance has been obtained from the computer simulation, the system 
should be tested via experiment in real environment. If the performance does not satisfy the 
specifications, which is likely to happen because of the imperfect plant modelling (such as 
nonlinearities etc.) that the original design does not take into consideration, changes must be 
made on the prototype until the system meets the specifications. 
3.2.2. Transient and Steady State Analysis 
Absolute stability of a control system is defined as whether or not the output of the system 
eventually comes back to its equilibrium state when the system is subjected to a disturbance. 
In equilibrium, a control system maintains the same output in the absence of any disturbance 
or input. In analysing and designing of a closed-loop control system, the dynamic behaviour 
of the system must be predictable, and absolute stability of the system is the most important 
characteristic of the dynamic behaviour. Using test signals, the absolute stability and 
performance of a control system can be easily tested. Step functions and impulse functions are 
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two of the commonly used test signals. 
With impulse signal input to the control system, the absolute stability of the control system 
can be tested. For the unit impulse signal x(t) = 8(1), due to X(z)= I, then the z-transform of 
the impulse response of the control system is: 
Y(z) = G(z)X(z) = G(z) 
and y(k), which is the inverse z-transform of Y(z), is the impulse response. 
While with impulse signal, the response of a closed-loop control system to a transient 
disturbance can be tested when the system is at equilibrium state, we can explore the transient 
response and steady state response of a closed-loop control system with a step input signal. 
The z-transform of the output of the closed-loop control system can be obtained as follows: 
z 
Y(z) = G(z)X(z) = -G(z) 
z -1 
and the inverse z-transform of Y(z) is the step response of the closed-loop control system. 
For example, for a control system, shown in Figure 3-3, having a following closed-loop pulse 
transfer function 
G(z)= H(z) = 2.49lxl0-;(1+2z-1 +z-2 ) 
l + H(z) l-l.9929z-1 + 0.993z-2 (3-5) 
X(z) E(z) H(z) Y(z) 
Figure 3-3 An example closed-loop control system 
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The impulse response and step response of the example closed-loop control system is shown 
in Figure 3-4 and Figure 3-5, respectively. 
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Figure 3-4 Impulse Response of the example Closed-loop System 
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Figure 3-5 Step Response of the example Closed-loop System 
The impulse response of the system shows that the output of the control system will 
eventually stay at its equilibrium state, which is 0, following the stimulation of the unit 
impulse signal at time 0. Such a system response will be superposed to the overall system 
output of any linear closed-loop control system at any time when the system is suffered from 
a unit impulse disturbance. 
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The step response of the system shown in Figure 3-5 indicates the transient and steady state 
response of the system to a fixed target signal. From Figure 3-5, a set of system specifications 
in time domain can be defined. 
Transient Response Analysis 
The transient response of the system to the step input defmes the delay time (td), rise time (t,.), 
peak time (tp), settling time (15), the maximum overshoot (Mp) and the damping ratio (~). 
Figure 3-6 shows the relationship between the damping ratio (~) and other transient time 
parameters in second order discrete time systems that have different values of damping ratio. 
The transient response shows the speed with which the system enters into its steady state. 
2 
1.5 
0.5 
20 40 60 80 100 120 140 160 
No. of Samoles 
Figure 3-6 Step responses of second order discrete time systems 
(natural frequency w,=0.8, sampling period T=O.ls, damping ratio t-=0~2) 
Steady State Error Analysis 
The steady state response of the system to the step input specifies the allowable tolerance (5) 
and the steady state error (e55) . The steady state response demonstrates how well the system 
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maintains its steady state. 
By use of the final value theorem, the steady state error of the discrete time control system 
shown in Figure 3-3 can be expressed as 
or 
e,, = lim e(k) = lim (1- z- 1 )E(z) 
k--i>a'J :--+1 
1. (l - z -I ) X( ) e,, = lffi 1 H( ) z 
z->1 + Z 
when the input of the system is unit step u(k), unit ramp ku(k), or unit acceleration signal 
k!u(k), respectively, the steady state error can then be obtained 
l 
e =---
'' l + K P 
for unit step input (3-6) 
l 
e, = K,. for unit ramp input (3-7) 
ess =-
K. 
for unit acceleration input (3-8) 
1-z-1 
where K P = lim H ( z) Is static position error constant, K v = lim H ( z) IS static 
z->1 z-->1 T 
velocity error constant, and K. =lim {l-z
2
-
1
)
2 
H(z) is static acceleration error constant. 
z-->1 T 
For type 0 system (in which there is no open loop pole at z=l), the steady state error in 
response to unit step input is finite. For type l system (in which there is one open loop pole at 
z=l ), the steady state error is zero in response to unit step input, but finite to unit ramp input. 
For type 2 system (in which there are two open loop poles at z=l), the steady state error is 
zero in response to both unit step and unit ramp input whereas finite in response to 
acceleration input. 
For example, the steady state error of the example system in response to the unit step input is 
and I+ H(z) = 1 , therefore the steady state error of the example closed-loop system is 
I- G(z) 
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e, = lim I = lim (1- G(z)) = 0.0036 
,_., I+ H(z) ,_., 
and the static position error constant is 
I K P =- -1 = 276.8 
e, 
3.2.3. Root Locus Analysis 
The basic characteristic of the transient response of a closed-loop control system depends 
very much upon the location of the poles of the closed-loop pulse transfer function, i.e., G(z), 
especially if the system has a variable open loop gain that varies the location of the closed-
loop poles. It is important for such a closed-loop system to choose gains that make the system 
stable. In order to choose the right gains for the closed-loop system, it is necessary to 
investigate the root locus of the system when the loop gain varies. On the other hand in the 
design of a closed-loop system with fixed gain, one may obtain an appropriate gain by 
moving the location of the poles to better or the desired location so as to improve the transient 
response characteristic of the closed-loop system. 
According to equation (3-2), the closed-loop poles are the roots of the following characteristic 
equation: 
l+H(z)=O (3-9) 
H(z) is the open-loop pulse transfer function. When the gain of H(z) varies, the roots of 
equation (3-9) will consequently be changed. The relationship between the pole location and 
the transient response of the closed-loop control system is shown in Figure 3-7. All the poles 
of a stable closed-loop system are within the unit circle. A pole at origin allows the output of 
the closed-loop system following the system input with one cycle time delay, however when 
the pole is in a place within the unit circle other than the origin, it will cause the system output 
either damped or oscillatory. Any pole outside the unit circle will cause the system unstable. 
Positive real pole makes the system response sluggish whereas the negative real pole causes it 
oscillatory (Figure 3-7 (a)). Generally, all complex conjugate pole pairs make the system 
response oscillatory, the closer pole pair to the unit circle will result in more oscillatory in 
system response. See Figure 3-7 (b) and (c) for the system responses caused by the poles 
whose locations are shown in Figure 3-7 (d) in the complex plane. 
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(a) Step responses from a single real pole 
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(b) Step responses from a pair of complex conjugate poles in left half plane 
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(c) Step responses from a pair of complex conjugate poles in right half plane 
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if <IPI > I) 
(d) Location of the poles in complex plane 
Figure 3-7 The effect of pole Location on transient response of closed-loop systems 
(p represents a pole of a closed-loop system. p; and p;• are complex conjugate pole pair.) 
3.2.4. Frequency Response Analysis 
The frequency response concept of closed-loop control systems is very useful for the analysis 
and design of either continuous time or discrete time systems. As the same for continuous 
time system analysis, the frequency response analysis of discrete time control systems is 
based on the Bode diagram that consists of two separate plots: the logarithmic magnitude of 
the open-loop transfer function (-201ogiH(w)l) versus logarithmic frequency, and its phase 
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angle (LH(w)) versus logarithmic frequency. 
Because in the z-plane the frequency appears as z = eJwT, if we apply the conventional 
frequency response analysis in the z-plane, the simplicity of the logarithmic plots will be 
completely lost. Furthermore, since the z-transformation maps each strip of the left half s-
plane into the interior of the unit circle in the z-plane (Figure 3-8), the conventional frequency 
response methods that are based on the entire left half plane does not apply to the z-plane. 
However, the difficulty can be overcome by transforming the pulse transfer function from z-
plane into w-plane using the so-called w-transformation. The w-transformation is a bilinear 
transformation and is defined by 
1 + (T / 2)w z =----'-----'----
1- (T / 2)w (3-1 0) 
where T is the sampling period. The inverse relationship between z and w is 
(3-11) 
This transformation is graphically shown by Figure 3-8. After the pulse transfer function H(z ) 
is w-transformed into H(w) , the conventional frequency response methods can be applied to 
the analysis and design of discrete time control systems. 
Figure 3-9 shows the Bode diagram for the follow transfer function 
~ 
rll 
H(z) = 0.1018 z + 0·9356 
z 2 - 1.5071z + 0.5071 
jw Im s plane z-plane -~ 
2jtr/T 
__t ;trtT 
a 
... 
c -jtr!T 
-2;trtT -1 
Im 
w-plane -~-----£~8 
d a 
+--_8 -------- (---l•• Re 
-2!f 
.__ ___ __,c -8 
Figure 3-8 Mappings between s-plane, z-plane, and w-plane 
51 of220 
50~--~~~~~~--~~~~~~----~~~~~ 
.. 
. . . : : : : 
... . 
-
: j l ll 
, , . . . K . . . . . . ' ' '" i 0 -; r · ! : :r~ -rrM~\rl · , -j · : , : 1r 
\9 -50 ....... + . • . • nr _ . . . . . . .rnG . . . . . . ... . _10o~--~~l~~ ~ ~~ ~i~!~--~~· ~: ~- ~~ ~~ ~~ ~~~----~~~·~!~'~'~' 
10-1 10° 101 102 
Frequency (rad/sec) 
0 .------r-----r-~, ...........-.--~--.-.-----.----~ 
~ -9Qr---+-~~~~tt ········t:-····1····• ·H·, ···~ ·+H······················,·········· i ·····~·····•···,·+•··H 
~ ~~i'--
..c.
cu -180 "' ....... ft'--... ~..i.: +·H·j·f·· ············r·····!···· + ···~ .... , ..... , .... , ... , 
~ ~~~~ 
-270~·-·· · ···· ·· ····· i···· · ········; ....... ; ...... ; .... ; ... ;.;; .. ; ........... ....... ; ............ ; ........ ; .. ; ...... ; ... ;c ... ; •• ; •. ;l ..................... ; ......... ; ..... ; ..... ; ..... ; .... ;. ;. H 
10-1 10° 101 
Frequency (rad/sec) 
Figure 3-9 Bode diagram for the given transfer function in w-plane 
In a Bode diagram, the gam margin Gm is defined as the magnitude of H(w) at some 
frequency at which its phase is 180°; while the phase margin Pm is defined as the phase of 
H(w) at some frequency at which its magni tude is OdB; the resonant frequency Fr is the 
frequency at which there is a peak value for the magnitude of H(w). For type 0 systems, the 
static position error constant Kp can be read indirectly from the magnitude plot of a Bode 
diagram, because low frequency asymptote is a horizontal line that intersects with w=O line at 
20IogKp dB. For type 1 systems, the intersection of the initial -20dB/decade segment (or its 
extension) with the OdB line has a frequency numerically equal to Kv . Finally, for the static 
acceleration error constant Ka, the intersection of the initial --40dB/decade segment (or its 
extension) with the w= l line has the magnitude of 20logKa. From the Bode diagram shown 
in Figure 3-9, we can read Gm= l4dB, Pm=50, and Kv=1.8, however Kp, Ka, and Fr are not 
available from this Bode diagram. 
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3.2 .5. Bilinear Transformation 
Transfonn method can be applied to translate a transfer function representing a continuous 
time system to its equivalent pulse transfer function representing a discrete time system, we 
can therefore use this technique to design a discrete time controller if its equivalent 
continuous time controller is already available, and bilinear transformation method is one of 
the popular techniques used in control system designs. 
Bilinear transformation method is a numerical integration method that uses the following 
mapping equation to discretize a continuous time system represented by a transfer function in 
s- plane: 
2 1- z-1 
s =- , where T is the sampling pe1iod 
T 1 + z-1 
(3-13) 
This mapping method is based on the area approximation by trapezoidal integration illustrated 
by Figure 3-10 where the area under y(t) between 2T and 3T is approximated by the shaded 
rectangle area: 
JJr y(t)dt = y(2T) + y(3T) T 2T 2 
0 T 2T 3T 4T 
t 
Figure 3-10 Approximation of area calculation by trapezoidal integration 
Extend this method to each sampling interval, the whole area under y(t) could be 
approximately calculated as follow 
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[I k T 
Jo y(t)dt =I -[y((n -1)T) + y(nT)] 
11=1 2 
(3-38a) 
applying z-transformation on both sides, then 
D [ f' (t)dt] = T I + z - I 
Joy 2 1- z -1 (3-38b) 
As shown in Figure 3-1 1, the equation (3-13) maps the entire left half s-plane into the area 
inside the unit circle in z-plane, and the entire imaginative axis in s-plane into one complete 
revolution of the unit circle in z-plane. 
However, due to the possible high frequency distortion, the bilinear transformation is usually 
used with frequency prewarping by replacing the frequency (a in equation (3-12), for 
1 ) . h 2 aT examp e wit -tan-. 
T 2 
lm 
s-plane 
Re 
I m 
z-plane 
. I \~ 
... LJ. Re 
Figure 3-11 Mapping between s-plane and z-plane by bilinear transformation 
(points b, c, and d in s-plane are in infinity, whereas in z-plane they approach ( -1 ,0)) 
By using the bilinear transformation and prewarping method, the analog system represented 
by the equation (3-12) can be converted into a discrete time system represented by the 
following pulse transfer function 
aT (1 + z - I ) tan -
2 
aT aT _1 1 + tan - - (1 - tan - )z 
2 2 
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3.2.6. System Compensation 
3.2.6.1 .Phase Lead Compensation 
As stated earlier, Hc(s) hence Hc(z) is a phase lead compensator if T1>T2. The Bode diagram 
of this compensator is shown in Figure 3-12. 
From the Bode diagram, it can be seen that the phase lead compensator has little effect on the 
frequency response at low frequencies, but improves the high frequency response, or transient 
response, so that larger gain can be used, with consequent improvement in steady state 
perfom1ance. 
10Gain dB 
! ........... 
5 ...................................... ·· /-/ ......... ; ................................................................ ; ............................................................. ~ 
0 '----='-~.____..__..____..__.'------------' 
1 G2 1 cf Ht 1 cf 
30
Phase deg 
20 
10 ....... . 
1 cf Hf 
Frequency (rad/sec) 
Figure 3-12 Bode diagram of a phase lead compensator (T=O.OOls, T 1=5, T2=2) 
Phase lead compensation is commonly used for improving stability margins and increasing 
the system bandwidth. Thus, the system has a faster transient response speed or a shorter 
settling time. However, its increased high frequency gains may be subjected to high frequency 
noise problems. 
3.2.6.2.Phase Lag Compensation 
When T1>T2, Hc(s) hence Hc(z) is a phase lag compensator, the Bode diagram of this 
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compensator is shown in Figure 3-13. 
Phase Jag compensation reduces the system gam at higher frequencies, therefore high 
frequency noises involved in the system can be attenuated, or the total system gain can be 
increased and thereby low frequency gain can be increased and the steady state accuracy can 
be improved. However, the phase Jag compensator reduces the system bandwidth, which 
slows down the system response speed. 
0Gaind\ 
-5 ...................................... \~""""'t""""'"'""'""'"""""""""""'""""""""t"""""""""""'"""""""'""""""""'"'-1 
-1Ln-----~----~----~----~----~----~ 
1 02 1 cfl 1 d Hf 
Phase deg 
o.-----~----.-----~~--~-----------. 
-1 ........... , ............................. . 
-2 
. . 
···l·····························································t··························································· 
1 cfl Hf 1cf 
Frequency (rad/sec) 
Figure 3-13 Bode diagram of a phase Jag compensator (T=O.OOls, T 1=2, T2=5) 
3.2.6 .3.Phase Lag-Lead Compensation 
Phase lead and phase Jag compensations improve overall performance in different ways. One 
is designed to improve the high frequency, or transient, response of the controlled process; the 
other is designed to improve its low frequency, or steady state, response. There is little 
interaction between the effects of the two and so both can be used together, in the same 
controller, with advantage. By cascading the phase lead compensator and the phase Jag 
compensator above with little modification, a typical phase Jag-lead compensator would be 
obtained 
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(a<l, {J> 1) (3-15) 
A Bode diagram of tills Jag-lead compensator is shown in Figure 3-14. 
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Figure 3-14 Bode diagram of a phase lag-lead compensator (T1=2, T2=20, a=0.1, {3=10) 
3.2.7. PlO Control 
3.2.7 .1.1ntroduction 
PID control has been successfully used in industry and many other areas over years due to its 
simplicity, quick response and efficiency. For a control object that has some wlknown 
dynamics, or its non-linearity is not small enough to be ignored, PID control is usually a 
common choice for start by offering satisfactory results. 
For a drug infusion control system, response speed is the most important requirement, and 
quick response is one of the main advantages of a PID conh·oller. The simplicity of a PID 
controller reduces significantly the requirement from computational resources for a closed-
loop anaesthesia system. 
Fuzzy control, neural network control and adaptive control have also been used in closed-loop 
anaesthesia control. However a large database has to be built before it could be used for 
closed-loop anaesthesia investigation using fuzzy logic control, while adaptive control and 
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neural network control have much slower response speed with heavy demand on 
computational capability. 
3.2.7.2.PID Control Law 
As suggested by its name, PID control consists of three control actions: proportional control, 
integral control, and derivative control, Kp, K;, and K,1 are known as the gains of these control 
actions, respectively. The PID controller acts on an error signal e(t), the proportional control 
simply multiplies the error with a constant; the integral control multiplies the integral of the 
error signal, or the accumulated error; whereas the derivative control multiplies the time 
derivative of the error signal, or the rate of change of the dynamic error. The integral control 
is introduced in the PID controller for reducing the steady state error, while the derivative 
control is to provide an anticipatory action to suppress the overshoots or undershoots in the 
response. Various type of PID control can be seen in industry or other areas, however, PI 
(proportional integral), PD (proportional derivative), and PID are the most commonly used 
PID type controllers. 
The PID control law and its s-domain transfer function are shown in (3-16) and (3-17). 
e(t) u(t) 
---+--.J Ki Is t---~ f-------
e(s) u(s) 
Kd s !---____/ 
Figure 3-15 A continuous PID controller 
u(t) = K e(t) + K r e(t)dt + K de(t) 
p I .L d df (3-16) 
(3-17) 
In order to obtain the pulse transfer function for the discrete time controller, we can discretize 
the equation (3-16). The integration term in (3-16) can be approximated using trapezoidal 
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integration shown in equation (3-14) and Figure 3-10, while the derivative term can be 
discretized by a two- point difference as shown in (3-18) and (3-19): 
~T e~D-~k-1)D 
u(kT) = K Pe(kT) + K; L-. -[e((n-1)T) + e(nT)] + Kd (3-18) 
PI 2 T 
The z-transforrnation on (3-18) gives 
(3-19) 
Hence the discrete time PID controller pulse transfer function is 
H (z)=K +K. T l+z-' +K 1-z-' 
c P '21-z-1 d T (3-20) 
From the continuous time transfer function ofPID controller in equation (3-17), we know PID 
controller is a special case of a phase Jag-lead controller. In fact, if we cascade a simple phase 
Jag compensator K1( I +sT1 ), which is basically a PD controller, and a simple phase lead 
compensator K2(1+-1- ), which is a PI controller, we obtain a phase Jag-lead compensator 
sT2 
having the following transfer function 
~ This has the same transfer function as the PID controller, here K P = K 1 K 2 (1 + -), 
Tz 
As a phase lead compensator, the PD control action affects the high frequency region, 
increases the phase lead angle and improves system stability as well as increasing the system 
bandwidth (and thus improving the transient response). As a phase Jag compensator, the PT 
control action affects the low frequency portion, increases the low frequency gain and 
improves steady state accuracy. The PID control action is a combination of the PI and PD 
control actions. 
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3.3. Higher Order Spectra 
3.3.1. Introduction 
Spectral analysis has been widely used in digital signal processing to extract important 
information that is "hidden" in the digital signal or data series. One of the most fundamental 
and useful tools for this purpose has been the estimation of the power spectrum of discrete-
time detem1inistic and stochastic processes. In power spectrum estimation, the process under 
analysis is assumed as a superposition of statistically unrelated harmonic components and the 
distribution of power among these frequency components is then estimated. However, power 
spectral analysis investigates only the linear relationship between the frequency components 
and suppresses their phase relations. 
The power spectrum provides the statistical description of a Gaussian process of known mean. 
In real world, it is common for a practical process, such as EEG signal, to deviate from 
Gaussianness or normality and to contain non-linearities, and this "hidden" information is 
extractable from estimating higher order spectrum such as bispectrum. 
Higher order spectra are defined in terms of higher order cumulants of a process. Suppose 
{X(k)} is a real stationary random process with zero mean (i.e., E {X(k)} =0), the Nth-order 
spectrum C(w1, w2 , ... ,w N-I) of the process {X(k)} is defined as the Fourier transform of its 
+<X> +<X> 
C(,,, '·' ,,, ) " "c (r r r )e-j(co,r,+ ... +mN_,r N-al 
'""1>'""2'""''""N-I = L..J"' L..J N I, 2, ... , N-1 (3-21) 
An important property for higher order spectra is that all higher order ( N ~ 3) spectra are zero 
for a stationary Gaussian process. 
Power spectrum and bispectrum are both the members of higher order spectra. By definitions, 
power spectrum is the second order spectrum while bispectrum is the third order spectrum. 
3.3.2. Power Spectrum 
Power spectrum has been used in a wide range of application areas such as bioengineering 
and telecommunication. If x(k) is a real, discrete, and zero-mean stationary random process, 
the autocorrelation sequence r(r) and power spectrum P(w) of this process are defined as 
r(r) = E{x(k)x(k + r)} (3-22) 
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-too 
P(w)= Lr(r)e-Jmr, (3-23) 
f=-<t) 
where E denotes expectation. Equation (3-23) demonstrates that power spectrum is a special 
member of higher order spectra with N=2 as shown in (3-24) 
-too 
C(wl)= Lc2(rl)e-Jm,r, (3-24) 
rl=-oo 
Power spectrum characterises the power distribution of the process x(k) over its frequency 
components, and all non-linear characteristics within this process is suppressed during the 
power spectrum estimation. 
Consider the following processes (Nikias and Raghuveer, 1987) 
(3-25) 
(3-26) 
where ~ = A1 + A2 (which means A1, A2 , A3 are harmonically related), and tp1, tp2 , tp3 are 
independent random variables uniformly distributed within [0, 21r]. In (3-25), 1..3 is an 
independent harmonic component because c/>3 is an independent random phase variable, 
whereas in (3-26) it is a result of phase coupling between ~ and ~. The power spectrum of 
x1 (k) and x2 (k) are demonstrated in Figure 3-16. 
Figure 3-16 Power spectrum of processes x1 (k) (without phase coupling) and x2 (k) (with 
quadratic phase coupling) shown in (3-25) and (3-26) 
61 of220 
3.3.3. Bispectrum 
Bispectrum, like power spectrum, is a special member of higher order spectra with N=3. If 
x(k) is a real, discrete, and zero-mean stationary random process, the bispectrum B(ml> m2 ) 
of this process is defined as 
(3-27) 
m;:;;---«> n=--oo 
where R(m, n) is the third order moment or cumulant sequence of x(k), and is defined as 
R(m,n) = E{x(k)x(k + m)x(k + n)} (3-28) 
From the definition ofbispectrum in (3-27) and (3-28), the following properties ofbispectmm 
can be identified 
• B(m1 ,m2 ) is periodic with a period of 2~r, i.e., B(m1 ,m2 ) = B(m1 + 2~r,m2 + 2~r) 
These properties indicate that the bispectmm in the triangular region of m2 ;o: 0, m1 ;o: m2 , and 
m1 + m2 ~ 1r (within region [ in Figure 3-17) is enough to completely describe the bispectrum 
of a process. 
Figure 3-17 The symmetry property ofbispectrum 
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For example, because of quadratic non-linearity, phase coupling between two frequency 
components of a process will have a contribution to the power at the frequency which is equal 
to their sum. Such phase coupling affects the third order cumulant or moment sequence and 
therefore bispectrum can be used to detect and characterise the non-linearity in the process. 
In the previous example processes defined in (3-25) and (3-26), the power spectral analysis 
regarded the both processes to carry the same information and failed to detect the quadratic 
phase coupling in the process x2 (k). However, the bispectrum analysis on the same processes 
reveals successfully the non-linearity contained in the process x2 (k). As shown in Figure 
3-18, the bispectrum of x1(k) is zero whereas that of x2 (k) shows an impulse at m,=A.r-and 
m;=),2 (if A.e: A.2) within the triangular region defined by m2 <:: 0, m1 <:: m2 , and m1 + m2 :<> n . 
Figure 3-18 Bispectrum of processes x1 (k) (without phase coupling) and x2 (k)(with 
quadratic phase coupling) shown in (3-25) and (3-26) 
This example has well demonstrated the capability of bispectrum in detecting and 
characterising the non-linearity of a system that has lead to its application in many areas 
including the analysis of EEG signal. 
3.3.4. EEG Application 
As introduced in Section 2.2.3, the EEG signal is a waveform representing the electrical 
activity of the brain. In particular, the bioelectrical activity of millions of neurons in the brain 
contributes to the information of an EEG signal with very complex non-linear dynamics. 
Embedded in that signal is information regarding frequency, amplitude and phase interactions 
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which change as the neuronal firing patterns change. As a result, the properties of the EEG 
may be significantly altered by anaesthetics, neuroactive drugs, hypothermia, and other 
physiologic changes that affect cerebral function. Hence the assessment of a patient's brain 
state during surgery has long been an objective of research in the field of EEG analysis. 
Like any other signals, the EEG signal can be broken down into a set of sine wave 
components such that when the components are combined together, the original signal is 
recovered. Traditionally, power spectral analysis is used to decompose the EEG signal and 
obtain the amplitudes or power of the sine wave components. A set of EEG-derived power 
spectral variables have been used to identify the anaesthetic states, such as median frequency 
(MF) and spectral edge frequency (SEF). 
However, as introduced previously, by using power spectral analysis on the EEG signal, one 
is implicitly making assumption that each sine wave component of the EEG waveform is 
independent and there are no relationships between the sine wave components. This is not 
true as almost all biological system, including the brain, exhibit non-linear behaviour and 
inter-component relationships are typically present in the signals generated by such non-linear 
systems. Therefore, an analysis teclmique that can detect and quantify non-linear changes of 
the EEG signal is needed to obtain a better estimation on anaesthetic states, and among them 
is the bispectral analysis. 
3.3.4.1.Median Frequency 
Median frequency is defined as the frequency below which it lies half of the power in the 
EEG wavefom1. By applying Fourier transformation on the EEG waveform, the contribution 
from each sine wave component to the total power of the EEG waveform can be easily 
calculated, and then the median frequency can be determined. 
Median frequency has been evaluated extensively by Schwilden, Schuttler and colleagues. 
They found (Schwilden, Stoeckel and Schuttler, 1989) by clinical experiments that during 
pre-anaesthetic base-line conditions, median frequency centred around I OHz, while during 
anaesthesia its contribution was confined to below 5Hz, and after the patients had responded 
to verbal commands in the recovery period, the median frequency stayed above 6Hz. Based 
on their findings, they concluded that median frequency of below 5Hz should be maintained 
when aiming at non-responsiveness to verbal commands during anaesthesia, and that the 
optimal range of median frequency is 2-4Hz to achieve a probability of 5% or less for the 
occurrence of signs of undue anaesthesia. They have implemented an adaptive closed-loop 
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system usmg median frequency feedback with the target median frequency of 2-3Hz 
(Schwilden, Schuttler and Stoeckel, 1987), and a number of clinical experiments have been 
done with the system using different drugs (Schwilden, Schuttler and Stoeckel, 1987; 
Schwilden, Stoeckel and Schuttler, 1989; Schwilden and Stoeckel, 1993; Schuttler et al., 
1995). It is reported that median frequency of 2-3Hz offers a level of anaesthesia sufficient to 
ensure unconsciousness (Schwilden, Schuttler and Stoeckel, 1987). However, to achieve this 
target, they had to stimulate the subjects every 1.5 minutes with six different acoustic and 
tactile stimuli so that higher drug concentration could be maintained with the same median 
frequency target. Another deficiency in using median frequency is that it is greatly affected by 
filtering and in particular, by the high-pass filter frequency. Furthermore, it is reported that 
there was no recorded value for median frequency that was 100% specific for 
unconsciousness and it is poorly correlated with blood concentration ofpropofol (Gajraj et al., 
1998). 
3.3.4.2.Auditory Evoked Response 
As stated in (Thomton and Newton, 1989): The auditory evoked response is the response in 
the EEG to a sound stimulus. It is extracted from the EEG by computer averaging, and 
consists of a series of waves representing the passage of electrical activity along the auditory 
pathway from the cochlea through the brain-stem to cortex. The auditory evoked response has 
three phases which are brain-stem response, early cortical response and late cortical response. 
Although AER is useful for assessing the depth of anaesthesia, which AER parameter is the 
best measure of the DOA remains controversial. The Kenny group (1992) uses an AER index, 
called LAS (level of arousal score), as the measure of the DOA in their CLAN system. They 
found that LAS appears to distinguish the awake from asleep state (Doi et al., 1997), to give 
more consistent values when using different anaesthetic agents (Schraag et al., 1998), and that 
LAS is the best index, in comparison with BIS, MF and SEF95, to distinguish the transitions 
from consciousness to unconsciousness (Gajraj et al., 1998). While Kenny et al choose LAS 
which is associated with the brain-stem response and late cortical response to measure the 
DOA, Roy et a! (1997), in their automatic feedback controlled propofol infusion system, use 
MLAEP (mid-latency auditory evoked potentials) which consists of the waves during 10-
60ms of AER and is also known as early cortical response to derive the DOA through wavelet 
analysis and neural network training, Webb et a! (1996) use the variations ofNb latencies in 
the early cortical response to assess the DOA. 
Although AER is the best indicator of the transition from consciousness to unconsciousness, it 
does not correlate with the blood concentration of propofol during the emergence from 
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anaesthesia (Doi et al., 1997) and the patients have to wear headphones during surgery to 
receive the sound stimuli. Occasionally muscle responses will be evoked by the stimuli and 
cannot be removed by the computer averaging {Thomton and Newton, 1989). Nb wave was 
found to be able to characterize the transition from responsive to unresponsive, however it is 
not consistent with all patients (Stanski, 1994). 
3.3.4.3.Bispectrallndex 
Clinicians administering anaesthetics and sedatives need to manage the hypnotic state of their 
patients, and patients undergoing surgery or intensive therapy require an adequate level of 
hypnosis to protect them from stress, awareness and recall of traumatic interventions. 
However, it is not currently possible to directly measure the hypnotic states. In clinical 
practice, an indirect assessment of hypnotic states is performed by observing physical signs 
and responsiveness to voice or touch at a lighter level of anaesthesia. Ideally, the hypnotic 
states should be assessed subjectively and automatically without introducing any stimulation. 
Potentially, this may provide better patient care. Bispectral Index or BIS, which describes the 
hypnotic states based on the bispectral analysis of EEG signal, has recently been developed 
by Aspect Medical Systems. 
Bispectral analysis was initially used by Bamett et al ( 1971) and Dummermuth et al (1971) to 
study the EEG's inter-frequency coupling in a number of anaesthetic states including waking 
and sleeping. However, little progress was made due to the heavy computational requirements 
from this analysis. More recently, with the advent of high speed and low cost computing, the 
research of bispectral analysis on EEG signal has become active. Such research includes the 
evaluation of the non-linear relationships in the EEG from multiple recording sites (Saltzberg 
et al, 1986), the assessment of anaesthetic adequacy (Billard et al, 1994; Leslie et al, 1995; 
Liu, Singh and White, 1996). 
While power spectral analysis suppresses the inter-frequency relationship, bispectral analysis 
measures the potential interactions between the wave components to determine whether 
dependent or harmonic components are present. As shown in Figure 3-18, the bispectrum 
quantifies the degree of phase coupling between every possible frequency pair combination 
and the frequency at their sum in order to detem1ine if the component waves are harmonics or 
fundamentals. 
The task of extracting clinically useful information from the bispectrum is to determine how 
changes in the bispectrum relates to changes in the EEG signal during the periods of altered 
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cerebral function, such as the administration of anaesthetics and neuroactive drugs. Visually, 
certain general patterns in the raw EEG signal have been recognised during anaesthesia when 
anaesthetic doses are increased. It has been noted that the EEG signal slows down and appears 
to become more synchronised. Power spectral analysis provides some identification of the 
"slow down" via increased delta frequency content. Bispectral analysis also trends these 
changes, but provides a measure of synchronisation via the degree of phase-coupling as well. 
The Bispectral Index was generated from both power spectral analysis and bispectral analysis 
using a sophisticated proprietary algorithm. It is a composite, numerical index which tracks 
changes in the cerebral state and quantifies the overall bispectral properties (frequency, power 
and phase) throughout the entire frequency range (Table 2-1). 
BIS is a real-time variable with values ranging from 0 to 100 showing hypnotic states or 
sedation levels. The bigger the value of the Bispectral Index, the lighter the depth of 
anaesthesia. Figure 3-19 shows a typical BIS trend in a volunteer study, in which the closed-
loop controlled propofol infusion lasted 55 minutes. 
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Figure 3-19 Typical BIS trend in a volunteer study 
Before the calculation of BIS, the EEG segments with artefacts and suppressed EEG are 
identified and rejected, thereafter the index is calculated by combining the EEG features 
selected from a set of candidate bispectral and power spectral variables. The power spectral 
variables are used to extract the information hidden in the power of each sine wave 
component, while the bispectral variable is used to characterise the degree of phase coupling 
between the frequency components (Aspect Medical Systems, 1995). 
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The bispectral index has been prospectively validated with a large clinical database. Different 
versions of the bispectral index exist and data produced with one version of BIS are not 
necessarily compatible with those produced with another. The early versions of BJS were 
evaluated using prediction of movement to skin incision at the beginning of a surgical 
procedure. Although the early versions of BIS have demonstrated to be a good predictor of 
movement response to skin incision (Kearse et al., 1994a; Vemon et al., 1995) and 
hemodynamic response to intubation (Kearse et al., 1994b) for the specific drug regimens, it 
is not a good predictor of movement across some conunonly used drug combinations that 
include the use of varying doses of opioids. The available version of BIS algorithm (version 
3.12) at the time of this project provides a measure of the effects of anaesthetics and other 
pharmacological agents on the hypnotic state of the brain (Kearse et al., 1995; Liu, Singh and 
White, 1996; Pearson et al., 1996). It was reported that the BIS both correlated well with the 
level of responsiveness and provided an excellent prediction of the loss of consciousness 
(Glass et al., 1997), and that BJS is linearly correlated with the blood concentration of 
propofol (Leslie et al., 1995; Doi et al., 1997) and the magnitude of the cerebral metabolic 
reduction caused by propofol and isoflurane anaesthesia which suggests that a physiologic 
link exists between the EEG and cerebral metabolism during anaesthesia that is 
mathematically quantifiable (Aikire, 1998). 
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4. A Mathematical Model of Closed-loop Controlled Anaesthesia 
4. 1. Introduction 
The development of the closed-loop anaesthesia (CLAN) control system includes system 
model development, test of the model, and the implementation of the physical system with 
hardware and software components. Modelling of the system before the design and 
implementation of the physical system has great advantage. A model provides an efficient 
way to investigate the closed-loop anaesthesia control with a wide range of control strategies. 
The problems associated with the closed-loop anaesthesia control (e.g. patient variability, 
drug interaction) can also be investigated with the model, which would significantly improve 
the reliability of the implemented system and patient safety. 
4.1.1. Feedback Signals 
For any closed-loop control system, a feedback signal that measures the desired effect of the 
control action is required. In a closed-loop anaesthesia system, the feedback signal is the 
depth of anaesthesia in patients. The choice of such feedback signal however is currently 
controversial due to the lack of a unifying definition for the depth of anaesthesia (Ogata, 
1987). The anaesthetic state is a complex function of unconsciousness, amnesia, analgesia, 
motionlessness, and autonomic stability. Although it is not yet possible to quantify the 
complete anaesthetic state when numerous drugs are used in operating theatres, meaningful 
feedback signals are available for some components of the anaesthetic state (e.g., muscle 
relaxation, hemodynamics, sedation). Currently median frequency, auditory evoked response 
and Bispectral Index are the feedback signals used in closed-loop anaesthesia systems for 
sedation control. 
In comparison with other commonly used DOA indicators, the Bispectral Index has the best 
correlation with the calculated blood propofol concentration (Doi et al., 1997), the best 
correlation with the magnitude of the cerebral metabolic reduction (Alkire, 1998) and is 
considered as the best indicator of DOA (Smith, Dutton and Smith, 1996). Therefore BIS is 
selected as the measure of depth of anaesthesia and therefore the feedback signal of the 
closed-loop anaesthesia system. 
4.1.2. Control Strategy 
The controlled object in closed-loop anaesthesia control is the depth of anaesthesia or DOA in 
patients. The complex and varying dose-effect relationship in individual patients during drug 
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infusion and the lack of a 'gold standard' in anaesthesia monitoring make the DOA control 
difficult. 
As introduced in Chapter 2, the dynamics of drug disposition in the human body is quite 
complex after a certain amount of drug has been infused, and the mathematical modelling of 
those dynamics are far from perfect. Some factors affecting the dose-effect relationship, such 
as health condition and drug history of patients, are not modelled or unknown; these cause 
variability among patients and even within a single patient being anaesthetised. On the other 
hand, significant non-linearity exists in all existing anaesthetic depth descriptors though their 
trends could linearly correlates with the drug effect, such as Bispectral Index. The control 
signal is also non-linear due to the fact that it is impossible to take any infused drug out of a 
patient. Another problem in closed-loop anaesthesia control is the drug effect hysteresis that 
varies from one patient to another. 
Since a closed-loop anaesthesia system could potentially be used with patients in the 
operating theatre during surgery, it is essential that such a system is able to respond quickly to 
any inadequate anaesthesia caused by stimulation while ensuring the safety of patients. A Pill 
controller is therefore a good choice for its quick response and less computational complexity. 
Target Controlled Infusion (TCI) has achieved significant success in clinical practice. Though 
TCI is an open-loop control scheme, the target drug concentration for individual patient is 
actually adjusted by an anaesthetist in practice, and this adjustment is based upon the depth of 
anaesthesia monitoring and the anaesthetist's experience. To take advantage of the TCI 
technology, a TCI component is to be used in the closed-loop anaesthesia system to drive 
directly an infusion pump, while the PID controller acts like the anaesthetist to adjust the 
target drug concentration of the TCI component. 
One of the major advantages of using a TCI system in the closed-loop anaesthesia system is 
that patient safety could be further ensured when the closed-loop control system malfunctions 
or the feedback signal is not available or bad in quality. In these circumstances, the closed-
loop control can be easily switched to open-loop TCI control, and switched back after the 
problem has been resolved. 
Due to the existence of non-linearity and unknown dynamics in the closed-loop anaesthesia 
system, a system control unit is introduced to monitor and modify the behaviour of the PID 
controller and the infusion rate given by the TCI. This unit also contains digital signal 
processing and improves the level of confidence on patient safety in the use of closed-loop 
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anaesthesia system. 
4.1.3. System Block Diagram 
Based on the above discussions, the block diagram of the proposed closed-loop anaesthesia 
(CLAN) control system is shown in Figure 4-1. 
Analgesic :·· ·T·cl·(~~~·j~~~;·~) ....................................................... , h 
_T_a_rg_e_t --.. •: I PK Model I .., [nfusion Rate j;-! ----------, 
: ................................................................... ~.~~~.~.~.~.?~ ..... .J 
Concentration-Effect 
Relationship 
................................................... 
: TCI (hypnotic) : 
Generator 
L...__ _ H_y_p_n_o_ti_c_e_ffi_e_ct_~..._----l EEG Monitor 14----E_E_G ___ _J 
Figure 4-1 The Block diagram of the closed-loop anaesthesia system to be investigated and 
evaluated on human subjects 
For the system shown in Figure 4-1 , two drugs can be infused simultaneously to achieve total 
intravenous anaesthesia. One is an analgesic agent controlled by a dedicated TCI component 
through the open-loop path, and the other drug is a hypnotic agent controlled by a feedback 
system through the closed-loop path with incorporation of another TCI component. In the 
open-loop path, an anaesthetist adjusts manually the target analgesic concentration, whereas it 
is the target controller that adjusts automatically the target hypnotic concentration ( Cr) of the 
associated TCI component in the closed-loop path. The TCI then generates a drug infusion 
rate (11) at which the drug is to be infused intravenously into patient. The closed-loop system 
starts the drug infusion with a bolus that is calculated by the TCI component from the DOA 
target using the relationship between drug concentration and drug effect. The supervision 
system is a central control and digital signal processing unit monitoring the quality of 
feedback signal, the error signal, the infusion rate generated, and the safety of patient. When 
the absence of quality feedback signal is persistent, for example, the supervision system 
would switch the closed-loop control to open-loop TCI control. 
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A mathematical model of the CLAN system shown in Figure 4-1 has been developed for the 
CLAN investigations on virtual patients. This model, as shown in Figure 4-2, consists of a 
pharmacokinetic model, a pharmacodynamic model which models the EEG monitor in the 
CLAN system, a patient model, a PID controller, a target generator, and an infusion rate 
generator. 
. .................................................. . 
~ TCI (hypnoti c)~ 
0 0 
H 0 ~ ypnohc 
. I PKr~el I . 
r························ · ······························· · ················~C : Ir 
i PID u Target l Ti Infusion Rat"1---41~ Patient 
Generator j ' Generator Model 
Target 
(BIS) 
... ....................... ··········· ......... . T.~rg~~- ~~~~-~~J~.!.~ ................. ~ 
Hypnotic effect (BIS) PD Model Concentration 
Figure 4-2 The mathematical model of the closed-loop path ofthe system shown in Figure 4-1 
The PK model and PD model in Figure 4-2 are reference models with population average 
parameter values, while the patient model is an independent pharmacokinetic model with 
patient specific parameter values to be defined in Section 4.4. 
4.2. Pharmacokinetic Model 
As described in Chapter 2, pharmacokinetics characterizes the dose-concentration relationship 
following a bolus infusion, and a pharmacokinetic model is a mathematical representation of 
this relationship. The drug distribution process in human body could be described with a 
hydraulic-like multi-compartment model as shown in Figure 2-3 and Figure 2-4. In this 
project, the three-compartment pharmacokinetic model with additional effect site 
compartment as shown in Figure 2-4 is adopted because it is widely used in clinical research 
for its simplicity with sufficient precision and computational efficiency. The mathematical 
representation of the pharmacokinetic model as shown in Figure 2-4 will be derived by 
constructing the dose-plasma concentration relationship and dose-effect site concentration 
relationship. For convenience, the pharmacokinetic model as shown in Figure 2-4 is 
reproduced in Figure 4-3. 
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Rapid Peripheral ~ Infusion Rate 
Comp:t2 ~ lilt) 
Slow Peripheral 
Compartment 3 
(V3) 
kl2~ Plasma 
CPcALc(t) 
(VI) 
!kiD 
Elimination 
k1e Effect Site keo 
CeaLcit) Elimination 
(V4) 
Figure 4-3 Three-compartment pharmacokinetic and one effect site compartment modelling 
for intravenous drug infusion 
where kij is drug transfer rate between plasma and rapid/slow compartments, keo is elimination 
rate of drug from effect site to environment; k1e is drug transfer rate from plasma to effect site; 
V; is volume of individual compartment with V4 negligible; /(t) is drug infusion rate over time; 
CpcALc{t) is predicted plasma concentration; CecALc{t) is predicted effect site concentration. 
[n Figure 4-3, the change of concentration in the central compartment at any time is related to 
the drug transfen·ed to and from the peripheral compartments, and the drug eliminated from 
and infused into the central compartment at that time. Similarly, the change of concentration 
in a peripheral compartment is associated with the drug transferred to and from the central 
compartment at any time. Hence the pharmacokinetic model can be characterized by the 
following differential equations: 
where CJ(t), Cl(t) , C3(t) are the drug concentrations (ng·m.f1) at time 111 the central 
compartment, rapid and slow equilibration compartments, respectively. 
By applying the Laplace transform, the differential equations become 
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Solving for CJ(s) and replacing it with CpcALc(s), gives 
where 
ao = kiOkz,kJI 
G1 = k10k21 + k10k31 + k12 k31 + k13k21 + k31 k21 
Gz = kiD + k,z + kz, + k,J + kJ, 
a 3 = 1 
b0 = k21 k31 V,-' 
b, = k2 , +k3,v,-' 
b - v.-1 
2- I 
Applying Laplace transform on (2-2) 
(4-7) 
(4-8) 
(4-9) 
where Dp(s) is the Laplace transformation of Dp(t) or the transfer function of the drug 
disposition dynamic system. Solving equations ( 4-7) and ( 4-9) for Dp(s): 
(4-10) 
Suppose a, {3, and y are the roots of the characteristic equation (polynomial denominator) in 
( 4-1 0), then Dp(s) can be rewritten as: 
( 4-11) 
or 
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D (s)=~+~+~ 
P s+a s+fJ s+y 
where A 1, A2, and A3 can be solved from equation ( 4-11) and ( 4-12) 
A _ b2a
2 
-b1a+b0 
1 
- ({J - a )(y - a) 
A - b2{J2 -b,{J+bo 
2 - (a- fJ)(y- fJ) 
A - b2y2 -b,y+bo 
J - (a- y)({J- y) 
( 4-12) 
(4-13) 
The drug disposition function Dp(t) as presented in equation (2-3) can be obtained by taking 
reverse Laplace transform on Equation (4-12): 
(4-14) 
On the contrary, the volume in central compartment (V1) and rate constants in a compartment 
model can be derived from the parameters of the corresponding mathematical model (i.e., A1, 
A2, A3 and a, /3, f?. 
Rewrite ( 4-11) as following 
where 
c0 = a{Jy 
c1 = af3 + fJr + ya 
c2 =a+ fJ +r 
c3 = 1 
d0 = A1f3y + A2ya + A3af3 
d, =A,(f3+r)+A2 (y+a)+A3 (a+fJ) 
d 2 = A1 + A2 + A3 
( 4-15) 
(4-16) 
Equations ( 4-1 0) and ( 4-15) should be identical, therefore for ( 4-8) and ( 4-16), the followings 
are true 
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i = 0,1,2,3 
j = 0,1,2 (4-17) 
Finally, the central compartment volume V1 and the rate constants (k10, k12, k13, k21 , k31}can be 
solved from equation (4-17). 
Now, the dose-concentration relationship in plasma has been constructed. However, to model 
the dose-concentration relationship at the effect site, the relationship between the plasma 
concentration and the-concentration at the site of drug action needs to be built. 
To calculate the-effect site drug concentration, another differential equation is identified: 
dCeCALC (t) 
-==..:...:.. =kleCpCALC(t)- keOCeCALC(t) 
dt 
Applying Laplace transform to equation (4-18): 
( 4-18) 
( 4-19) 
Considering that k1e and keo are equal in value because of the negligible volume of the effect 
site compartment, then 
(4-20) 
or 
(4-21) 
where Dc(s) is the transfer function. From equations (4-20) and (4-21), the drug disposition 
function from plasma to the effect site-(D,;(t)) and the effect site drug concentration (CecALc(t)) 
can be described by the following equations. 
D (t)=k e-k,rJ e eO (4-22) 
(4-23) 
This drug transfer process-can be represented by a dynamic system shown in Figure 4-4. 
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De(t) 
Figure 4-4 Drug disposition dynamic system of effect site 
The complete dose-effect site concentration relationship can then be obtained by combining 
equation (4-10) and (4-21), and described by the following system: 
l(t) CecALc(t) 
.. 
Figure 4-5 Drug disposition dynamic system (dose-concentration relationship) 
where J(t) is the infusion rate over time, CecALc(t) is the effect site drug concentration over 
time, and Hp(s) is the transfer function of this dynamic system in Laplace domain defined by 
the following expression: 
(4-24) 
So far, the effect site concentration can be estimated from the dose of the drug infused, and 
( 4-1 0) and (4-24) define the generic mathematical expression of the transfer function of drug 
disposition in plasma and effect site. Different sets of parameters are associated with different 
patients. A TCI module of the closed-loop anaesthesia system uses a set of population average 
parameters, whereas the patient models to be presented later use a wide range of paran1eter 
sets in the investigations. 
4.3. Pharmacodynamic Model 
Pharmacodynamics characterizes the relationship between drug concentration at site of action 
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and the intensity of biological effect, (i.e., the concentration-effect relationship). This 
relationship, in pharmacology, is described by a sigmoid model (Holford and Sheiner, 1981) 
shown in Figure 2-5, and the mathematical expression of this relationship is presented in (2-
4). However, if a descriptor, like Bispectral Index, represents a deeper anaesthetic depth with 
a smaller value, the corresponding sigmoid model and its mathematical expression are 
different from those presented previously. These are shown in Figure 4-6 and equation (4-25). 
er 
E = Eo. (1 - r ) - Emax 
C +Cr 0 
( 4-25) 
100 Eo 
80 
-u Cl) 60 ffi y = 7 Cl 40 :J y=3 ... 
c / 20 
Emax Co 
0 
0 1 2 3 4 5 
Drug Concentration 
Figure 4-6 Pharmacodynamic sigmoid model for drug effect descriptors like Bispectral Index 
(Eo : baseline effect, Emax : max effect, Co : drug concentration to achieve 50% of effect) 
The pharmacodynamic sigmoid model represented by equation (4-25) generally deftnes the 
shape of the sigmoid curve. However, different patients may have their own models 
characterized by a set of pharmacodynamic parameters (i.e. , Eo, Emax, Co, and J1. Figure 4-6 
shows three versions of the model with varying y values (J=3, 7, 11). 
The sigmoid model is mathematically complex, especially when r is not an integer. However 
the dose-effect relationship for some drugs might be roughly linear, for example, dose-BIS 
effect (Doi et al. , 1997; Leslie et al. , 1995), in which case a linear approximation of the 
sigmoid model could exist and has the following forms depending upon the definition of the 
anaesthetic depth descriptor. 
E = kxC 
or if smaller descriptor value represents a deeper depth of anaesthesia 
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(4-26) 
E=-kxC+b (4-27) 
where k is the slope of the relationship line, and b is the baseline value of the drug effect. Doi 
et al (1997) derived, by linear regression on the data obtained from a group of patients, a 
simple linear relationship equation for concentration-BIS effect in their clinical study. This 
relationship is shown in equation (4-28). 
BJS(k) = - 12.837 x C(k) + 93.582 
BIS(z) = -12.837C(z) + 93 ·582z 
z -1 
( 4-28) 
(4-29) 
where BJS is the Bispectral Index, and C is the steady -state drug concentration in plasma. 
Steady state is a state in which the drug concentrations in plasma and at effect site equilibrate, 
and this meets the requirement of the concentration-effect relationship. The pharmacodynamic 
sigmoid model for BIS effect for patients who have concentration-effect relationship 
described by the equation ( 4-28) can be reconstructed and is shown in Figure 4-7 where the 
thick line is the approximation of the sigmoid curve. 
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BIS=-21.7C+ 125.9 
10 Co 
0 ~------~------~------~----~---~----~ 
0 2 4 
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6 
Concentration 
8 10 
Figure 4-7 Pharmacodynamic sigmoid models for BIS-Propofol concentration relationship 
In Figure 4-7, they axis is drug effect or Bispectral Index (BIS), the x axis is steady state or 
effect site drug concentration (C), BIS0 is baseline BIS effect (B1So=93.582), BISmax is 
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maximum BIS effect (BISmax=O), Co is effect site drug concentration when 50% of drug effect 
has been achieved, and y is the steepness of the relationship curve (F3 in this case). 
The pharmacodynamic model represented by equation (4-28) is used for the test of 
pharmacokinetic variability in patients, whereas other two pharmacodynamic models are to be 
used as variations for the test of pharmacodynamic variability in patients. These two models 
have the following mathematical representations as shown in Figure 4-7. 
BIS(k) = -21.7.C(k) + 125.9 (1.2~C~5.8) (4-30) 
BIS(k) = -7.02.C(k) +59 (O~C~8.4) ( 4-31) 
For above two arbitrarily selected pharmacodynamic models, the HIS-Concentration 
relationship is only valid within the specified range of drug concentration. The reason to 
choose these two linear models is based upon the fact that, for most patients in general 
anaesthesia, the propofol drug concentration would likely fall within 2-6 mcg/ml for the 
majority period of drug administration time, and the linear models shown in equation (4-30) 
and ( 4-31) approximately represent the BIS-Concentration relationship when propofol drug 
concentration C is 2-4 mcg/ml or around 6 mcg/ml. The slopes of the two linear models may 
change when the steepness of the sigmoid curve (y) varies. 
4.4. Patient Model 
Now it is clear that the drug distribution of a patient can be described by a set of 
pharmacokinetic/dynamic parameters, that is to say that a patient could be modelled by 
specifying these parameters. However, it is not known which pharmacokinetic/dynamic 
parameter sets are the extremes in the whole population of patients, with which the patients 
need the most or least drug to achieve a certain level of anaesthesia than the others. 
To investigate patient variability, the pharmacokinetic parameters obtained by Gepts et al 
(1987) and the pharmacodynamic parameters by Doi et at (1997) are used to model the 
patients for testing the mathematical model and the closed-loop anaesthesia system to be 
developed. The pharmacokinetic parameters are summarised in Table 4-1. The table also 
gives the upper and lower 95% confidence interval (Cl) calculated from the mean and the 
standard deviation. The data from Table 4-1 are used to model a range of hypothetical patients 
and the TCI component of the closed-loop anaesthesia system. 
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Table 4-1 Mean, standard deviation (SD) and 95% confidence intervals (Cl) of 
pharmacokinetic rate constants and central compartment volume, Gepts et ai (1987) 
Mean SD Upper 95% Cl Lower95% Cl 
k10(min"1) 0.119 0.0688 0.1357 0.1023 
kdmin"') 0.114 0.206 0.164 0.064 
k13(min-1) 0.0419 0.0304 0.0493 0.0345 
k21 (min"') 0.055 0.1094 0.0815 0.0285 
k31{min-1) 0.0033 0.0025 0.0039 0.0027 
V1{litre) 16.924 6.957 20.2 13.6 
The drug transfer rate constant ke0 is usually calculated from patient's weight and the drug 
effect peak time. The range of 1-2.4 minutes for propofol was reported from the latest 
research (Schnider et al., 1999) on the peak time of drug effect, therefore the peak time values 
of I minute and 2.4 minutes are used together with their mean value (1.7 minutes) for the 
patient models. For pharmacodynamic models of patients, the linear regression model 
presented in (4-28) is used as the population average model along with the linear models 
presented in (4-30) and (4-31). 
The drug effect peak times and the linear pharmacodynamic model parameters are 
summarized in Table 4-2. 
Table 4-2 Drug effect peak time and pharmacodynamic model parameters 
average high low 
1p (min) 1.7 2.4 I 
k -12.837 -21.7 -7.02 
b 93.582 125.9 59 
In the closed-loop anaesthesia system shown in Figure 4-1, a pharmacokinetic model is built 
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into the TCI component for hypnotic propofol infusion. This PK model acts as a standard 
reference model to estimate the drug concentration in patients, and a population average PK 
model, which is the mean value listed in Table 4-1 and listed separately in Table 4-3, is 
adopted for this purpose. The peak time (tp) of drug effect shown in Table 4-3 is the mean 
value obtained by Sclmider et al (1999). 
Table 4-3 Population average pharmacokinetic model parameters of the TCI component for 
propofol infusion in closed-loop anaesthesia system 
0.119 0.114 0.0419 0.055 0.0033 16.9 1.7 
For analgesic alfentanil infusion driven by another TCI component shown in Figure 4-1, the 
population average PK model in patients shown in Table 2-5 is used. The pharmacokinetic 
parameters of this model are reproduced in Table 4-4. 
Table 4-4 Population average pharmacokinetic parameters of the TCI component for 
alfentanil infusion in closed-loop anaesthesia system 
PK Parameters Value or Expressions 
KIO Age> 40yr (0.356- (0.00269. (Age- 40))) I V1 
(min-1) Age~Oyr 0.356N1 
K12 (min-1) 0.104 
K21 (min-1) 0.0673 
K13 (min-1) 0.017 
KJI Age> 40yr 0.0126- (0.000113 . (Age- 40)) 
(min-1) Age~Oyr 0.0126 
v. Men 0.111 . Weight (in kg) 
(litre) Women 0.111 . 1.15. Weight (in kg) 
tp(min) 1.376 
In both Table 4-3 and Table 4-4, drug effect peak time tp is used together with patient's 
weight for the calculation of k.0, the elimination rate of drug from effect site to environment. 
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Because alfentanil infusion is entirely controlled by TCl in open-loop due to lack of real time 
measure of drug effect, no other patient models are developed. 
For the investigation of closed-loop anaesthesia with pharmacokinetic variability on propofol 
infusion, 9 hypothetical patients (Patientl-Patient9) are modelled by using the data from 
Table 4-l and Table 4-2. The 9 hypothetical patients, shown in Table 4-5, are obtained from 
the combination of upper 95% Cl, lower 95% Cl, and the peak times. Patientl-3 have the 
mean pharmacokinetic rate constants but different peak times, Patient4-6 have the rate 
constants with the values of the lower 95% Cl and are associated with the same range of peak 
times, while the rate constants of Patients7-9 take the values of the upper 95% Cl. Under the 
linear assumption of the drug distribution process, Patients 1-9 would roughly represent the 
population studied by Gepts et al (1987). The parameters k and b are pharmacodynamic 
properties of the 9 patients. They are assumed to be constants with population average values 
for the investigation on pharmacokinetic variability. 
Table 4-5 PK/PD parameter set of hypothetical patients with pharmacokinetic variability 
Parameters Patient! I Patient2 I PatientJ Patient4 I PatientS I Patieot6 Patient? I PatientS I Patient9 
kw(min'1) 0.119 0.1023 0.1357 
k12(min-1) 0.114 0.064 0.164 
k13(min-1) 0.0419 0.0345 0.0493 
k21 (min-1) 0.055 0.0285 0.0815 
kJI(min-') 0.0033 0.0027 0.0039 
V1(litre) 16.9 
tp (min) 1.7 I 2.4 I 1.0 1.7 I 2.4 I 1.0 1.7 I 2.4 I 1.0 
k -12.837 
b 93.582 
It is worth noting that the pharmacokinetic parameters ofPatientl are the same as those in the 
TCl reference model, and this patient is therefore a reference patient to demonstrate the biased 
drug concentration responses from other patients. From the pharmacokinetic parameter values 
listed in Table 4-5, it is confirmed that the largest overshoot would occur in Patient6 due to 
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the smallest clearance rates (k10, k12, and k13) and shortest drug effect peak time (tp). and on 
the contrary the largest undershoot will be in PatientS who has the largest values in clearance 
rates and peak time. 
The hypothetical patients listed in Table 4-5 are used for the investigation of effect from 
pharmacokinetic variability on drug infusion. To investigate the characteristics of 
pharmacodynamic variability in intravenous drug infusion, another group of virtual patients 
(Patient10-Patient1S) are constructed using Patientl, Patient6, and PatientS together with 
varying pharmacodynamic model parameters listed in Table 4-2. This group of virtual 
patients is listed in Table 4-6. 
Table 4-6 PKIPD parameter set of hypothetical patients with pharmacodynamic variability 
Parameters PatientiO Patientll Patientl2 Patient13 Patientl4 Patientl5 Patientl6 Patientl7 Patient IS 
kw(min-1) 0.119 0.1023 0.1357 
kdmin-1) 0.114 0.064 0.164 
kn(min-1) 0.0419 0.0345 0.0493 
k21(min'') 0.055 0.0285 0.0815 
kJI(min-1) 0.0033 0.0027 0.0039 
V1(litre) 16.9 
!peak (min) 1.7 1.0 2.4 
k -12.837 -21.7 -7.02 -12.837 -21.7 -7.02 -12.837 -21.7 -7.02 
b 93.582 125.9 59 93.582 125.9 59 93.582 125.9 59 
Tto test the robustness of the closed-loop anaesthesia system, an extensive set of 7SI25 
hypothetical patients is modelled with the PK/PD parameters shown in Table 4-7. 
Table 4-7 Pharmacokinetic paran1eters used to model 7S125 hypothetical patients 
k 10(min- ) tpeak(min) V ,(litre) 
0.1023 0.064 0.0345 0.02S5 0.0027 1 13.6 
0.11065 O.OS9 0.03S2 0.04175 0.003 1.35 15.3 
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0.119 0.114 0.0419 0.055 0.0033 1.7 16.9 
0.12735 0.139 0.0456 0.06825 0.0036 2.05 18.5 
0.1357 0.164 0.0493 0.0815 0.0039 2.4 20.2 
The rate constants and the central compartment volumes (V 1) in Table 4-7 are obtained by 
interpolating the data listed in Table 4-l. The peak time values are interpolation values from 
the peak time range listed in Table 4-2. Suppose to take randomly one entry from each 
column in Table 4-7, there are 57 or 78125 permutations in total, and each of these 
pemmtations can be used to model a virtual patient. The robustness test of the closed-loop 
anaesthesia system is only on pharmacokinetic variability to reduce the number of 
hypothetical patients, and all these patients have the population average pharmacodynamic 
characteristics (see Table 4-5). 
4.5. Target Controller 
The target controller consists of a PID controller and a target generator as shown in Figure 
4-1. As introduced in Chapter 3, PID control is a simple and fast response control scheme in 
which the control signal consists of three tem1s namely proportional, integral, and derivative 
terms. The PID control law and its z-domain discrete transfer function are described m 
equations (3-16) and (3-20), and are reproduced in equations (4-32) and (4-33). 
f,T e(k)-e(k-1) 
u(k) = K Pe(k) + K; ~ -[e(n -1) + e(n)] + Kd ---'--.:...__-'------'-
n=l 2 T 
(4-32) 
H (z)=K +KTl+z-' +Kdl-z-' 
c P '21-z-1 T (4-33) 
where u(k) and e(k) are control signal and error signal at time t=kT, Hc(z) is the z-domain 
transfer function of the PID controller, T is the sampling period (see Section 6.2), and Kp, K; 
and Kd are the gains of the controller which are designed in Section 6.6. 
The PID controller modifies the target concentration of the TCI system in the target generator 
in the following way 
Cr (k) = Cr(k -1) + u(k) (4-34) 
The pulse transfer function is 
85 of220 
H ( ) _ Cr(z) _ 1 T z - -
ll(z) 1-z-• (4-35) 
If the measured BIS value is below the target BIS previously set, which indicates a deeper 
than desired anaesthesia, a negative control signal u(k) would be generated, and this would 
decrease the target propofol concentration for the TCI, otherwise a higher target concentration 
is to be generated to produce a deeper anaesthesia. 
4.6. Infusion Rate Generator 
The infusion rate generator within a TCI component gives the drug infusion rate to the two 
anaesthesia pumps for either a hypnotic agent or an analgesic agent. The infusion rate can be 
easily solved from equation (4-9) if plasma is the site of target, and from Figure 4-5 and 
equation (4-24) the infusion rate can be obtained when effect site is the site of target. The 
solutions are presented in (4-36) and (4-37). 
Infusion rate when targeting on plasma: 
(4-36) 
Infusion rate when targeting on effect site: 
(4-37) 
4. 7. Discussion and Conclusion 
The development of the mathematical model assumes linear dose-concentration and linear 
dose-effect relationships. However, those relationships may vary in patients or even within a 
single patient during the course of drug infusion. This patient variability is now technically 
not quantifiable, and therefore the mathematical model is developed as a population average 
model. In clinical practice, this patient variability would bring uncertainty on the control of 
anaesthesia. 
The limitation of the developed mathematical model comes from pharmacokinetics and 
pham1acodynamics, where some of the factors that affect the drug disposition are not 
modelled (si.Jch as age, sex, and health condition), and the linear approximation of patient 
specific sigmoid model introduces modelling error. 
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Though Bispectral Index has been evaluated as the best descriptor of anaesthetic depth, it 
lacks quantitative precision. The value of BIS under a specific depth of anaesthesia varies in 
patients, and BIS itself measured in a patient may be oscillatory over time even when drug is 
infused at a fixed maintenance rate. 
In summary, a mathematical model of a closed-loop anaesthesia system has been developed. 
This model models all the components within the proposed CLAN system including the 
reference pharmacokinetic/pharmacodynamic model with population average parameters, 
patient models with patient specific parameters, target controller and infusion rate generator. 
The mathematical model is developed in a way that allows replacement of any component 
models in anticipation of any progress in understanding the pharmacokinetics and 
pharmacodynamics in the future, and it provides a useful tool for further investigation on 
closed-loop anaesthesia control. 
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5. Investigation of Closed-loop Anaesthesia 
5. 1. Introduction 
Taking advantage of the mathematical model of closed-loop anaesthesia system, the following 
sections are to investigate closed-loop anaesthesia and identify the major problems existing in 
an intravenous drug delivery system. All investigations are based upon the mathematical 
model of the closed-loop path in the system shown in Figure 4-1. 
As can be seen in Figure 4-l, the drug infusion is directly controlled by the TCI component of 
the CLAN system based upon a target drug concentration given by the target controller. Two 
sites are usually used as the sites of target: plasma and effect site. Targeting on plasma results 
in a slow growing of drug concentration without overshoot. However, it takes a significantly 
longer time to achieve the desired drug effect. On the other hand, targeting on effect site 
anticipates the drug distribution loss before the desired drug effect has .been achieved, and 
hence additional drug is to be infused to compensate the distribution loss of drug. This results 
in overshoot in drug concentration but less time is taken to achieve the desired drug effect. In 
this Chapter, a control scheme in which the target site is switched between plasma and effect 
site is investigated. 
This investigation also explores the nature of pharmacokinetic and pharmacodynan1ic 
variability in patients and how this variability affects the drug delivery by using 18 
hypothetical patients listed in Table 4-5 and Table 4-6. Finally, the mathematical model is 
used for the investigation of closed-loop anaesthesia with the same patients. This 
investigation demonstrates how the CLAN model solves the problem of patient variability. 
Unless explicitly stated otherwise, a target Bispectral Index of 65 is applied to achieve light 
anaesthesia (Baker, Sleigh and Smith, 2000), whereas an equivalent target drug concentration 
of 2.2265 mcg/ml is used when only a TCI model is required. The target concentration is 
derived fr01n the Bispectral Index target using the HIS-concentration relationship presented in 
Section 4.3. 
5.2. Targeting on Plasma or Effect Site Drug Concentration 
When TCI is used to target on plasma, the target drug concentration would be achieved in 
plasma immediately after a bolus infusion as drug concentration peaks almost instantaneously 
in plasma. However, if effect site is the target site, there will be a delay or hysteresis for the 
effect site drug concentration to reach the target concentration, and this delay varies from one 
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patient to another. 
Due to the delay of drug transfer from plasma to effect site, part of the bolus will be lost 
during the drug distribution, and look-ahead compensation for the drug distribution loss is 
therefore needed. In effect site target control mode, this compensation is incorporated into the 
initial bolus. 
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Presented in Figure 5-l and Figure 5-2 are the results from the computer simulations of the 
developed TCI model implemented in MATLAB. Figure 5-1 shows the predicted plasma drug 
concentration (Cp) and effect site drug concentration (Ce) over time when targeting either in 
plasma or effect site, while Figure 5-2 shows the drug infusion rate generated by the reference 
model from two control modes. 
The reason why there is no overshoot in maintenance phase when targeting on plasma is 
because the infusion rate is significantly low and the drug infusion is continuous (see Figure 
S-2). With the low rate and continuous infusion, the compensation for the drug distribution 
loss is only for 5 seconds rather than I. 7 minutes as is the case when targeting on effect site. 
This small compensation is not big enough to cause the overshoot. 
Although targeting on plasma can achieve the target plasma concentration almost instantly 
and maintains the target smoothly, effect site is the site of dnig effect and represents the level 
of anaesthesia. When targeting on plasma, it takes about 4.5 minutes for the effect site 
concentration to reach the target concentration, whereas 1. 7 minutes is needed if effect site is 
the target site. In maintenance phase, effect site targeting causes overshoot in drug 
concentration periodically due to· the look-ahead compensation, the infusion rate is 
intermittent and high, while plasma targeting maintains a stable effect site concentration with 
a steady, continuous, and much lower infusion rate. 
5.3. Targeting on Mixed Sites 
By combining the advantages of both TCI infusion schemes, the slow effect site concentration 
response in induction phase presented by plasma targeting and the periodical overshoot in 
maintenance phase caused by effect sit~ targeting can be solved. Figure S-3 and Figure SA 
present the result from the mixed site target control strategy, where effect site target control is 
used for the induction and plasma target control for the maintenance. In this target control 
strategy, the initial bolus is calculated using effect site as the target site. When predicted effect 
site concentration peaks and reaches the target concentration (at 1.7 minute}, the target site is 
switched to plasma. 
There is no drug infusion after the initial bolus until the target site is changed into plasma (see 
Figure S-4). Thereafter the drug was infused with a low maintenance rate calculated by the 
reference model that aims at compensating the drug distribution loss in the body of patient. 
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The maintenance infusion rate becomes lower and lower because the loss of drug in a patient 
is getting smaller and smaller according to the mathematical model of this process. 
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Figure 5-3 Plasma and effect site drug concentration when targeting on mixed sites (Cp: 
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5.4. Exploring Patient Variability 
According to clinical observations, inter-individual variability exists in human patients in 
pharmacokinetics and pharmacodynamics during drug administration. To investigate how this 
patient variability behaves when the hypnotic agent propofol is given, the pharmacokinetic 
model (TCI) and pharmacodynamic model (BIS-Concentration relationship) developed in 
Chapter 4 are used together with the 18 virtual patients modelled in Table 4-5 and Table 4-6. 
Both models are implemented in MA TLAB and run on each of the 18 virtual patients in turn. 
The mixed site target control scheme is used for the following investigation of inter-
individual variability in patients. 
One of the basic assumptions implied in the previous investigations in sections 5.2 and 5.3 ~ is 
that the patient's pharmacokinetic/pharmacodynamic characteristics are the same as described 
by the population average reference models. In reality, this is not true because of patient 
variability. Due to the identical reference model, the same initial bolus and maintenance 
infusion rate shown in Figure 5-4 are generated by the system for virtual patients 
Patientl ~Patientl8 intending to achieve and maintain drug concentration of 2.2265 mcg/rnl at 
effect site. However, the TCI system fails to do so on most of these vittual patients. The result 
of the investigation on pharmacokinetic variability is shown in Figure 5-5, Figure 5-6, and 
Figure 5-7, where plasma and effect site drug concentration in Patientl ~Patient9 are marked, 
and the infusion rate over time for the patients is the same as shown in Figure 5-4. 
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It can be seen from Figure 5-6 that the drug concentration profile of Patientl is exactly the 
same as predicted by the reference model because the patient pharmacokinetic model is the 
same as the reference model. HoWever, comparing to the reference model, Patient2 has a 
longer time for the infused drug to be transferred from plasma to effect site (2.4 minutes for 
drug effect peak time). At 1.7 minute, the effect site drug concentration in Patient2 is lower 
than predicted, and the low maintenance infusion rate from then slowly brings the effect site 
drug concentration up to the target at about 6.5 minute since then the drug concentrations in 
plasma and effect site equilibrate. For Patient3, the effect site drug concentration is higher 
than predicted at 1.7 minute due to the shorter peak time (1.0 minute) and the additional drug 
in the initial bolus for look-ahead compensation. It takes 1.3 minutes for the effect site drug 
concentration in Patient3 to fall to the equilibration concentration that is also the target 
concentration. Figure 5-5 also confirms the fact that the plasma drug concentration in the 
three virtual patients is identical as they have the same drug transfer rate constants. 
Nevertheless, the actual responses from the rest of the patients are quite different from 
Patientl, 2, and 3 because they have phannacokirtetic characteristics other than those 
described by the reference model. Figure 5-6 shows the responses of Patient4, 5, and 6. 
Implied by the values of the rate constants in a pharmacokinetic model, the dominant rate 
constants are elimination rate constant (k10) and the one describing drug transfer from the 
central compartment to the rapid compartment (k12). Dlie to the smaller values of k10 and k12 
in the pharmacokinetic models of Patient4, 5, and 6, the distribution loss of drug over time is 
over estimated by the reference model, and therefore the loss of drug in those patients gets 
over compensated and the equilibration drug concentration is then higher than the predicted 
(see Figure 5"6). Again, because of the difference in drug transfer delay (peak time) or 
hysteresis, the plasma and effect site drug concentration equilibrate at 1.7 minutes, 6.5 
minutes; and 2.5 minutes for Patient4, 5, and 6, respectively. For Patient7, 8, and 9, on the 
contrary, the distribution loss of drug over time is under estimated by the reference model due 
to the larger values in k10 and k12, and hence the loss of drug is under compensated for these 
patients that causes the equilibration drug concentration to be lower than the predicted (see 
Figure 5-7). The time for the plasma and the effect site drug concentration to equilibrate is I. 7 
minutes, 6.5 minutes, and 3 minutes for Patient?, 8, and 9, respectively. 
What about the patients whose drug distribution loss within a unit time (determined by the 
values of k10 and k12) is within the range of that of Patient4, 5, 6, and Patient 7, 8, 9, or 
outside this range? Based upon the linear l!SSumption of the pharmacokinetic model; we know 
that the equilibration drug concentration of these patients must be some values that are lower 
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than that of Patient4, 5, and 6, and higher than that of Patient?, 8, and 9, or outside this range. 
Under this TCT control scheme, any different values in peak time would only either slow 
down or speed up the equilibration of plasma and effect site drug concentration, and have no 
influence on the steady state effect site drug concentration maintained by the TCI system. 
Although most of the patients will be over or under compensated by the TCI system, the 
compensation infusion rate is too low or the amount of drug distribution loss is too small and 
it is in an exponential decay as time goes on. This guarantees that a stable equilibration drug 
concentration would eventually be maintained in any patient. 
The results shown in Figure 5-5, Figure 5-6 and Figure 5-7 present the drug concentration 
response of intravenous drug delivery with presence of pharmacokinetic variability. For the 
investigation of pharmacodynamic variability, the pharmacodynamic model is used to obtain 
the Bispectral Index or the drug effect from propofol drug concentration. This investigation is 
carried out on the hypothetical patients Patient} O~Patient 1 8, and the results are presented in 
Figure 5-8 (a), (b), and (c). 
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Figure 5-8 Drug effect in Bispectral Index in Patient 1 0-Patient 18 against the predicted effect 
(BIS _r is the BIS calculated by pharmacodynamic model from propofol drug concentration 
predicted by the TCI reference model, BISi is the BIS calculated by pharmacodynamic model 
from propofol drug concentration predicted by the model of the i1h patient 
Figure 5-8 shows the pharmacodynamic variability in patients (Patient 1 O- Patient18) who 
have the largest pharmacokinetic variability within Patientl-Patient9. Figure 5-8 (a) presents 
the results from virtual patients with population average drug clearance rates and peak time, 
while Figure 5-8 (b) shows the results from patients with slower drug clearance rates and peak 
time, and the results from patients with faster drug clearance rates and peak time are 
demonstrated in Figure 5-8 (c). BIS_r is predicted by the built in population average PK/PD 
models. The steady state values of BIS _r are the desired BIS values, and various deviations 
from BIS_r can be seen from the BIS responses of Patient11 - Patientl8. However, these 
deviations can be minimised with the use of closed-loop control technique as will be seen in 
the following investigations. 
5.5. Investigation of the CLAN System Model on Patient Variability 
5.5.1. Methods 
As discussed earlier, the built-in PK/PD models describe the drug distribution/effect of an 
average population and not for a specific individual patient. A real patient may therefore 
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respond to an anaesthetic drug in a different way from that described by the reference model 
(see Figure 5-5, Figure 5-6, Figure 5-7, and Figure 5-8) and a different stable level of 
anaesthesia other than that predicted by the reference model may be maintained in a patient. 
In this section, we will show how the proposed closed-loop anaesthesia or CLAN system will 
theoretically bring all the virtual patients to the desired level of anaesthesia without knowing 
the 'true' PK/PD characteristics of the patients, and the degree of variability of an individual 
patient's PK/PD against the population average. 
Two investigations on the mathematical CLAN model have been carried out. One explores 
the behaviour of the CLAN model with existence of pharmacokinetic variability in 
hypothetical patients Patient1-Patient9, while the other looks at how the CLAN model 
handles the pharmacodynamic variability in virtual patients Patient I 0-Patient 18. 
The basic idea lying in the CLAN system is to minimise the difference between the actual 
stable equilibration drug concentration/effect and the predicted one seen in Figure 5-6, Figure 
5-7, and Figure 5-8, and to speed up the equilibration for patients with large values in drug 
effect peak time (e.g., Patient2, 5, and 8). To achieve these goals, the PID controller modifies, 
in real time, the target drug concentration of a built-in TCJ system that targets on mixed sites. 
5.5.2. Investigation on Pharmacokinetic Variability 
In clinical practice, the drug effect target would be changed up or down intra-operatively by 
the anaesthetist to meet the need of appropriate depth of anaesthesia in different stages of 
surgery. To simulate this dynamic requirement, BIS target in this investigation is changed 
down to an arbitrary value of 50 to achieve a deeper anaesthesia and is thereafter changed 
back to another arbitrary value of 65 before the infusion stops. 
To achieve the best control performance, the PID controller gains designed in Section 6.5 
were manually fine-tuned to individual patients, and the results are listed in Table 5-l. PID 
controller gains have significant influence on the performance of the CLAN system, and there 
are sets of gains for each patient from which the best control performance would be achieved. 
Table 5-l lists one of them for each patient. 
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Table 5-l Optimal PID controller gains for hypothetical patients of Patient 1- Patient9 
Patient kp ki kcJ 
1 0.0024 0.000022 0.34 
2 0.0015 0.000008 0.1 
3 0.0012 0.00009 0.1 
4 0.0012 0.00001 0.125 
5 0.0024 0.00005 0.18 
6 0.0024 0.00001 0.18 
7 0.0019 0.00001 0.1 
8 0.0024 0.00002 0.29 
9 0.0008 0.00009 0.11 
-
The effect site propofol drug concentration (Ce) and Bispectral Index (BIS) in the 9 
hypothetical patients Patientl - Patient9 from this investigation are presented in Figure 5-9 and 
Figure 5-10. 
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All computer simulations start with the same initial bolus (mlfkg) infusion to all patients 
expecting to achieve the desired target in BIS, and then the infusion stops temporarily with 
active system monitoring on Bispectral Index that is calculated from the effect site drug 
concentration in the patient involved using population average pharmacodynamic model as 
shown in Table 4-5. Once the drug effect of the initial bolus reaches its maximum indicated 
by a peak value in BIS, the PID controller takes over the control and resumes drug infusion. If 
the value of BIS feedback indicates a lighter anaesthesia than the target, then the PID 
controller will decrease the target concentration of the built-in TCI system, otherwise the 
target concentration will be increased. Whenever the value of BIS feedback is close to the BIS 
target, the TCI system will target on effect site, and otherwise on plasma. Because the shortest 
cycle available from the anaesthesia monitor Aspect A-1 000 is 5 seconds on which the 
Bispectral Index is updated, a new target concentration to the TCI system is generated from 
the PID controller in every 5 seconds. 
After the bolus infusion and the change down in Bispectral Index target, the BIS falls quickly 
in some patients (e.g., Patient6) but slowly in others (e.g., PatientS), and there are Bispectral 
Index overshoots in some patients (e.g., Patient6) and undershoots in others (e.g., Patient8). 
However, the Bispectral Index target is quickly achieved and maintained in all hypothetical 
patients. It also shows that a period of time is needed for the CLAN system to re-achieve the 
target when it is changed. 
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5.5.3. Investigation on Pharmacodynamic Variability 
This investigation is based upon the virtual patients Patient! 0-Patientl8 in whom 
pharmacodynamic characteristics vary. However, the pharmacokinetic characteristics of 
Patientl0-Patientl2 inherit from ·Patient! with population aVerage parameter values, and 
those of Patientl3-Patientl5 are the same as that in Patient6 with least drug distribution loss 
(smallest drug clearance rates and shortest drug effect peak time) in Patientl-Patient9, while 
those ofPatientl6-Patientl8 are identical to that in PatientS with most drug distribution loss 
(largest drug clearance rates and1longest drug effect peak time) in Patientl-Patient9. The PID 
controller gains for Patient!, 6, and 8 are also applied on PatientJO ...... Patient18 as shown in 
Table 5-2. Apart from PatienHO; the controller gains used might not be the optimal gains for 
all other patients due to the additional pharmacodynamic variability. 
Table 5-2 PID controller gains for hypothetical patients of Patientl0-Patientl8 
k p kl ·kci 
Patient 10 0.0024 0.000022 0.34 
Patient 11 1 0.0024 0.000022 0.34 
Patient 12 1 0.0024 0.000022 0.34 
I 
Patient 13 1 0.0024 0.00001 0.18 
Patient 14 I 0.0024 0.00001 0.18 
Patient 15 0.0024 0.00001 0.18 
Patierit 16 0.0024 0.00002 0.29 
Patient 17 0,0024 0.00002 0.29 
Patient 18 0.0024 0.00002 0.29 
Because the BIS can never reach 65 from the pharmacodynamic model ofPatientl2, '15, and 
18 ·listed in Table 4-6, the BIS target is therefore set to 50 in this investigation. 
The results of this investigation are presented in Figure 5-.I: i, and Figt~re 5-12; Figure 5-11 
shows the effect site propofol drug concentrations in Patient! 0-PatienHS, while Figure 5-12 
presents the BIS responses from these patients. 
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As in the previous investigation, the simulations begin with the same initial bolus (ml/kg) 
infusion to all patients to achieve the BIS target, and the PID controller takes over the control 
when the drug effect peaks. Bispectral Index is calculated from the effect site drug 
concentration in patients using the pharmacodynamic models listed in Table 4-6. The same 
control scheme as used in the previous investigation is used here. 
With pharmacodynamic varibility in Patient! O-Patientl8, although the BIS target is 
successfully achieved and maintained in all patients, the predicted effect site propofol 
concentrations in these patients are stabilised at different levels. 
5.6. Discussion and Conclusion 
By using optimal gains, the target Bispectral Index is achieved within 5 minutes either after 
the induction bolus infusion or after the change up/down of the target Bispectral Index. 
In this chapter, the problems with regard to using a TCI system for drug infusion control have 
been investigated; it has also been investigated why there is patient variability, how this 
variability affects the drug administration, and finally how the developed CLAN system 
model solves these problems. 
The investigation on TCI infusion control scheme in intravenous drug delivery identifies that 
targeting on mixed sites would achieve the best control performance. Targeting on plasma 
solely results in a stable drug concentration response at effect site with a long set-up time. 
However effect site targeting scheme achieves a quick but oscillatory response in effect site 
drug concentration (see Figure 5-l ). The level of oscillation depends upon the drug effect 
peak time in the patient in question. The reason why the two targeting schemes result in 
different behaviours is that the drug infusion is continuous when targeting on plasma, whereas 
when targeting on effect site the drug infusion is intermittent as shown in Figure 5-2. Due to 
the instant peak of plasma drug concentration, drug is infused during every update cycle to 
compensate the drug distribution loss for the next cycle when targeting on plasma. However, 
when targeting on effect site, the effect site drug concentration reaches its peak 1.7 minutes 
after the drug is infused. To achieve the target drug concentration at effect site, extra drug 
must be infused to compensate the drug distribution loss over the 1. 7 minutes. All drug 
infused to achieve the target is given in a bolus, and there is no drug infusion during majority 
period of time (see Figure 5-2). 
The result from this investigation suggests that plasma could be targeted for the maintenance 
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of anaesthesia, while effect site could be used as the target site in induction of anaesthesia and 
whenever insufficient anaesthesia is indicated. Figure 5-3 shows the optimal open-loop drug 
infusion control performance when targeting on the mixed sites, and Figure 5-4 shows the 
history of infusion rates generated by this control scheme. 
The patient variability has been thoroughly investigated usmg 18 hypothetical patients 
constructed from a published pharmacokinetic and pharmacodynamic parameter set. The 
investigation shows that the pham1acokinetic variability results in approximately a constant 
difference between the predicted effect site drug concentration by reference model and the 
actual drug concentration in a specific patient (see Figure 5-6 and Figure 5-7). When targeting 
on mixed sites, if the drug effect peak time is different from the population average value, this 
difference affects only the transient drug concentration response. The result of simulation on 
Patientl-3 (see Figure 5-5) shows the effect from drug effect peak time that is the only 
difference between the patients and the built-in reference PKIPD models. 
In general, in comparison with the reference model, the shorter the peak time, or the smaller 
the drug elimination rate (k10) and distribution rates (k12, k13), or the larger the redistribution 
rates (k21 , k31 ), the more the system is susceptible to overshoot. The opposite is also true for 
undershoot. 
While pharmacokinetic variability causes steady state difference between drug concentration 
predicted by the population average pharmacokinetic model and that in a specific patient, 
pharmacodynamic variability results in steady state difference between drug effect or 
Bispectral Index predicted by the population average pharmacodynamic model and that in a 
specific patient even if the effect site drug concentrations are the same. This is demonstrated 
in Figure 5-8( a) in which the results of investigation on Patientl-3 are presented. Because the 
pharmacokinetic paran1eters in Patientl-3 are identical to the population average values, only 
pharmacodynamic variability exists in Patientl-3 against the reference model. 
When pharmacokinetic variability and pharmacodynamic variability co-exist in patients, the 
effect site drug concentrations and the drug effects in these patients should vary unless in rare 
cases the two types of patient variability interact so that the drug effects happen to be the 
same. The co-existence of pharmacokinetic and pharmacodynamic variability makes the drug 
effect more unpredictable as shown in Figure 5-8 (b) and (c). 
Due to the introduction of closed-loop control technology, the CLAN system successfully 
achieves and maintains the target level of anaesthesia with either pharmacokinetic or 
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pharmacodynamic variability or the both. The steady state differences between the effect site 
drug concentrations in patients and those predicted by the reference model (see Figure 5-6 and 
Figure 5-7) disappear (see Figure 5-9}, while the steady state differences between the drug 
effects in patients and those calculated by the reference models is no more existent (see Figure 
5-12). In the CLAN system, the role of the PID controller is to minimize these differences as 
quickly as possible. After the PID controller takes over the infusion control, it examines the 
Bispectral Index of the patient against the target every 5 seconds. If the BIS value is less than 
the target (i.e., overshoot), it will stop (or not resume) the infusion until the BIS rises to the 
target. However, if the BIS value is larger than the target, the PID controller will generate a 
new target concentration that is higher than the previous one for the built-in TCI system, and 
the TCI system then decides which site should be targeted on and generates a new infusion 
rate for the next cycle. This process is clearly seen in the responses of Patient6 and PatientS 
shown in Figure 5-10, and Patient 15 and Patient 17 shown in Figure 5-12. 
In conclusion, the infusion control scheme of using mixed target sites shows great advantage 
in drug infusion control over that using a single target site. The patient variability causes 
problem for drug infusion controlled by TCI and needs human intervention to adjust the target 
concentration, while a closed-loop anaesthesia system has the ability to achieve any drug 
effect target with the presence of patient variability. 
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6. Design of Closed-loop Anaesthesia System 
6. 1. Introduction 
Previously, a mathematical model based upon the system defined in Figure 4-1 has been 
developed, and the major potential problems associated with closed-loop anaesthesia control 
have been investigated using the model. To verify the developed mathematical model of 
closed-loop anaesthesia on real patients in typical clinical environment, a prototype of closed-
loop anaesthesia control system was designed in the following sections and implemented. A 
real CLAN system is essential for further investigation of closed-loop anaesthesia because a 
number of assumptions are made in the mathematical model. In the design and 
implementation of the CLAN system, these assumptions were taken into consideration to 
cope with any possible non-linear behaviour of the system. The system to be designed 
includes both the open-loop path and the closed-loop path shown in Figure 4-1 for the 
infusion of alfentanil and propofol. 
6.2. System Specifications 
The specifications of the desired closed-loop control system consist of both hardware 
specifications and software specifications. The hardware specifications describe the physical 
components of the system available at the time the project started for this investigation, while 
the software specifications specifies the theoretical performance of the control system and are 
designed in the following sections. 
6.2.1. Hardware Components and Interfaces 
To carry out the CLAN investigation, a CLAN system consisting of the hardware components 
shown in Figure 6-1 was built. All necessary software device drivers were developed. The 
specifications of these available equipments are listed below: 
Personal Computer: 120 MHz CPU 
Anaesthesia Pump: 
EEG Monitor: 
4 RS-232 serial communication ports with an extra l/0 card 
8MB RAM 
2 Graseby 3400 pumps with maximum infusion rate of 1200 mllhour 
Aspect A-1000 EEG Monitor (with a digital signal converter) 
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Figure 6-1 Physical components ofthe CLAN system 
In this system, RS-232 RTS/CTS modem protocol is used for the host PC to control the 
pumps, while RS-232 null modem protocol is used to receive the data transmitted from the 
EEG monitor. The cables connecting the PC with the pumps and the monitor were made with 
the wiring described in Table 6-1, and the RS-232 serial communication protocols 
implemented i11 the CLAN system for the communications are shown in Table 6-2. 
Table 6- 1 RS232 Cable wiring between the PC, pumps, and EEG monitor 
PC RAW EEG PORT PROCESSED EEG GRASEBY 3400 
PORT PUMP 
DB9(FEMALE) DB9(FEMALE) 
DB9(FEMALE) DB9(FEMALE) 
CONNECTOR CONNECTOR 
CONNECTOR CONNECTOR 
2(RxD) 3(Data Out) 3(Data Out) 3(Data Out) 
3(TxD) 2(Data In) 2(Data In) 2(Data In) 
5(GND) 5(GND) 5(GND) 5(GND) 
?(RTS) No Connection No Connection 8(Handshake In) 
8(CTS) No Connection No Connection 6(Handshake Out) 
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Table 6-2 Serial communication protocols for the RS232 serial ports 
PARAMETER GRASEBY 3400 A-1000 A-1000 
PUMP RAW EEG PORT PROCESSED EEG 
PORT 
COMPort COM4 COM1 COM2 
Baud Rate 9600 19200 9600 
Data Bits 8 8 8 
Stop Bits 1 1 1 
Parity No Parity No Parity No Parity 
Handshake Hardware(CTS/RTS) NO NO 
6.2.2. Sampling Period 
Bispectral Index is calculated within the Aspect A-1 000 EEG monitor based on the EEG 
waveform with a sampling frequency of 128Hz, however, the Bispectral Index is updated 
from the monitor at a selectable periods of 5, 10 or 15 seconds. To obtain the highest response 
speed from the CLAN system, 5 seconds update period was therefore used. 
6.2.3. PID Controller 
The specifications of the PID controller were given in time domain so that a search algorithm 
can be applied through computer simulation to find the desired controller gains. The 
specifications include rise time, maximum overshoot, settling time, and stead-state error as 
defmed in Figure 3-5 in Section 3.2.2. 
Because the CLAN system is safety critical, the fundamental requirement from a controller to 
be used in such a system is its response speed to any inadequate anaesthetic level. Based on 
this requirement, an aggressive rise-time of 50 seconds and a settling time of 75 seconds were 
chosen to obtain a reasonable fast response from the resulted PID controller since the drug 
effect peak time after a bolus infusion typically ranges from 1 to 2.4 minutes (Schnider et al., 
1999). 
Typical maximum overshoot for a PID controller is around 25%. In theory, a quicker response 
would be obtained from a larger maximum overshoot. However, this leads to a longer settling 
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time and results in more oscillation before the target has been achieved. This is not desired in 
a CLAN system using Bispectral Index which is not truly monotonic. Therefore a 10% 
maximum overshoot was set for the controller to compromise between the response speed and 
the smooth trend of Bispectral Index. As for steady state error, 10-3 is more than enough as 
Bispectral Index itself is oscillatory and the maximum measuring precision in Bispectral 
Index is 0.001. 
6.2.4. Data Acquisition 
Data acquisition is a software component in the CLAN system to collect and store the raw and 
processed EEG data sent from the from A-1 000 EEG monitor, and to extract the Bispectral 
Index from the data stream. This involves with the implementation of the following 
functionality: 
• RS-232 device driver for collecting data from raw/processed EEG ports 
• One second period based raw EEG data packet real-time collection and storing 
• Five seconds period based processed EEG data packet real-time collection and storing 
• Synchronisation capture and reconstruction capability 
• Bispectral Index (BIS) data extraction, processing, and storing 
6.2.5. Anaesthesia Pump Control 
To control the Graseby 3400 infusion pumps from the host PC, the following functionalities 
are required in the device driver: 
• RS-232 communication driver 
• Pump messages processing 
• Regular infusion rate update 
6.2.6. Patient Safety Control 
As a safety critical medical control system, the CLAN system should be able to cope with any 
hazards they may happen. The following is a list of the functionalities the CLAN system 
should have: 
• Switching between open-loop control and closed-loop control 
• Emergency control 
• Detect source of hardware failure and solve the problem if possible 
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• Capable of stopping, resuming and restarting infusion at any time 
• Feedback signal quality control 
• Warning messages 
• Error Messages 
6.2.7. User Interface 
A user interface is required for the user to start/stop the drug infusion, and where necessarily 
to control the system externally. In case of the need to change syringe, pausing/resuming the 
drug infusion is required. When the quality of BIS data is bad or BIS is absent for a 
significant amount of time, the closed-loop control should be switched to open-loop control to 
protect the patient. Furthermore, the CLAN system should allow the user to change any 
patient specific parameters and the BIS target or target drug concentration. 
A full list of the commands to be provided in the CLAN system is as follows: 
• Starting, pausing, resuming and stopping infusion 
• Syringe change 
• Switching between open-loop control and closed-loop control 
• Changing target site between plasma and effect site in open-loop control 
• Changing some system parameters, such as controller gains, threshold values controlling 
stop and resuming infusion 
• Changing closed-loop target 
• Starting and stopping data storing 
• Starting and stopping event logging 
• Making or cancelling comment 
• On-line searching logged event or comment 
• Screen redrawing 
• System exit 
6.3. Data Acquisition 
The Aspect A-1000 EEG monitor is used in the closed-loop control system to measure the 
drug effect or depth of anaesthesia from the EEG signal measured in patients. A number of 
EEG variables are calculated from the EEG signal within the monitor, which includes 
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Bispectral Index or BIS, spectral edge frequency, median frequency, and so on. A complete 
list of the variables calculated in the monitor is given in Table A-8-2. As discussed 
previously, BIS is fed back to the control system as the measure of the depth of anaesthesia. 
Every 5 seconds, the EEG monitor sends all the calculated EEG variables in a data packet to 
its Processed EEG Port in ASCII format. It transmits the digitised raw EEG binary data 
packet along with a copy of the processed EEG variables in another binary data packet to its 
RAW EEG Port every second. The san1pling rate of the raw EEG signal is set to 128 samples 
per second on the monitor. 
6.3.1. Packet Format from RAW EEG Port 
Each packet from the raw EEG port starts with a header and ends with a checksum. Multi-
byte numbers are transmitted least-significant byte or word first. The data packet shown in 
Table 6-3 contains the processed EEG variables for all the channels including the combined 
channels that are the average of either channel I and 2 or channel 3 and 4. The packet shown 
in Table 6-4 is the raw EEG data that consists of 4 channels of interleaved EEG data. 
Table 6-3 Processed variables packet- 128 samples/second 
Header (byte)= Oxab 
Type (byte) = 5 
Sequence Number (16 bits) 
Host Revision Number (3 bytes) 
DSC Revision Number (byte) 
Artefact Flags for each of the 6 channels (4 bytes each); 
(4 measured channels+ 2 combined channels) 
Calculated Data for each of the 6 channels (25 variables 
(4 bytes each) per channel) 
Checksum (16 bits) 
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Table 6-4 Raw EEG packet- 128 samples/second 
Header (byte)= Oxab 
Type (byte) = 2 
Sequence Number (16 bits) 
Raw EEG data, 4 channels interleaved 
Checksum (16 bits) 
Each raw EEG sample is a 16-bit 2's complement binary word with a range of +32767 to -
32768 and a resolution of 0.050015 mY/unit. In the raw EEG packet, the raw EEG data from 
the four channels are interleaved, such that the first word is from channel l, the second from 
chrnmel 2, then channel 3, chrnmel 4, and channel 1 again. The srnnpling rate of 128 samples 
per second makes the one-second-packet size of l 030 bytes in total. In the processed variable 
packet, after the transmission of the unique data pattern, the A-1000 sends the artefact flags 
indicating the types of artefacts (if any) detected within the previous cycle. The artefact flags 
are bit-mapped and listed in Table A-8-l. Each artefact flag word is a 32-bit unsigned integer. 
Following the artefact flags are all of the variables for channel 1, then all of the variables for 
channel 2, and so on. Each variable is a 4-byte lEEE single-precision floating-point value, and 
is listed in Table A-8-2. The appearance of the variables in the list shows the transmission 
order. 
6.3.2. Data Format from Processed EEG Port 
The processed EEG port transmits the processed data for 4 channels plus 2 channel pairs, along 
with impedance values, error codes, and a header record, in an ASCII format. This port can 
receive conm1ands that alter the types of data to be transmitted. 
There are four basic types of records transmitted by the processed EEG port: 
• Header Record- describes each field of the Data Record 
• Data Record - contains all processed EEG variables 
• Impedance Record - contains impedrn1ce values from the impedance check 
• Error Record - contains an error code 
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Each record starts with a unique string of characters, and ends with a Carriage Return (<CR>), 
followed by a Line Feed (<LF>) character. Fields within the records are delimited using the 
"pipe" character ("1", ASCII 7CH). 
hnpedance records are transmitted only when the impedance check is in progress and an error 
record is transmitted when an error is detected while header record is disabled. The examples of 
error record, impedance record and data record are shown in Appendix A 
The Data Record contains all of the processed EEG variables for the 4 channels plus 2 
combined channels. The record starts with the current date and time (MM/DDIYYYY 
HH:MM:SS) and ends with a Carriage Return, followed by a Line Feed character. Following 
the information on system settings are the variables calculated from the channel l EEG signal 
and the artefact flags of the channel I during the last cycle, and then the variables and artefact 
flags for channel 2, 3, 4, 5, and 6. All variables except the artefact flags are right-justified 
decimal numbers. The 32-bit artefact flags and artefact detection enable words are represented 
as 8-digit hexadecimal numbers (see Appendix A for artefact flag definitions). 
6.3.3. Implementation of Data Acquisition 
In data cornnmnication between the PC and the RAW EEG port of the EEG monitor, the 
header, type, sequence number, host revision number and DSC revision number in the data 
packets form a unique data pattern and are therefore used for synchronisation. For processed 
EEG data communication, the current date is used as the synchronisation string. If 
synchronisation for any port is lost, then the contaminated binary data packet or ASCII data 
packet will be saved to an error file accordingly with time stamped (raweeg.err for raw EEG 
data packet containing errors and proeeg.err for processed EEG data with error). The 
reconstruction of synchronisation will take a minimum of one second for raw EEG port and five 
seconds for processed EEG port. 
The data amount in binary data packets from raw EEG port is fixed (1030 bytes/second) while 
that in ASCII data packet from processed EEG port varies (maximum<2000 bytes) due to the 
possible error records and impedance records. Although the data transmission to the two ports is 
concurrent, the time needed to transmit the whole ASCII data packet is about 2.3 seconds. In 
implementation, therefore, we program the serial I/0 ports of the PC to receive the incoming 
data continuously and to work in the background. The received data from both ports are stored 
in two large sizes of I/0 port buffers that can hold at least five seconds data, and the buffered 
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data will be taken away for processing and archiving every five seconds. The size of the buffer 
holding binary data from raw EEG port is at least 1030. 5=5150 bytes. However, the closed-loop 
system can not read the buffer on the basis of exact five-second period due to the busy work of 
the system. The maximum amount of buffered data is 8312 bytes, and the buffer size is set to 
9300 bytes for this reason. For the data from processed EEG port, the closed-loop system reads 
the buffered data at the middle of the idle time of the port, that is 3.65 seconds from the 
beginning of a packet transmission, and the port buffer size is set to 2400 bytes. With 2.7 
seconds idle time of the transmission port, this setting proves to be safe for the receiving of the 
processed EEG data. 
Both the raw EEG data and processed EEG variables are stored in the PC for off-line analysis. 
Bispectral Index is extracted from the data stream to provide the feedback signal for the 
control system and is also stored under a dedicated directory. To avoid the large size of the 
data files, the incoming data are split into sections and stored in files under the dedicated 
directories according to the type of the data. For implementation of this strategy, each raw 
EEG data file contains only five minutes data, and each processed EEG data file contains the 
data of fifteen minutes while BIS file contains two hours data due to the low data rate. A data 
archive directory structure has been built for this purpose (Appendix B). 
The real time data acquisition process is depicted in Figure 6-2. 
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Figure 6-2 Flow diagram of data acquisition 
6.4. Target Controlled Infusion 
Target controlled infusion is used to control the two Graseby pumps and generate the infusion 
rates for hypnotic propofol and analgesic alfentanil. For each drug, a TCI with appropriate 
pharmacokinetic model is dedicated. 
A TCI consists of a pharmacokinetic model, a drug infusion rate generator, and a pump 
driver. The block diagram of such a TCI is shown in Figure 6-3, where Cp (Ce) is the drug 
concentration in plasma (at effect site) predicted by the PK model, Cr is the target drug 
concentration, C is either Cp or Ce depending on the Target Site Control, LlC is the difference 
between C and Cr, and I is the infusion rate to achieve the target concentration. 
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Figure 6-3 Block diagram ofTCI open-loop system 
In implementation of the above TCI system, part of the C code from freeware ST ANPUMP 
(Steven L. Shafer, Aneathesiology Service (112A), PAY AMC, 3801 Miranda Ave, Palo Alto, 
CA 94304, USA) is used with pennission. 
6.4.1. Implementation of Pharmacokinetic Model 
The drug concentration estimation algorithm described in (Jacobs, 1990; Bailey and Shafer, 
1991; Shafer and Gregg, 1992) is used for the implementation of the pharrnacokinetic model. 
Generally, for an n-compartment pharmacokinetic model where n is a positive integer, the 
theoretical calculation of plasma drug concentration defined in equation (2-2) could be 
rewritten in the following discrete form: 
k 
CpCALd..k)= TL/(m)Dp(k-m) 
m=O 
If define a state variable R;(k) as follow 
then 
k 
R;(k) = L I(m )A;e -Ai(k-m)T 
m=O 
11 
CpCALd..k) = T L R;(k) 
i=l 
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(6-1) 
(6-2) 
(6-3) 
. 
At time (k+ 1 )T, the R;(k+ 1) can be calculated using (6-2) 
k+l 
R;(k+l) = LI(m)A;e-Ai(k+l-m)T (6-4) 
m=O 
Breaking the summation range, (6-4) can be expanded as 
k 
R;(k+1)= LJ(m)A;e-Ai(k+l-m)T + J(k+1)A; (6-5) 
m=O 
If the infusion rate over the period from t to t+~t is a constant I, then 
k 
R;(k+1) = e-AiLI(m)A;e-Ai(k-m)T + A;f (6-6) 
m=O 
This is equivalent to 
(6-7) 
Using equations (6-3) and (6-7), a recursive algoritlun to calculate the plasma drug 
concentration can be derived as follows 
-AiT CpcALd.k+ 1) = e CpcALd.k) + T A;f (6-8) 
The first term in (6-8) represents the decay of the plasma drug concentration in the patient 
over the period from kT to (k+ I )T while the second term is the contribution from drug 
concentration by the drug infused at a constant infusion rate I over the same period. For three-
compartment pharmacokinetic model (n=3), A; can be obtained from equation (4-8) and (4-
13), and A; are the roots of the characteristic equation (polynomial denominator) of Dp(s) 
shown in equation (4-11), i.e., a,~. and y, respectively. 
Similarly, the algorithm to calculate the effect site drug concentration can be obtained 
11 
CecALd.k+ 1) = e.;,;CecALd.k) + LBJ 
i=l 
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(6-9) 
6.4.2. Infusion Rate Algorithm 
As stated earlier, the drug infusion rate is generated from the target drug concentration and the 
drug concentration predicted by the population average pharmacokinetic model. Though the 
equations can be easily solved for infusion rate in the frequency domain, the implementation 
of these equations in the time domain are complicated, a modified Jacob algorithm (Jacobs, 
1990) is therefore used in implementation. 
If at time kT, the drug concentration is CpcALc{kl) and a target concentration of Cr is given 
and required to be achieved at time (k+ l)T. In original Jacob algorithm (Jacobs, 1990), as 
shown in Figure 6-4, two pharmacokinetic simulations are needed to work out the drug 
concentrations at (k+ J)T (i.e., CpcALc1(k1) and CpcALC2(k1)) with two arbitrary infusion rates 
(/1(k1) and h(kl)) over the next period from kT to (k+ J)T. Because of the linear relationship 
between the drug concentration gained and the amount of drug infused, the infusion rate to 
achieve the target concentration is easy to obtain from the line equation of the tilt line. 
Drug Concentration 
CpCALd(k+/)1) 
CpCALC/((k+/)1) ........................... : 
Infusion Rate 
Figure 6-4 Original Jacob infusion algorithm (/1(k1), h(kl): test infusion rates; I (kl): 
infusion rate to achieve target concentration Cr) 
The drawback of this algorithm is that the pharmacokinetic simulation has to be done twice at 
time kT and the slope of the line changes each time a new infusion rate is needed, therefore a 
modified infusion rate algorithm, which uses a fixed slope for all infusion rate updates and 
requires only one pharmacokinetic simulation at time kT, is used for instead. This algorithm is 
illustrated in Figure 6-5. 
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Figure 6-5 Modified Jacob infusion algorithrll 01 and l1: bolus infusion rates to achieve drug 
concentratioin CpcALCJ and CpcALCl at time O, respectively; llCpcALC : unit drug concentration 
after the drug infusion with unit infusion rate of 1 ml/hour.kg at time 0 for Tseconds) 
This algorithm is based on the viewpoint at time 0 and before this time point zero drug 
concentration is assumed. At time 0, the drug concentration will be zero if there is no drug 
infusion, and if the infusion rate is I ml/hour:kg from time 0 to time T then the drug 
concentration will be llCpcAw Therefore a line (Figure 6-5) representing the relationship 
between an infusion rate and the resulted drug concentration can be drawn based on these 
facts. This relationship can be mathematically described by the line equation (6"10): 
c pCALC = llC pCALC X I (6-10) 
where I is the infusion rate and CpcALC is the resulted drug concentration after T seconds. 
Therefore, if the drug concentration needs to be increased from CpcALc(kl) at time kT to 
CpcALc((k+1)1) at time(k+1)T, the infusion rate can be calculated by (6-11) which is derived 
from(6-10): 
C pCALc((k + I~T)- C pCALc(kT) I (kT) = -----"-.:.=--'--------"-==----
llCpCALC 
6.4.2.1. Targeting on Plasma 
(6-11) 
Considering that the drug concentration at time kT will decline while drug is being infused 
during the next period, the compensation is therefore needed for this drug loss. Suppose the 
plasma dmg concentration at time kT is estimated as CpcALc(kl), and at time (k+ I )T the drug 
concentration will decline to CpcALc((k+l )1) if no dmg is infused over the period from kT to 
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(k+ I )T. This can be obtained from phannacokinetic simulation at time kT. Hence the infusion 
rate to achieve target plasma concentration C7(kl) at time kT can be calculated from (6-12): 
Cr(kT)- CpCALc((k + 1)T) l(kT) = ___:_--~=-=------
t1C pCALC 
(6-12) 
Theoretically, any plasma target concentration could be achieved and maintained using this 
infusion algorithm. To achieve the target concentration in anaesthesia induction, a single 
initial bolus is required and the bolus infusion rate 1(0) could be calculated with the zero 
initial condition CpcALc(1 )=0. 
As the unit plasma drug concentration or scale factor t1CpcALC is calculated on the basis of 
sampling period T, the infusion rate update period should also be set to the same constant Tto 
avoid loss of accuracy. 
6.4.2.2. Targeting on Effect Site 
Although the infusion rate generation algorithm for targeting on plasma is simple, the one for 
targeting on effect site is more complicated because of the hysteresis of drug effect after drug 
infusion. When effect site becomes the site of target, the infusion rate given to the anaesthesia 
pump is supposed to result in a peak effect site concentration that is equal to the target drug 
concentration. This implies that iterations of calculating the effect site drug concentration 
with incremental infusion rates are required. 
Suppose no previous drug infusion has been given. The unit effect site drug concentration 
(t1CecALc) is similarly defined as the maximum effect site concentration at peak time (tp=Nl) 
after the infusion with a unit infusion rate of 1 mVhour over a sampling period T. Here NT is 
the initial drug effect peak time that is equal to the population average peak time of 1.7 
minutes. Using the same method as used for calculating the infusion rate when targeting on 
plasma, the infusion rate J(k) over a sampling period Twould be 
l(kl) Cr(kT)- CecALc((k + n)T) 
t1CecALC 
and 17.05 t1CecALC = --
IV 
(6-13) 
Where C7(k) is the target concentration at effect site at time kT, and CecALc(k+n) is the peak 
effect site drug concentration at time (k+n)T where n varies and depends on the drug 
concentration at time kT and the infusion rate I(k) to be given. t1CecALC can be obtained from 
either simulation or mathematical integration, and w is the weight of the patient. 
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To solve the equation (6-13) for I(k), a recursive search mechanism for the dynamic number n 
is used. It is worth noting that equation (6-12) is actually a special case of equation (6-13) 
with n= 1, and that there will be no further infusion between (k+l )T and (k+n)T if the target 
concentration remains unchanged during this period. 
The recursive search algorithm for infusion rate is shown in the following flow chart. 
tp(k) = tp(k-1) 
Cdecayett(k) = GetDecayedConc(C(k), fp(k)) 
l(k) = GetlnfusionRate(Cr(k), Cdecay.ti(k)) 
lp(k) = FindPeakTime(tp(k) , I(k) , C(k)) 
Cdecayetf(k) = GetDecayedConc(C(k), lp(k)) 
C11ew(k) = GetNewConc(l(k) , lp(k)) 
Cpeak(k) = Cdecayeti{k) + C.rew(k) 
110 
yes 
( stop ) 
Figure 6-6 Flow chart of the infusion rate generation algorithm for targeting on effect site 
In above flow chart, lp(k) is the drug effect peak time estimated at time kT, while lp(k-1) is 
previous peak time estimated at time (k-1 )T. J(k) is the infusion rate to be given at time kT, 
C(k) is the effect site concentration at time kT, and Cr(k) is the target effect site concentration 
120 of220 
-------
at time kT. Cc~ecayed(k) is the effect site drug concentration after decay over the period of time 
of fp(k) without infusion but estimated at time kT. Cnew(k) is the peak effect site drug 
concentration after T -second drug infusion if no drug has been infused before this. Cpeak(k) is 
the peak effect site drug concentration after lp(k) but estimated at time kT. Due to the linear 
assumption, Cpeak(k) is the sum of Cdecayed{k) and Cnew(k). 8 is a small constant and used for 
controlling the precision of the infusion rate generation. Functions GetDecayedConc( ) and 
GetNewConc( ) are the implementation of the first and second term of the equation (6-9), 
respectively, while function GetlnfusionRate( ) is the implementation of equation (6-13). The 
function FindPeakTime( ) implements a numeric search algorithm based on the estimated 
effect site drug concentration and infusion rate at time kT. 
' 6.5. PID Controller 
6.5.1. Design Method 
The PID controller is used in the CLAN system for updating the target concentration of the 
TCI controlling infusion of hypnotic agent propofol. The closed-loop path of the CLAN 
system described by Figure 4-1 is redrawn in Figure 6-7 for the purpose of PID controller 
design. 
.................................................................. 
PID 
Controller 
u Target 
Generator 
l .. .I~.~~.~ .. ~.~.~~!~~.~~.~ ............. . 
: •• •• •• • • •• • •• • • • • •• •• • • • •• • 0 • •• •• • • • 0 • ••• • • • ~ 
TCI (hypnotic) j 
Generator 
. . 
......... ..... ................................ 
.._ __ H_yp_n_o_ti_c_e_ffi_e_ct _____ --1 EEG Monitor ~e---E_E_G __ ___, 
Figure 6-7 The closed-loop path of the CLAN system described by Figure 4-1 
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However, the order of this system is quite high due to the two pharmacokinetic models 
(reference model in the TCI and patient model). Instead of designing the PID controller in a 
high-order system, a simpler closed-loop system shown in Figure 6-8 is designed, and then 
the controller gains are converted into those that can be used in the system shown in Figure 
6-7 or Figure 4-1 with the same control performance. 
_B_I_s_...,~ 
Target %/- - ,..... 
e(k) 
=t-
A~ 
PID 
Controller 
u(k)_...~, . 1EEG EEG 
... w Pattent
1 
... 
Monitor 
Figure 6-8 Direct PID controlled closed-loop anaesthesia system 
(w is the weight of the patient) 
BIS(k) 
_... 
.. 
In the closed-loop system shown in Figure 6-8, the PID controller directly gives the infusion 
rate, no phannacokinetic model is used for the infusion control, hence no target drug 
concentration involves explicitly. 
Suppose u1(k) is the output of the PID controller in Figure 6-7, and u2(k) is that in Figure 6-8, 
rewriting (6-13) to (6- 15) gives 
!(k) = 0.05865w(Cr (k)- CecALc (k + 11)) (6-15) 
This implies that for any change of target drug concentration made by u1(k+n) in the target 
generator when CecALc{k+n) = CT(k), the pump will infuse drug with infusion rate of 
0.05865wu1(k) during the next T seconds. For the desired closed-loop system (Figure 6-7) to 
have the same transient and steady state characteristics as the direct PID closed-loop conh·ol 
system (Figure 6-8), the infusion rates generated by the two systems from the identical error 
should be the same. This resu lts in the fo llowing relationship between the two systems: 
wu 2 (k) = 0.05865wu 1 (k) or u 1 (k) = 17.05u 2 (k) (6-16) 
If kpt. ku and kdt are the PID controller gains in the system shown in Figure 6-7, and kp2• k;2 
and kd2 are those in the system shown in Figure 6-8, then (6-16) implies 
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(6-17) 
The PID controller gains were obtained using the following method: 
1. Estimate initial gains (kp1, ku and kd1) for the system shown in Figure 6-7 from system 
response specifications defined Section 6.2.3 
2. Convert these gains into the gains (kp2, kil and kd2) in the system shown in Figure 6-8 
using ( 6-1 7) 
3. Using repeatedly computer simulation, search for the best set of gains which meets the 
specifications of system response 
4. Evaluate the searched controller gains using Bode diagram, root locus, and the unit 
step response 
5. Convert the gains kp2, k;2 and kd2 back into the gains kp1, ku and kd1 using (6-17), and 
use manual adjustment to refine the gains 
6.5.2. Estimation of Initial Gains 
PID controller gains can be initially estimated from the system specifications, i.e. rise time, 
steady state error, and the relationship between the drug concentration and BIS effect. From 
(4-28), the following relationship exists between the change in drug concentration and the 
change in BIS. 
!':..C = -MJS I 12.837 (6-18) 
Suppose the system shown in Figure 6-7 has been at steady state before time kT without 
steady state error, if the Bispectral Index was increased by 1 (anaesthesia becomes lighter) at 
time kT, then this relationship suggests that the drug concentration must have been decreased 
by -1/12.837 /lg/ml or -0.0779 /lg/ml at the same time. Therefore, the PID controller is 
supposed to increase the target concentration for the pharmacokinetic model to compensate 
this loss in concentration, i.e. u(k)=0.0779 /lg/ml, and consequently increase the BIS value by 
I. However, this compensation should be spread over 50 seconds (rise time) or I 0 sampling 
periods because of the hysteresis of drug effect with target concentration increased by 
0.0779/10 or 0.00779 /lg/ml at each cycle on average. Because the main contribution to the 
extra target concentration is from proportional term, therefore, k pl x e(k) ""0.00779 x e(k) or 
kpl ""0.00779. 
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For estimation of the integration gain, the following assumption was made: the minimum 
contribution to the extra target concentration should be made when the steady state BIS error 
has been accumulated to l. Because the BIS precision is 0.001, so kil x l ""0.001/12.837 or 
kil ""7.79x 10-5 . 
Derivative term in the PID controller made its contribution to the extra target concentration 
only when the rate of BIS error changes even if an outstanding BIS error is present. Once the 
rate of change and the error are both positive, it indicates that the anaesthesia starts to become 
inadequate at a significant speed. Because this is a one-off anticipated contribution, this 
contribution should be large enough to stop this trend as soon as possible. 
Considering a BIS error of 5 occurs at steady state without steady state error, the proportional 
term will add k pi x error = 0.00779 x 5 or 0.03895 ~tg/ml to the target concentration at 
current cycle, and will contribute at least 0.03895 x lO ~tg/ml in total (as the BIS error will 
keep growing due to the hysteresis) within the next 50 seconds (rise time, 10 sampling 
periods) as aforementioned. Clearly, the contribution from the proportional term at this cycle 
is far less than enough to stop the rise of BIS. Therefore, a one-off contribution, as large as 
the minimum contribution from the proportional tem1 ( 0.03895 xI 0 ~tg/ml), from the 
derivative term seems to be a reasonable start for the estimation of the initial derivative gain. 
Because the system is assumed at steady state with zero error when the BIS rise happens, so 
the initial derivative gain can be estimated as follows based on (4-32). 
kdlx (S-0)-(0-0)<-<0.03895xl0 k 03895 h r· h )" . d f5 ·- or dl "" . , w ere IS t e samp mg per10 o 
T 
seconds. 
In summary, the gains of the PID controller of the system shown in Figure 6-7 have initially 
been estimated from the specifications as the following values. 
k pi ""0.00779 kdl ""0.3895 (6-19) 
6.5.3. Search of Optimal Gains 
Considering the infusion rate J(k) is proportional and Hp(s) is inversely proportional to the 
weight (w) of the patient involved, the mathematical model of the control system shown in 
Figure 6-8 is shown in Figure 6-9 with EEG Monitor replaced by the population average 
phmmacodynamic model. 
124 of220 
...... .. ..... ........... .......... ..................................................................... 
. . 
. . 
BIS 
.., _ 
Target + : w 
BIST(k) __i_ ! 
~: 
. . 
......................................................................................................... 
Figure 6-9 The mathematical model of the control system shown in Figure 6-8 
The discrete transfer function representation of the closed-loop system within the dotted 
rectangle is shown in Figure 6-10. 
Figure 6-10 Discrete transfer function of the dotted system in Figure 6-9 
(this closed-loop system is no longer associated with the patient weight) 
By using ( 6-17), the initial PID controller gains in the system shown in Figure 6-10 are 
obtained as follows. 
-4 k p2 ~ 4.57 X 10 ki2 ~ 4.57 x 1 o-6 kd2 ~ 0.0228 (6-20) 
The simplified system shown in Figure 6- 10 was implemented in MA TLAB environment, and 
simulations were run repeatedly with specified PlO controller gains to search all possible set 
of gains that meet the specifications specified in Section 6.2.3 (i.e. the maximum overshoot, 
rise time and steady state error). 
In order not to miss any valid gains, a downward search was performed within the range 
specified in Table 6-5 with search steps shown in the same table. In each run of the 
simulation, only one of the three gains was changed. 
The actual values of the parameters describing system performance, i.e. the maxtmum 
overshoot, rise time and steady state error, were stored together with the associated gains that 
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meet the specifications. When the search finished, all stored gains were examined again to 
search for the gains with the best performance. 
Table 6-5 Parameters for PID controller gain search 
kp k; kd 
Start value lOOxl0-5 lOOxl0-7 0.1 
Search step w-5 10-7 0.001 
End value 0 0 0 
After the simulation, following gains were found through the search algorithm: 
-4 kpz = 3.9x10 k;z = 3.7 X 10-6 kdz = 0.028 
With further tuning by hand, the following optimal gains were obtained for the system shown 
in Figure 6-8: 
kdz = 2.843 x 1 o-2 (6-21) 
This results in the PID controller discrete transfer function represented in (6-22) 
H (z) = 0.006085z 2 - 0.011754z + 0.005687 
c (z-l)z (6-22) 
6.5.4. Gain Evaluation 
The patient model in Figure 6-10 should be the model of a patient with unit weight (i.e., 1 kg). 
Since the PID controller was designed in z-domain, the conversion of patient model (Hp(s) in 
equation (4-24)) ins-domain to z-domain (Hp(z)) is required. This can be done by inserting a 
zero-order hold (ZOH) before the continuous time controlled object. The transfer function of 
the ZOH is (1- e -Ts) , which should be absorbed by and discretised along with the patient 
s 
model in the fom1 of 
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The conversion is done through bilinear transformation with the following population average 
pharmacokinetic parameters (time unit of second is used instead of minute): 
k,o = 0.002533/sec, 
k12 = 0.00345/sec, 
k 13 = 0.00067/sec, 
k21 = 0.00 153/sec, 
k31 = 0.00008/sec, 
keo = 0.00865/sec (calculated from the drug effect peak time of 1.7 minutes m 
pharmacokinetic simulation), 
V1 = 0.159w ml, where w is the weight (kg) of the patient 
T= 5 seconds (sampling period), 
This bilinear transformation gives 
H (z) = 0.81813z 5 + 0.82471z 4 -1.6231lz 3 -1.63626z 2 + 0.80499z + 0.81156 
P z 5 -3.91707z 4 +5.75306z 3 -3.7549lz 2 +0.91892z 
Hence the numerator vector and the denominator vector of the patient model are 
numd = [0.81813 0.82471 -1.62311 -1.63626 0.80499 0.81156] 
dend = [1 -3.91707 5.75306 -3.75491 0.91892 0] 
The open-loop Bode diagram, root locus, and the closed-loop (no PID controller) unit step 
response can be obtained with the following MATLAB functions: 
[mag, phase, w] = dbode(numd, dend, T); 
margin(mag, phase, w); 
figure; rlocus(numd, dend); 
[numd, dend] = feedback(numd, dend, 1, 1); 
figure; dstep(numd, dend, 40); 
The Bode diagram (negative gain and phase margins), root locus, and the unit step response 
of the system excluding the PID controller all indicate an unstable closed-loop system if no 
compensation to the system is made. 
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Figure 6-11 The Bode diagram of the system in Figure 6-10 without PlO controller 
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Figure 6-12 The root locus of the system in Figure 6-10 without PlO controller 
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Figure 6-13 The unit step response of the system in Figure 6-1 0 without PID controller 
By using the following vectors obtained from (6-22), the Bode diagrams and the root locus of 
this PID controller are drawn in Figure 6-14 and Figure 6-15, respectively. 
numc = [0.006085 -0.01 1754 0.005687]; 
denc = (1 - 1 0]; 
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Figure 6-14 The Bode diagram ofthe designed PlO controller 
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Figure 6-15 The root locus of the designed PID controller 
Hence the new open-loop pulse transfer function can be formed by the following MATLAB 
function 
[nurnd, dend] = series(numc, denc, numd, dend) 
The Bode diagram, root locus, and unit step response of the compensated closed-loop control 
system can be obtained by the following MATLAB functions and are shown in Figure 6-16, 
Figure 6-17, and Figure 6-18: 
[mag, phase, w] = dbode(numd, dend, T); 
margin(mag, phase, w); 
figure; rlocus(numd, dend); 
[numd, dend] == feedback(numd, dend, 1, 1); 
figure; dstep(numd, dend, 120); 
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Figure 6-16 The Bode diagram ofthe compensated system 
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Figure 6-17 The root locus of the compensated system 
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Figure 6-18 The unit step response of the closed-loop PID control system 
From the results shown by Figure 6-16, Figure 6-17, and Figure 6-18, one could see the 
designed PID control system has a good performance with gain margin of 17.9dB and phase 
margin of 63 .7deg. The system has a quick rise time (5 samples or 25 seconds) and settling 
time (8 samples or 40 seconds) with steady state enor of 1.17e-007. The maximum overshoot 
of the system is 6%. They all meet the system specifications expected before the design. 
One can easily simulate the designed system with any BIS target using the following 
MATLAB code. Figure 6-19 shows an example for the BIS target of65. 
BIS_Target = 65; N = 100; k = O:N-1 ; 
CT = (93.582- BIS_Target)/12.837; 
X = CT.ones(l ,N); 
Y = filter(numd,dend,X); 
BIS = -12.837.Y + 93.582; 
plot(k,BIS); 
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Figure 6-19 The response of the closed-loop PID control system to the BIS target of 65 
6.5.5. Manual Adjustment 
Using (6-17), the gains of the PID controller of the system in Figure 6-7 can be obtained from 
those of the system in Figure 6-8 as follows: 
k p i = 17.05k pZ = 0.0066, kil = 17.05k;2 = 0.000063 and kd1 = 17.05kd2 = 0.4848 
The response of the system using above PID controller gains is shown in Figure 6-20. 
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Figure 6-20 The BIS response of the closed-loop system to the BIS targets of 65, 50, and 65 
(Kp = 0.0066, Ki = 0.000063, Kd = 0.4848) 
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Figure 6-20 shows that the step response of the system is excellent by the use of the designed 
controller gains. However, once the BIS target is changed, which always happens in a 
smgery, the initial system response is oscillatory and it takes a long time to be settled. This is 
because the gains were designed without taking the possible change in BIS target into 
consideration. Therefore a fine-tuning on the controller gains was performed manually using 
trial and error approach, and the following optimal gains were found: 
kp = 0.0024 k; = 0.0000475 kd = 0.365 (6-23) 
However, the controller gains in (6-23) are only optimal to the patients whose PK/PD 
parameters are identical to the PKJPD model used in the design, i.e. the reference model. 
These gains were used as the start point to tune the optimal gains for individual patients in 
Section 5.5.2. 
Figure 6-21 shows the satisfactory system response when using the above optimal gains. 
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Figure 6-21 The BIS response of the closed-loop system to the BIS targets of 65, 50, and 65 
(Kp = 0.0024, K; = 0.0000475, Kd = 0.365) 
6.6. System Control by Supervision 
The CLAN system is assumed to be linear when developing its mathematical model. However 
a biomedical control system is safety critical, and a mechanism is needed to deal with any 
unknown non-linear dynamics. There are also some occasions where the infusion control 
needs to be supervised at a higher level, such as negative or maximal infusion rate, minimal or 
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maximal target drug concentration, change of BIS target etc. This is carried out at the system 
level to look after the CLAN system and make sure that the infusion is going well and the 
patient is safe. The system control unit is basically a central control and digital signal 
processing unit. The following sections describe how it works under various events. 
6.6.1. Normal Operation 
Under normal operation, the supervision system routinely performs the safety checks on 
infusion pump (and the second pump if two drugs are given) and the EEG monitor by reading 
their status. The pumps themselves could stop the infusion and enter into alarm status 
whenever they detect anything wrong with the pumps or the syringes. If this happens, the 
supervision system will issue an audio and visual warning signal, and automatically set up the 
pump communication again. If the alarm from the pump continues, physical intervention is 
required to clear the alarm. The supervision system can also identify whether the RS232 
cables linking the PC and the pumps are disconnected or the power cables of the pumps and 
are disconnected. 
Another routine safety check is on the EEG monitor. Since the data acquisition reads the raw 
EEG data and the processed EEG data in a block every five seconds from the buffers, an 
empty buffer indicates a RS232 cable disconnection or a persistent communication error for 
the last five seconds between the host PC and the monitor. Whenever such an error occurs the 
supervision system will launch an alarm along with an appropriate warning message 
displayed on the screen. If the buffers are not empty but the synchronization for either port is 
lost, an alarm and a warning message will also be given. The current data packet(s) will be 
treated as bad packet(s) and will be rejected and put into an error file. 
The quality of Bispectral Index is monitored whenever a new BIS value becomes available. 
The new BIS value could be lost due to a loss of synchronisation or cable disconnection, or 
could be a fixed error value indicating that the EEG signal quality is bad and the monitor 
cannot produce a valid Bispectral Index for the current cycle. The new BIS value could also 
be incorrect due to a contaminated EEG signal, and this may happen when the impedance 
between the electrodes and the skin increases. 
If the loss of the Bispectral Index is persistent, the supervision system will force the closed-
loop control to be switched to open-loop control using the TCI control scheme until the 
problem is solved automatically or manually if necessary. As soon as the Bispectral Index is 
available again the closed-loop control will be enabled with the PID controller reset and 
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restarted. 
Through statistical analysis of the clinical data obtained from the volunteer and patient 
studies, a mechanism has been developed to detect the contaminated Bispectral Index. Rates 
of change in Bispectral Index trend are used for this purpose. This mechanism is only used for 
removing the impulse noise from BJS trend. 
The detection of impulse noise is based on the fact that the change of Bispectral Index is 
relatively smooth. From the result of statistical analysis on the clinical data, the rate of change 
(defined as db) below ±5 or the second order rate of change (defined as ddb) below ±0.8 are 
allowed otherwise an impulse noise is assumed. The quality of EEG signals has been taken 
into consideration for determining these values. This result implies that the maximum valid 
change in Bispectral Index in either direction is 25(e.g. 60, 85 or 60, 35) and the maximum 
oscillation in Bispectral Index is ± 1 0( e.g. 55, 65, 55 or 55, 45, 55). The second order rate of 
change criterion is only used when two adjacent changes are in different direction (i.e. the 
occurrence of oscillation). In the clinical experiments on volunteers, the maximum db and ddb 
are 3.36 and 0.55 respectively. The db and ddb waveforms in the worst case with the 13th 
volunteer in propofol infusion study are shown in Figure 6-22 where the drug infusion started 
after 10 minutes baseline EEG recording. The maximum value of db was caused by the large 
overshoot that was the patient response to the initial bolus infusion. 
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Figure 6-22 The rates of change in Bispectrallndex in the worst case of clinical trial 
(where db(n) = [BIS(n)-B IS(n- 1 )]/~t, ddb(n) = [db(n)-db(n-1)]/L\t, and L\t = 5 seconds) 
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6.6.2. Anaesthesia Induction 
The anaesthesia induction is closed-loop controlled and starts with an initial bolus calculated 
from the target Bispectral Index, and then the CLAN system waits for the drug effect or BIS 
to reach its peak value. If the peak BIS value does not reach the target then another bolus will 
be given and this process will be repeated until the target BIS has been achieved. The peak 
BIS value is detected by performing a moving average on the current and part of the history 
of BIS values. 
6.6.3. Anaesthesia Maintenance 
As the PID controller only updates the TCI's target concentration, the infusion rate is 
calculated within TCI according to the site of target and the error between the target 
concentration and the estimated. However, which site for the TCI to target on is dependent on 
the BIS error. 
During maintenance of anaesthesia, the Bispectral Index trend is relatively smooth, and the 
BIS error is usually small, and consequently the TCI targets on plasma to get the best control 
performance. Nevertheless, the effect site will become the site of target when the BIS error is 
large enough, and this would re-achieve the BIS target quickly. A threshold value for BIS 
error is used for controlling the target site. This value can be set for an individual subject at 
any time during the infusion depending on the pattern of the BIS trend in a certain period. The 
threshold value is normally within the BIS value range of 1-3 and is set to 2 by default 
according to computer simulation and clinical experience. 
6.6.4. Response to Light Anaesthesia and Stimulation 
Light anaesthesia usually occurs when the patient is stimulated physically or by 
environmental noises during surgery. Quick response from the CLAN system is required on 
these occasions. 
BIS value will rise when the anaesthetic depth becomes lighter, which results in a big enough 
BIS error to force the TCI to target on effect site and consequently a bolus or a series of 
boluses will be given to re-achieve the target. The supervision system will monitor this 
process and stop the drug infusion when the BIS value is about to drop. This is because the 
drug effect will peak with hysteresis. Though the BIS error reaches an extreme value at the 
time the infusion is stopped, the error will begin to drop until the drug effect peaks. This way 
the CLAN system would reduce the overshoot to the minimum. Again, the rate of BIS change 
is used for the CLAN system to detect the peak BIS error. 
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6.6.5. Response to Overshoot and Undershoot 
As can be seen in the clinical trials, the overshoot of Bispectral Index, either large or small, 
happens from time to time. However it is impossible to take the infused drug out of a patient, 
and the CLAN system will wait until the BIS value becomes close to the target. The infusion 
will be stopped and the PID controller will be disabled and reset when overshoot occurs. 
Because of the oscillatory nature ofBispectral Index, an overshoot threshold value for the BIS 
error is used to define the overshoot. This value is set by default to -2.5 according to clinical 
observation and statistical analysis and can be set for an individual subject at any infusion 
time. 
The PID controller will be restarted when the Bispectral Index returns from an overshoot and 
becomes close to the target. It is too late to restart the drug infusion when the BIS error is zero 
due to the hysteresis, and therefore the overshoot threshold value in BIS error is used for 
resuming the infusion earlier and helping prevent big BIS jumps. 
BIS prediction is another mechanism used by the CLAN system together with the overshoot 
threshold value to prevent sudden BIS jumps. The CLAN system monitors the first and 
second derivatives of the BIS change rate (i.e. the rate ofBIS change and the rate ofBIS error 
change) and uses the following prediction formula to predict the next BIS value: 
where en= (BISn- BISn-t)IT, and an= (en- en-t)IT 
The first target concentration after the return from overshoot will be the estimated plasma 
drug concentration, and the first target site will be on plasma in order to achieve a smooth 
transition. 
6.6.6. Emergency Handling 
The supervision system monitors the perfom1ance of each hardware component in the closed 
loop system for any possible malfunction or failure, the quality of the Bispectral Index signal 
for any impulse noise, and the perfom1ance of the PID control. The CLAN system will 
automatically respond to any hardware and software failure or malfunction. If the failure or 
malfunction of the system is not recoverable, the infusion control will be automatically 
switched from closed-loop control to open-loop TCI control and the PID controller will get 
reset, and the target drug concentration will remain on the same value as the one at the time 
the closed-loop control stops. As soon as the system failure or malfunction disappears, the 
closed-loop control comes back into operation. 
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6. 7. Interactive User Interface 
An interactive user interface is implemented for the user to input patient information and set 
the runtime conditions (e.g., target of Bispectral Index, target concentration, maximum target 
concentration, etc.) before and during running the control system. While the system is 
running, the interactive user interface allows the user to control externally the system via 
various commands shown on the screen. It also allows making comments for any clinical 
events occurred at runtime, and all events recorded are accessible at run time. 
The interactive user interface provides an information rich screen display which includes the 
states of pumps and EEG monitor, current infusion rate, target Bispectral Index and target 
concentration, measured Bispectral Index and estimated plasma and effect site concentrations. 
See Appendix E for details. It also provides an efficient way to externally control the system 
either for normal operation or for emergency handling. It provides the commands to start, 
pause, and restart the drug infusion, and to change syringe and resume infusion. It allows the 
run-time modification of a number of system parameters that include target BIS, target 
concentration, PID controller gains (kp, k;, k.t), maximum target concentration (plasma or 
effect site), and the threshold BIS errors. Also the user can manually switch between closed-
loop control and open-loop control if needed. Please refer to the Appendix E for a complete 
list of the available external commands. 
6.8. Test of Closed-loop Anaesthesia System 
6.8.1. Test of System on Patient Safety 
In the design and implementation of a biological automatic control system, safety 
considerations are essential otherwise the control system would result in unpredictable or 
even disastrous consequences. Before the use of such a system, the possible sources of error 
should be anticipated so that the errors could be avoided or corrected automatically. 
In a closed-loop control system, errors may arise from both software and hardware. The 
possible software errors may include programming errors, unreasonable or even wrong 
actions of control algorithm, communication errors, limited infusion pump precision. On the 
hardware side, the possible errors might arise from the disconnection of power cable from the 
pumps or monitor, the disconnection of the RS232 serial communication cables, and the 
disconnection of the electrode leads and IV line. Also the improper positioning of the syringe 
will cause infusion problem. The programming errors are bugs in the code, and the control 
algorithm associated errors may be the errors caused by the non-linear dose-response 
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relationship that could be seen from time to time in the clinical practices and experiments. 
Errors could also occur due to the inherent limitation of the algorithm, while communication 
errors are those generated by noise over the RS232 cables. Figure 6-23 summarizes the 
sources and the types.ofthe possible errors. 
Potential 
Sources 
of Errors 
Software 
Sources 
Hardware 
Sources 
Programming -----~Bugs 
r-----Non-linear dose-response 
Control Algorithm~ . . 
Algorithm limitations 
CommUnication----- Noises over RS232 cable 
Pump --------Precision and physical limitation 
Power Failure------cable disconnection 
Communication Failure --cable disconnection 
.---rv line disconnection 
Syringe -----l 
~----Improper positioned 
-----Electrode leads off 
Figure 6-23 Possible sources and types of errors in the CLAN system 
Generally, software errors could be avoided by careful coding of the system, or identified and 
automatically corrected by the system. However for the hardware errors, the system could 
only give either audio or visual warnings, manual interventions by the user are required. It is 
essential for a medical control system to be able to correct automatically the software errors if 
any, identify the hardware errors, give both audio and visUal warning signals to the user, and 
take proper action before the errors cause problem. 
In the CLAN system, all hardware errors have been deliberately generated, and the CLAN 
system is able to give appropriate warnings and take proper actions. 
6.8.2. Test of System on Virtual Patients 
As the PID controller is not an adaptive controller that is capable of adjusting the gains itself 
to adapt to the dynamic controlled object, a single set of controller gains are needed for all 
patients. This universal gain set could be generated in many ways, the only principle for 
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obtaining such gains is that an acceptable control performance must be guaranteed by those 
gains on the whole population under study. A possible method to do this is to average the 
gains available. The AverageGain set is therefore obtained by averaging the kp, Id, and kd 
columns in Table 5-1 , the original optimal gains for the nine patients are re-listed together 
with the AverageGain in Table 6-6, where Patientl ~Patient9 are defined in Table 4-5 . 
Table 6-6 Population average PID controller gains 
kp ki kd 
Patient 1 0.0024 0.000022 0.34 
Patient 2 0.0015 0.000008 0. 1 
Patient 3 0.0012 0.00009 0.1 
I Patient 4 0.0012 0.00001 0.125 
-! Patient 5 0.0024 0.00005 0.18 
Patient 6 0.0024 0.00001 0.18 
Patient 7 0.0019 0.00001 0.1 
Patient 8 0.0024 0.00002 0.29 
Patient9 0.0008 0.00009 0. 11 
AverageGain 0.0018 0.000034 0. 169 
The effect site drug concentrations in these nine virtual patients are shown in Figure 6-24 with 
average gains used in the CLAN system, and the Bispectral Indexes are shown in Figure 6-25. 
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Figure 6-24 Effect site drug concentrations in the nine patients controlled by the CLAN 
system using average gains (Ce6, Ce8: effect site drug concentration in Patient6 and Patient8) 
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Figure 6-25 Bispectra1 tndexes in the nine patients controlled by the CLAN system 
using average gains (BIS6, BIS8: Bispectraltndex in Patient6 and PatientS) 
To do a robust test on the prototype CLAN system before usmg it in any clinical 
environments, the 78125 simulated patients defined in Table 4-7 are used with the average 
PID controller gains. To avoid running out of memory because of the huge amount of data to 
be generated, these 78125 hypothetical patients are equally divided into 5 main groups, each 
of which consists of 5 sub-groups. Therefore the whole test consists of 25 sub-tests, and each 
sub-test tests 3125 hypothetical patients in one go. 
Each main group contains 15625 patients having identical central compartment volume, and 
each sub-group containing 3125 patients whose drug effect peak time are the same. The 
patients within each sub-group therefore have identical peak time value and central 
compartment volume with different permutation in the 5 rate constants. 
To avoid redundant information, only the time evolution of the Bispectral Index of the 
patients is presented here because of the assumed linear relationship between the effect site 
drug concentration and the Bispectral Index. Figure 6-26, Figure 6-27, and Figure 6-28 show 
the simulation results on the patients in three of the five main groups (46895 patients), 
respectively. These hypothetical patients have either the maximal or mean or the minimal 
central compartment volumes defined in Table 4-7. The means and standard deviations of 
Bispectral Index in a main group (Vc= l6.9 litres) are presented in Table 6-7. 
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Figure 6-26 Simulation result on 15625 patients with central compartment volume of 16.9 
litres (tpeak: drug effect peak time; each of the 5 figures presents the result on 3125 patients) 
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Figure 6-27 Simulation result on 15625 patients with central compartment volume of 13.6 
litres (tpeak:: dmg effect peak time; each ofthe 5 figures presents the result on 3125 patients) 
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Figure 6-28 Simulation result on 15625 patients with central compartment volume of20.2 
litres (tpeak: drug effect peak time; each of the 5 figures presents the result on 3125 patients) 
The patients associated with Figure 6-26 have the mean central compartment volume of 16.9 
litres, and those associated with Figure 6-27 have the minimal volume of 13.6 litres, while 
those associated with Figure 6-28 have the maximal volume of20.2 litres. 
Table 6-7 Mean and standard deviation ofBispectral Index of a patient group (Vc = 16.9 
litres) 
BIS Sub-group1 Sub-group2 Sub-group3 Sub-group4 Sub-groupS 
Target tpeak=l min tpeak=l.35 min tpeak=l.7 min lpeak=2.05 min tpeak=2.4 min 
No. ofpatients - 3125 3125 3125 3125 3125 
10-20 minutes 65 64.43±0.98 64.76±0.37 64.73±0.34 64.73±0.32 64.74±0.30 
30-40 minutes so 49.21±1.33 49.80±0.40 49.75±0.39 49.75±0.36 49.75±0.35 
50-60 minutes 65 64.77±0.25 64.80±0.25 64.81±0.25 64.79±0.25 64.74±0.24 
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The control performance of the CLAN system on the other two main groups of the patients 
falls either between those shown in Figure 6-26 and Figure 6-27 for the group having the 
volume of 15.3 litres, or between those shown in Figure 6-26 and Figure 6-28 for the group 
having the volume of 18.5 litres. 
6. 9. Discussion and Conclusion 
All components in the CLAN system shown in Figure 4-1 have been designed and 
implemented. The software components are written in C language. The design has met the 
desired specifications. The prototype of the CLAN system is tested on a population of 
hypothetical patients. Though the Bispectral Indexes from the patients do not converge to a 
single value in this robust test, the control performance is as expected and the performance is 
acceptable. 
Though the CLAN system designed and implemented is specifically for controlling the 
infusion of hypnotic propofol and analgesic alfentanil, it supports the delivering of other 
analgesics by selecting them in the command file. However, the PID controller gains have to 
be redesigned with an appropriate pharmacodynamic model so that the CLAN system can be 
used for delivering other hypnotics with closed-loop control. Some other anaesthesia pumps 
such as Harvard and T-Med are also supported by the CLAN system. 
The result of the simulation study on the 78125 patients demonstrates that the designed 
CLAN system is capable of achieving, tracking, and maintaining dynamic Bispectral Index 
targets in a population with a broad range ofPKIPD parameter values. 
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7. Evaluation of the Closed-Loop Anaesthesia (CLAN) System 
7.1. Introduction 
Automated control systems have widespread application in critical applications. However, 
their use in medical care is relatively unusual. After intensive simulations on the virtual 
patients and appropriate electrical testing the closed-loop system was evaluated in volunteers 
and patients. Each clinical study was approved by the Ethical Committee and all subjects gave 
consent in writing. Considerable attention was given to electrical safety for the entire 
apparatus. An isolation transformer is used for providing the power supply for all equipment, 
and formal electrical checking is carried out on individual items of the complete assembled 
system. 
Initial testing took place on volunteers. This allowed complete control over the experimental 
protocol without impingement of clinical (surgical) factors. Nevertheless, safety of volunteers 
is paramount and this was reflected in the staffing, general equipment and location. 
After testing of the CLAN system on volunteers with physical stimulation or N20 inhalation, 
it was further tested on patients undergoing knee surgery with epidural, and finally on patients 
undergoing back surgery with alfentanil for total intravenous anaesthesia delivery. 
7.2. Safety Test of CLAN System 
The real time safety tests have been done on the CLAN system when running in simulation 
mode. The ability of hardware malfunction identification and if possible correction were 
tested with the running of two Graseby 3400 pumps and the Aspect A-1000 EEG monitor. 
In these tests, error conditions were deliberately created, and then fixed thereafter. The 
following is a list of the tests that have been done. 
• 
• 
• 
Disconnecting/Re-connecting each of the three RS232 cables from computer, Graseby 
3400 pumps, or the A-1000 EEG monitor. 
Disconnecting/Re-connecting the power cables of the pumps and EEG monitor 
Creating/Fixing error from seating the syringes 
The CLAN system responded to the deliberately created errors by giving appropriate visual 
and audio warning messages, and as soon as the error condition disappeared, the CLAN 
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system was able to resume correctly. If the problem was from the pumps or syringes, then the 
pumps would be re-initialised and the infused volume would be set to those before the error 
condition had arisen. 
7.3. General Methods 
Volunteer experiments took place in the "anaesthetic room" of a standard NHS operating 
theatre. In addition to the research engineer, a qualified anaesthetist (typically more than one) 
and a trained anaesthetic assistant were present. All experiments with the CLAN system were 
fully controlled by the medical staff, and the role of the research engineer was limited to 
supervising the operation of the software, input of data required by the experiments and 
offering technical advice. 
The "anaesthetic room" is a standard clinical environment including all necessary and routine 
equipment. "Standard" monitoring was applied to all volunteers/patients including non-
invasive blood pressure, pulse-oximetry and ECG. The experimental area was fully enclosed 
and "Do not disturb" signs were placed on the external doors. Volunteers wore standard 
cotton "theatre greens", patients wore "theatre gowns" and all lay on a standard operating 
theatre trolley. A full range of routine and emergency drugs, and clinical equipment was 
immediately to hand. Use of a written checklist ensured a thorough preparation of all relevant 
items. 
For all subjects of the four clinical studies, five electrodes were attached to the forehead of 
subjects to obtain two channel (bipolar, Fpl(+), F7(-), Fpz(ground), and Fp2(+), F8(-), 
international 10-20 system electrode placement chart) EEG signals. The impedance between 
any electrode and the skin was maintained below lOkQ (usually less than 5 kQ) to guarantee 
the quality of the EEG signals. 
Every 5 seconds a Bispectral Index and some power spectral variables were calculated from 
the EEG signals by a built-in proprietary algorithm (BIS V3.12 for the first three studies, BIS 
V3.30 for the fourth study) installed in the Aspect A-1000 EEG monitor, the raw EEG signals 
containing artefacts were set to be rejected from these calculations. Throughout each 
experiment, the two channel raw EEG signals, BIS and all the other derived EEG variables 
were recorded by the CLAN system. BIS and some other EEG variables (including total 
power, SEF, MF, etc.) were displayed on the screen in real-time. Blood pressure and heart 
rate were also monitored in accordance with normal clinical practice. The full list of the A-
1000 EEG monitor settings for all subjects is given in Appendix D. 
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To take full advantage of the computer processor speed, the CLAN system ran in pure DOS 
mode on a 120MHz Compaq personal computer with the A-1000 EEG monitor and the 
Graseby 3400 anaesthesia pump(s) connected via RS232 interfaces. The control scheme and 
the population average PID controller gains, which were used in the simulations on 78125 
virtual patients, were used for all cases of the four studies. Other dynamic configurations of 
the CLAN system are listed in Appendix C. 
For the purpose of statistical analysis on the clinical data obtained from the experiments, 
induction time is defined as the time spent by the CLAN system from start of infusion until 
the BIS value reaches target or below BIST. (1 +4%) if then the BIS trend becomes stable, here 
BIST is the BIS target. BIS stable time is defined as the time from start of infusion to the time 
from which the BIS trend is persistently within BIST. (1±4%). Recovery time is defined as the 
time from the termination of infusion to the time the patients woke up. Since the times at 
which the patients opened their eyes were not recorded for all patients, for those the eye-open 
times were not recorded, the recovery time is defined from the termination of infusion until 
BIS value reaches 90 according to other reports (Epstein, 1998; Baker, Sleigh and Smith, 
2000) and our own clinical observation. Finally, the predicted wakening concentration is the 
predicted effect site propofol concentration when patients woke up or BIS reached 90 after the 
termination of infusion. 
Above methods and definitions apply to all clinical studies. 
7.4. Propofol Sedation on Volunteers 
7.4.1. Objective 
The CLAN system was first tested on volunteers for propofol sedation. The objective of this 
study is to test the performance of the CLAN system on controlling the level of sedation in 
human subjects with or without external stimulation but without interference from an 
analgesic agent. 
7 .4.2. Methods 
For all subjects in this study, no premedication was given before the experiments. The target 
Bispectral Index was set to 65 to achieve hypnotic effect(Baker, Sleigh and Smith, 2000) in 
the volunteers, and the experiment protocol for this study is shown in Figure 7-1 that includes 
5 periods. 
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Figure 7-1 Experiment protocol for volunteer study with propofol and stimulation 
With regard to the time length for each of the 5 periods, there is a trade-off between the 
perfect science and practicality/safety in a clinical experiment involving human beings. The 
lengths of experiment periods above were chosen on practical considerations and clinical 
experience from a senior anaesthetist, which was likely to allow proper equilibration of the 
subject in each of the experimental conditions whilst giving an overall experimental 
"envelop" which was practicable. 
Five minutes stimulation was given during the maintenance period of anaesthesia by a nerve 
stimulator applied to the wrist with an electrical current of 30mA during the first two minutes 
increased to 40mA during the other three minutes of the stimulation. 
7.4.3. Results 
Thirteen fit volunteers (ASA I&II, 23-57 years, 56-92kg, 8 men and 5 women) entered into 
this study. The experiment protocol was completed in 12 volunteers with satisfactory results 
from 11 of them. The characteristics of the 13 volunteers are listed in Table 7-1. 
Table 7-1 Characteristics of the volunteers for propofol sedation 
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Volunteer 1 2 3 4 5 6 7 8 9 10 11 12 13 Mean (SD) 
Gender M F M M M M F F M M M F M 
Age (years) 30 31 23 40 29 57 29 35 28 39 31 40 29 33.9 (8.6) 
Weight(kg) 74 72 76 73 80 90 57 56 80 92 64 80 80 74.9 (1 0.9) 
Height (cm) 180 160 183 175 175 183 157 168 175 186 174 180 183 175.3 (8.9) 
The protocol was not completed in the first subject due to long-lasting absence of BIS value 
from the EEG monitor and the propofol infusion was then manually switched to TCI control. 
The clinical data obtained from this volunteer is therefore excluded from the statistical 
analysis. The failure was caused by bad contact between the electrodes and skin when the 
subject moved, which in return caused a high impedance (over 10,000 ohm with 2,000 ohm 
recommended) between the brain signal and the external signal amplifier of the EEG monitor. 
The experiment protocol defined previously in Figure 7-1 was not exactly followed due to 
various unavoidable reasons including hospital staff temporary availability and equipments 
malfunction. The actual protocols perfonned in volunteers are shown in Figure 7-2. 
Generally, the experiment protocol was changed in volunteers 1, 3-5, 9, and 11. Subject 3 was 
not given stimulation at all because the desired BIS target was never achieved. For the 4th 
subject, there was a large overshoot (BIS4 in Figure 7-3) during the sedation induction, and 
the stimulation was not given until the BIS returned to around the BIS target at a time 25 
minutes after the start of infusion, and infusion stopped immediately after stimulation on this 
subject. Pump failures (all caused by subject's body movement) forced 11 minutes delay in 
giving stimulation to the 5th volunteer. The stimulation to the 9th subject was given 5 minutes 
before the schedule due to the earlier stabilisation of Bispectral Index in this subject. The 
infusion started 3 minutes after the schedule in subject 11 because of a problem of syringe 
seating. 
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Figure 7-2 Actual experiment protocols performed in volunteers (bottom - planned protocol) 
The measured Bispectral Index (BISi for the ith volunteer) and the predicted propofol 
concentration in plasma (Cpi for the ith volunteer) and at effect site (Cei for the i1h volunteer) 
are presented in Figure 7-3, Figure 7-4, Figure 7-6, Figure 7-7, and Figure 7-8, respectively. 
Figure 7-5 is the combined figure of Figure 7-3 and Figure 7-4 but normalised to the 
stimulation time. The lower the BIS value, the deeper in depth of anaesthesia. The x axis 
shows the time in minutes after the start of infusion in all figures except for the Figure 7-5 
where the x axis shows the time after the start of stimulation. 
The data on predicted plasma and effect site drug concentration estimated by the reference 
model were never archived by human mistake in the experiment with the fourth subject. 
Before the experiment with the 8th volunteer, the CLAN system was designed to automatically 
stop archiving the predicted concentrations after the termination of infusion. Therefore, the 
predicted concentrations during recovery period are not available from the first volunteer to 
the 7th volunteer. 
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Figure 7-3 Expected BIS trends in 10 volunteers (BISi: Bispectral Index in the ith volunteer) 
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Figure 7-5 The BIS trends in 11 volunteers normalised by stimulation time indicated by the 
blue bar 
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Figure 7-6 Predicted effect site propofol concentration of9 volunteers in propofol sedation 
(Cei: predicted concentration in volunteer i, data lost in the 4th volunteer) 
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Figure 7-7 Predicted plasma propofol concentration of 9 volunteers in propofol sedation (Cpi: 
predicted concentration in volunteer i , data lost in the 4th volunteer) 
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Figure 7-8 Predicted propofol concentration in plasma and at effect site in the 3rd (Cp3, Ce3) 
and 13th (Cpl3, Cel3) volunteers 
153of220 
The induction time, BIS stable time, recovery time, and predicted wakening concentration 
(see Section 7.3 for definitions) in individual volunteers are listed in Table 7-2. The 3'd 
subject is omitted from these statistics because the BIS target was never achieved in this 
subject. 
Generally, the CLAN system achieved the BIS target in the 12 subjects in 3.2(1.4) minutes 
and successfully stabilises the BIS trends in 7.2(6.0) minutes after the start of infusion. While 
6.4(2.4) minutes after the end of infusion, the predicted effect site concentration or predicted 
wakening concentration was 1.3(0.4) mcg/ml, and the BIS values measured in the subjects 
reached 90 at which 3 subjects opened their eyes, and 5 of them became responsive to audio 
stimulation, however no records were made on the others. 
Table 7-2 Induction time, BIS stable time, recovery time, and predicted wakening 
concentration for the 12 volunteers in propofol sedation study 
~ Volw1teer 2 3 4 5 6 7 8 9 10 11 12 13 
Induction Time 2.6 NIA 2.7 5.0 2.2 4.2 2.1 1.7 5.7 1.9 4.8 2.2 
(min) 
BIS Stable Time 2.6 NIA 8.4 6.8 4.2 6.7 7.9 1.7 12.1 1.9 4.8 22.6 
(min) 
Recovery Time 3.5 NIA 6.0 3.5 10 5.2 6.5 7.3 6.1 9.4 3.5 9.1 
(m in) 
Wakening NIA NIA NIA NIA 0.9 NIA 1.5 1.1 1.7 1.0 2.1 1.1 
concentration* 
*effect stte concentratton m mcg/ml 
Mean 
(SD) 
3.2 
(1.4) 
7.2 
(6.0) 
6.4 
(2.4) 
1.3 
(0.4) 
In response to the same dose (in mg/kg) of initial bolus during the induction of sedation, the 
Bispectrallndexes in four volunteers (volunteers 2, 9, 11, and 12) were successfully brought 
to the target, overshoot can be seen in four volunteers (minimal BIS value of28.1, 45.3, 35.9, 
and 15.6 in volunteers 4, 6, 8 and 13, respectively), whereas undershoot occurred in the other 
four (volunteers 3, 5, 7, and 1 0). Overshoot or undershoot after the anaesthesia induction 
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bolus infusion is expected in subjects because of inter-patient variability. 
To achieve the BIS target in the four volunteers with undershoot, more drug was infused by 
the CLAN system when BIS value was above the target indicating a lighter anaesthesia. This 
was associated with the rise in predicted propofol concentration (by the reference model) both 
in plasma instantly and at effect site with hysteresis (see Figure 7-6 and Figure 7-7). Three of 
these four volunteers (subject 5, 7, and 10) developed overshoot (39.5, 39, and 41.8 in BIS, 
respectively) because of this extra drug, whereas the amount of drug infused was still not 
enough to achieve the BIS target in the other volunteer or subject 3. 
After a stable BIS was maintained (except for the 131h volunteer), a five-minutes long painful 
stimulation was given to volunteers. All volunteers physically responded to the stimulation 
(peripheral nerve stimulator at the wrist with electrical current of 30mA for 2 minutes 
followed by 40mA for 3 minutes), which indicated that anaesthesia became light because of 
the stimulation. A significant BIS rise was expected after the physical stimulation. The BIS 
values of the I 0 volunteers rose in response to the stimulation though the time to start 
responding varies in subjects. The CLAN system at the same time infused more drug into the 
volunteers in order to bring the BIS values back to the target, the more the BIS value rose in a 
subject, the more drug was given. Some volunteers developed overshoot (e.g., volunteer 12) 
and some did not. The BIS target was achieved again during or after the stimulation 
depending on the PKIPD characteristics of individual subjects. After the infusion had stopped, 
the recovery was quick (minimum of 3.5 minutes) in some subjects but slow (up tolO 
minutes) in others. This depends on the drug elimination rate of individual subjects. 
The BIS target was never achieved in the third volunteer in whom the maximal predicted drug 
concentration safety limit (5 mcg/ml) was hit, which expectedly prevented this subject from 
being given enough drug to achieve the target while the measured BIS was below the target. 
While in the experiment with the thirteenth volunteer, the BIS value was stabilised after 22.6 
minutes. Figure 7-4 and Figure 7-8 show the measured Bispectral Index, predicted propofol 
concentrations in plasma and at effect site of the third and the thirteenth volunteers. Table 7-3 
gives the means and standard deviations of BIS values during the maintenance period (after 
anaesthesia induction as defined in induction time) before (Period 2) and after (Period 4) the 
stimulation and those during (Period 3) the stimulation period. It also gives the overall mean 
and standard deviation on all 12 subjects during each of the three periods (63.1(8.2), 
66.1 (11.4), and 63.8(5.3) for those before, during, and after the stimulation, respectively). 
There is no data for volunteer 4 during the Period 3 as the infusion was terminated 
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immediately after the stimulation period (see Figure 7-2) due to the infusion time length 
limitation for the experiment protocol. After anaesthesia induction, the BIS target was best 
maintained before and after the stimulation (Period 2, 4) but worst maintained during the 
stimulation (Period 3). This is because BIS usually rises during or after stimulation (indicated 
by the arrows in Figure 7-3) as expected, which increases the deviation. The overall control 
performance of the CLAN system can be represented by the mean and standard deviation 
Mean(SD) on all data during the three periods in all 12 volunteers: 63.9±8.7. The last column 
of this table shows the mean (SD) values excluding the subject 13, which gives the overall 
performance of64.5 (4.9). 
Table 7-3 The Mean(SD) values ofBIS in volunteers in propofol sedation study 
I~ Volunteers 2 3 4 5 6 7 8 9 10 11 12 13 All All* 
Period 67.5 NIA 62.6 62.2 64.9 62.2 64.9 66.2 63.5 64.8 66.2 49.8 63.1 64.6 
2** (2.9) {3.0) (2.5) (2.6) (2.6) (3.0) (3.1) (1.3) (2.6) (4.1) (19.0) (8.2) (3.5) 
Period 68.8 NIA 63.3 62.0 66.3 66.0 65.4 62.5 65.3 64.9 70.9 71.5 66.1 65.5 
3 (9.9) (1 0.3) (6.8) (9.0) (3.0) (4.5) (2.0) (3.8) (3.2) (7.2) (30.1) {11.4) (7.1) 
Period 63.4 NIA NIA 58.6 65.5 64.0 64.8 64.0 65.4 64.1 59.1 68.6 63.8 63.2 
4 (2.6) (2.2) (2.9) (2.0) (4.3) (2.9) (1.7) (1.4) (9.5) (7.8) (5.3) {4.7) 
All 66.9 NIA 62.7 61.4 65.4 63.7 65.0 64.9 64.9 64.7 65.7 58.7 63.9 64.5 
Periods (5.6) (5.6) (4.0) (5.0) (3.0) (3.9) (3.2) (2.8) (2.5) (7.4) (22.8) (8.7) (4.9) 
*all subjects excludmg subject 13 **after anaesthesia mduchon 
Table 7-4 shows the Mean (SD) values of the predicted effect site concentration during the 
three periods in 12 subjects. As explained previously, the predicted concentration in subject 4 
was not archived. The Mean (SD) value of the predicted effect site concentration in subject 3 
is calculated on the data from the time the predicted effect site concentration became stable 
(i.e., reached the maximal concentration safety limit of 5.0 mcg/ml) up to the end of infusion. 
The last column shows the mean (SD) values excluding subject 13. 
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Table 7-4 The Mean(SD) values of Ce in volunteers in propofol sedation study 
I~ Volunteers 2 3 4 5 6 7 8 9 10 11 12 13 All All* 
Period 2.6 NIA NIA 3.8 2.2 5.0 2.3 2.4 2.7 2.2 2.1 1.7 2.6 2.8 
2** (0.3) (0.6) (0.1) (0.2) (0.1) (0.2) (0.0) (0.1) (0.1) (0.5) (0.9) (0.9) 
Period 4.4 NIA NIA 5.1 2.8 4.6 2.4 2.3 2.8 2.1 3.1 1.3 3.1 3.3 
3 (0.7) (0.2) (0.5) (0.1) (0.1) (0.3) (0.1) (0.1) (0.4) (0.2) (1.2) (l.l) 
Period 4.7 NIA NIA 4.1 3.0 4.7 2.6 2.0 2.7 2.0 4.2 2.7 3.3 3.3 
4 (0.1) (0.3) (0.1) (0.0) (0.1) (0.1) (0.0) (0.0) (0.4) (0.4) (1.0) (1.1) 
All 3.5 5.0 NIA 4.1 2.5 4.8 2.4 2.3 2.7 2.1 2.8 2.0 3.1 3.2 
!Periods (I. I) (0.1) (0.7) (0.4) (0.2) (0.2) (0.3) (0.1) (0.1) (0.9) (0.8) ( 1.2) (1.1) 
*all subjects excludmg subject 13 .. **after anaesthesia mduct10n 
7.4.4. Discussion 
The results from this study on the 13 volunteers show that the propofol infusion was well 
under control of the developed closed-loop anaesthesia or CLAN system except for the first 
and the last (or 13th) volunteers, and Bispectral Index was shown to be a good descriptor of 
sedation level. 
The performance of the CLAN system on all subjects except for the 13th subject was clinically 
acceptable. Once the BIS was stabilised, the CLAN system was able to maintain stable state. 
The mean (SD) values of BIS in subject 2 to subject 12 during the three periods (Period 2 to 
Period 4) were 64.6(3.5), 65.5(7.1), and 63.2(4.7), respectively with a target BIS of 65. The 
overall performance during all three periods was 64.5(4.9). The best result was obtained from 
Period 2 after anaesthesia induction, whereas the worst result came from the stimulation 
period or Period 3. The CLAN system successfully re-stabilised the BIS during or after the 
stimulation and achieved the mean (SD) value of 63.2(4.7) in BIS after the stimulation. The 
ability of the CLAN system to re-achieve and re-stabilise the BIS during or after the 
stimulation meets the requirement in clinical practice. 
Because of inter-subject variability, subjects were actually in different levels of sedation when 
the BIS was stably maintained at around 65. Any environment noises could awake those 
157 of220 
subjects who were in lighter levels of sedation. This can be confirmed from some subjects in 
whom the BIS rose from the stable state during the maintenance phases (before or after the 
stimulation) while they were moving or talking. However, the CLAN system successfully re-
achieved the BIS target within a short period of time. 
BIS oscillation occurred in subject 10 and 13 before the BIS was stabilised in 12.1 minutes 
and 22.6 minutes, respectively. For subject 10, it seems the PID controller gains are not 
suitable for this volunteer. The BIS and predicted concentrations are redrawn and shown in 
Figure 7-9. The initial bolus did not achieve the BIS target in the subject. When the loop was 
closed at 2.8 minutes the CLAN system steadily gave drug to the subject. This process can be 
seen on the predicted plasma concentration Cp (thin line). However too much drug was given 
so that overshoot occurred, and this process repeated once more before the BIS was stabilised 
eventually in 12.1 minutes. 
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Figure 7-9 Bispectral Index (upper line) and Predicted concentrations in subject 10 (physical 
stimulation time is indicated by the blue bar) 
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Drug effect hysteresis and inappropriate PID controller gains could be two of the main 
reasons for the BIS oscillation in this subject. 
As explained in Chapter 2, hysteresis is the additional time needed for the drug concentration 
in the brain to rise and induce anaesthesia after the infusion of any amount of drug, it is also 
known as drug effect peak time or tp. When the built-in PK model is targeting on effect site, it 
always gives such drug infusion rates so that the predicted effect site concentration would be 
the target concentration (generated by the PID controller) after the hysteresis. Consequently, 
more drug must be given to compensate the drug distribution loss during the hysteresis in 
order to achieve the target after it. This means that the predicted drug concentrations (Ce and 
Cp) will be inherently oscillatory if using this infusion rate generation scheme. In clinical 
practice, there is a need to achieve a desired anaesthesia level as quickly as possible. 
Therefore, this scheme is always used if undershoot occurs. When BIS is stable, however, the 
infusion scheme of targeting on plasma is used, which does not incorporate the hysteresis 
effect and so provides smooth predicted concentrations. This scheme takes longer time to 
achieve the desired target if used when an undershoot occurs. 
On the other hand, the PID controller in nature tends to be oscillatory at the beginning of 
achieving a target since the gains were not tuned to a specific patient. Although the PID 
controller has been tuned to minimise this oscillation and made a trade-off between the 
oscillation and response speed for the patients described in Chapter 5, it is only optimal for 
the patients with population average pharmacokinetic and pharmacodynamic parameters. 
When the BIS value becomes greater than the target, the PID controller starts to increase the 
target effect site concentration used by the pharmacokinetic model to generate the infusion 
rate. However, the infused drug takes effect with delay or hysteresis, and before the drug 
effect can be measured, the BIS will continue rising, and the controller keeps increasing the 
target concentration. If the controller gains were too large for a particular subject, then 
excessive drug would have been given during this process, which consequently causes 
overshoot, i.e., BIS falls lower than the target. Theoretically, the longer the hysteresis is, the 
larger the overshoot would be. This is the reason why overshoot often happens after 
undershoot in response to stimulation, and could be one of the contributions to the BIS 
oscillation seen in subject 10 and 13. 
The worst oscillatory BIS occurred in subject 13 on whom the CLAN system spent 22.6 
minutes to stabilise the BIS near the end of the infusion. The BIS trends and predicted 
propofol concentrations in this subject are unique and interesting. The detailed result is given 
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in Figure 7-10. 
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Figure 7-10 Bispectral Index (BIS), target concentration (Ct), effect site drug concentration 
(Ce), and infusion rate (IR) of the propofol infusion in volunteer 13 
As discussed previously in relation to subject 10, the hysteresis and PID controller gains 
would have both contributed to the overshoots in subject 13. However another contribution to 
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the oscillation in the 13th subject would be the possible development of natural sleep that 
affects the Bispectral Index in the same way as the depth of anaesthesia (Sleigh et al., 1999). 
The additional BIS value the natural sleep adds on the top of the BIS value measured from the 
depth of anaesthesia could disappear immediately by stimulation. In a subject (volunteer) or a 
patient with epidural, there is no painful (nociceptive) input. Accordingly they may fall into 
natural sleep. If the resultant BIS is lower than the target, then the CLAN system will suspend 
infusion, which progressively withdraws the propofol from the patient. If there is external 
acoustic stimulation, the arousal may wake the patient in whom the drug concentration is 
insufficient to maintain unconsciousness in the absence of sleep. 
The initial bolus caused overshoot in this subject (BIS=47), and the subject possibly 
developed natural sleep afterwards that could be the reason why the BIS value was further 
down to 15. There had been no drug infusion at all for 8.3 minutes after the initial bolus, and 
the BIS reached a minimum. During this period, the drug was progressively eliminated from 
the body, and the predicted effect site propofol concentration (Ce) dropped down to 1.1 
mcg/ml when BIS was 16 and the subject opened his eyes. This is very similar to the recovery 
process of this subject in which the BIS value reached 91.2 when Ce=l.l mcg/ml at the time 
9.1 minutes after infusion had been terminated. The same predicted drug concentration (Ce) 
and the fact of eye-open suggest that the subject was likely awakened from natural sleep with 
a BIS value of 16. The drug infusion in response to the increasing BIS error prevented a larger 
extreme BIS value as seen in recovery period. Thereafter the natural sleep was possibly 
developed again during the second overshoot (low BIS). The infusion had been turned off for 
6.0 minutes from I 0.8 to 16.8 minutes after the start of infusion due to the second overshoot. 
Stimulation was given from the 15th minute, subsequently the subject was aroused earlier and 
the BIS reached a larger extreme value of91.2 at the time of 17.2 minutes after the start of 
infusion. 
People could fall asleep whilst anaesthetized. The Bispectral Index could then represent either 
the depth of anaesthesia, or the depth of natural sleep (Sleigh et al., 1999), or a mixture of 
both. After infusion has been stopped and the drug effect has reached its peak, with the 
possible existence of natural sleep the Bispectral Index could go up towards lighter 
anaesthesia at a smaller rate, or oscillate within a range, or even go further down. The BIS 
trend depends upon the depth of anaesthesia, the level of the possible natural sleep developed, 
and the external stimulation. Since a slow wave sleep could result in a BIS value as low as 20 
with zero drug concentration (Sleigh et al., 1999), a low drug concentration with a significant 
low BIS value in a subject would suggest that the subject is in a deep sleeping state or an 
161 of220 
altered state of "consciousness", and eventually the subject could be easily awakened by an 
external stimulation. The wakening drug concentration may vary in a wide range depending 
upon the pharmacokinetic and pharmacodynamic characteristics in individual patients, the 
depth of sleeping state and the level of external stimulation. When a subject wakes up from a 
low drug concentration, a sharp rise in BIS will be measured immediately. 
Natural sleep has been modelled into a virtual patient with the following pharmacokinetic 
characteristics: 
• 
• 
• 
• 
• 
• 
t_peak = 0.5 minutes 
k10=0.03 min·1 
k12=0.02 min·1 
k13=0.01 min·1 
k21=0.01 min·1 
k31 =0.008 min·1 
This patient is simulated with following methods and essential assumptions in calculating the 
drug concentrations with additional contribution from natural sleep to Bispectral Index: 
• The BIS target is 65 (or equivalent initial effect site target concentration of 2.23 
mcg/ml after conversion from the BIS target). 
• The virtual patient develops natural sleep as soon as the calculated effect site drug 
concentration reaches 2.5 mcg/ml, and the virtual patient enters into the altered state of 
"consciousness" until the virtual patient wakes up. 
• Bispectral Index is maintained below the target (deeper level of anaesthesia than the 
target) due to the contribution from natural sleep, and consequently no drug is infused 
any more. 
• Drug concentrations in plasma and at effect site (Cp_2 and Ce_2 in Figure 7-11) 
steadily drop down due to the pause of drug infusion, which indicates that the 
anaesthetic level in the virtual patient becomes lower and lower whilst the Bispectral 
Index keeps below the target. 
• An external stimulation happens as soon as the effect site concentration (Ce_2 in 
Figure 7-11) drops down to 1.5 mcg/ml, and the virtual patient is awakened by this 
stimulation. 
• The Bispectral Index jumps to well above the target due to the sudden withdrawal of 
the contribution from natural sleep, and this results in a big bolus infusion that is 
designed in this simulation to bring the drug concentration in the virtual patient (Ce_2 
in Figure 7-11) up to above 2.5 mcg/ml again. 
• The above process repeats for 60 minutes. 
The result of this computer simulation is shown in Figure 7-11 that is similar to the result 
obtained from the 131h volunteer (see Figure 7-10 (b)). 
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Figure 7-11 Computer simulation with natural sleep modeled in a virtual patient (upper thin 
lines: calculated drug concentrations (Cp_2, Ce_2) in the virtual patient, lower thick lines: 
drug concentrations (Cp _1, Ce _ I) predicted by the reference model) 
In the above simulation, the trend of predicted effect site concentration (Cp_1 and Ce_l in 
Figure 7-11) shows the oscillatory property with repeatedly modelled natural sleep and 
external stimulation. However, it does not mean that the BIS oscillation will last forever in 
real clinical environment. In fact, the BIS in subject I 0 and 13 were stabilised in 12.1 and 
22.6 minutes, respectively. In subject 13, infusion was terminated at 25 minutes and then BIS 
started rising. The change of rate in BIS values became significantly low before the 
termination of infusion. This suggests that the BIS would have been kept stable for some time 
if the infusion continued. 
The effect site concentration on which a patient would begin to develop natural sleep or be 
awakened by external stimulations might depend on a number of factors, such as the depth of 
anaesthesia, and the level of external stimulation. Therefore the values chosen in the 
simulation would not fit all patients but may demonstrate on what could happen with natural 
sleep and external stimulation. 
The PKIPD parameters are chosen so that the initial bolus will induce a deep anaesthesia on 
which the development of sleep would be possible with BIS target of 65. If the desired depth 
of anaesthesia is deeper, say BIS value of 40 to 50 (or 4.14 to 3.36 mcglml after BIS to Ce 
conversion), then the same simulation result could be obtained from some of the virtual 
patients defined in Chapter 5. 
Another important cause to the BIS oscillation measured in the subject 13 would be the inter-
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subject pharmacodynamic variability. Clearly, this subject requires much less drug than any 
volunteers in this study to achieve the same BIS target. 
Because no measurement on plasma drug concentration was made in any subject of this study, 
therefore there is no way to explore the pharmacoldnetic variability in subjects for this study. 
However the pharmacodynamic variability in subjects during anaesthesia induction is shown 
in Figure 7-12. 
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Figure 7-12 Bispectral Indexes (upper set of lines) and predicted effect site concentrations (in 
mcglml, lower set oflines) in induction 
The initial bolus infusion achieved 2.23mcg/ml in predicted effect site concentration in all 
subjects in around 2 minutes. However the drug effect shown by the Bispectral Index differs 
in the subjects at the same time or shortly after. While the BIS target was achieved and stable 
in 4 subjects (subject 2, 9, 11 , and 12), undershoot was developed in another 4 subjects 
(subject 3, 5, 7, and 10), and overshoot was developed in the others (subject 4, 6, 8, and 13). 
The BIS and predicted effect site concentration after the induction are shown in Figure 7-13. 
While the BIS was maintained stable at the same BIS target in most subjects, the predicted 
effect site concentration was maintained stable in different levels. The BIS and predicted 
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concentration in subject 3, 7, and 13 demonstrate the typical pharmacodynamic variability in 
this study. 
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Figure 7-13 Bispectrallndexes (upper set of lines) and predicted effect site concentrations (in 
mcglml, lower set oflines) after induction 
While subject 7 maintained a predicted concentration of 4.8(0.2) mcglml with a stable BIS of 
63.7(3.0) at the target, the BIS in subject 3 was well above the target at 73.2(5.9) with a 
higher and stable predicted concentration of 5.1 (0.1) mcglml. On the contrary, the BIS in 
subject 13 was oscillating between 93.1 and 15.4 before stabilised at the target, whereas the 
concentration was oscillating between 0.9 and 2.2mcglml and stabilised at 3mcglml. 
Clearly, subject 13 needs much less drug then anyone else in this study to achieve the same 
BIS target. Because the amount of drug to be infused depends upon the BIS error and the PID 
controller gains, therefore, the gains used with subject 13 should have been significantly 
smaller. This would produce smaller changes in target effect site concentration for the 
reference model and hence less drug would be given. Otherwise, BIS oscillation is likely to 
occur. 
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This study demonstrates that there is no single non-adaptive PID controller and fixed 
reference PK/PD model that can encompass all patients in a population due to the inter-patient 
variability. To obtain optimal resultr fo all patients, an adaptive controller is ideal to provide 
more accurate infusion rates. Furthermore, any controller to be used to control depth of 
anaesthesia should be aware of and anticipate the clinical difference between anaesthesia and 
natural sleep, which the BIS cannot differentiate. 
The CLAN system did not achieve the BIS target in the 3'd subject due to the maximal 
concentration limit of Smcg/ml set for the first three subjects. The safety limit was then set for 
the individual subject just before the infusion started and made on-line modifiable for the 
successive experiments. If there were no such limit or the limit was set to a high enough 
value, the BIS target should have been achieved with a higher drug concentration. Though 
this result was not expected it shows the system's ability to ensure the safety of patients by 
setting a safety limit on predicted drug concentration. 
7.5. Propofoi/Nitrous Oxide Sedation on Volunteers 
7.5.1. Objective 
Nitrous Oxide (N20) is commonly used as a supplement to propofol infusions to provide 
analgesia and additional hypnosis. After the success in propofol sedation study on volunteers, 
we further tested the CLAN system for propofol/N20 sedation on another set of fit volunteers. 
The objective of this study is to investigate whether there is any interaction between the two 
drugs (propofol and nitrous oxide) as far as measured BIS is concerned. 
7.5.2. Methods 
For all subjects selected for this study, no premedication was given before the experiments. 
The BIS target was again set to 65 to achieve hypnotic effect (Baker, Sleigh and Smith, 2000) 
in the subjects. Figure 7-14 shows the experiment protocol for this study. 
The CLAN system started from S minutes baseline recording without infusion. In the 
meantime, the volunteers were told to keep quiet with eyes closed. After the base-line 
recording, a 20-minute propofol infusion was given to all volunteers for the induction and 
maintenance of sedation, and then IS-minute propofol infusion with the uptake of SO% N20 
followed by another IS-minute propofol infusion without nitrous oxide uptake. The infusion 
was terminated at the 501h minute while the CLAN system continued to record clinical data 
for 10 minutes or longer for the recovery of the subjects. All other methods described in 
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Section 7.3 apply. 
- base-line recording 
- propofol infusion without N20 
- anaesthesia induction & maintenance -recovery 
- propofol infusion with N20 inhalation 
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Figure 7-14 Experiment protocol for volunteer study with propofol and N20 
Because overshoot happened too often following undershoot in previous study, therefore the 
PID controller gains were adjusted through computer simulation to achieve following goals: 
• Reduce the drug administration when a big BIS error occurs in case the hysteresis is 
long (e.g., during induction or subject is awaked by stimulation). This was done by 
choosing a smaller integration gain Ki. 
• Increase the response speed by using a bigger differential gain Kd. This means the 
bigger positive difference between the two continuous BIS samples, the more drug 
will be given, and the infusion will be shut off earlier when the BIS drops due to this 
change. 
• Increse the proportional gain Kp accordingly to improve the response speed. 
A new set of PID controller gains meeting above requirements were manually tuned from 
computer simulation and used in this study: 
Kp=0.0024 
Ki=O.OOOOl 
Kd=0.18 
7.5.3. Results 
Eight fit volunteers (ASA I&II, 23-41 year, 62-97 kg, 5 men and 3 women) entered into this 
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study, the characteristics of these subjects are summarised in Table 7-5. Sedation was 
achieved in all subjects with or without the presence of nitrous oxide. 
For best presenting the results from this study, the measured Bispectral Index (BISi for the ith 
volunteer) and predicted propofol concentration in plasma (Cpi for the ith volunteer) and at 
effect site (Cei for the iLh volunteer) in the eight subjects are split into two parts as shown in 
Figure 7-15, Figure 7-16, and Figure 7-17. 
Table 7-5 Characteristics of the volunteers for propofol/N20 sedation 
Volunteer 1 2 3 4 5 6 7 8 Mean (SD) 
Gender M M F F M M F M NIA 
Age (years) 30 38 41 31 23 29 30 41 32.9 (6.4) 
Weight (kg) 80 86 76 73 73 97 62 63 76.3 (11.6) 
Height (cm) 175 185 168 160 173 192 170 166 173.6 (l 0.4) 
- BIS1 -BIS2 - BIS3 - BIS5 --BIS8 --Ce1 -Ce2 - Ce3 - Ce5 - Ce8 
100 12 ~ 
90 change syringe 11 E 0, 
80 10 2.. c 
9 .Q 
)( 70 8 i§ CD c 
"0 60 CD 
.s 7 0 c 
~ 50 6 0 (.) 0 Si 2i 40 5 
Cl) 8. iii 30 4 e Q. 
3 2 20 2 iii 
10 0 1 & 
0 0 w 
0 5 10 15 20 25 30 35 40 45 50 55 60 
minutes 
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Figure 7-17 Plasma propofol concentrations in 8 volunteers in propofol/N20 study 
Figure 7-15 shows the Bispectral Indexes (BIS) and predicted effect site propofol 
concentrations (Ce) in five volunteers (subject 1, 2, 3, 5, and 8) while Figure 7-16 presents 
those in the other three volunteers (subject 4, 6, and 7). The predicted plasma propofol 
concentrations (Cp) in the eight subjects are given in Figure 7-17. In all three figures, the x 
axis shows the time in minutes after the start of infusion. 
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Table 7-6 Induction time, BIS stable time, recovery time, and the predicted wake 
concentration (Ce) in the 8 volunteers in propofol/N20 sedation study 
~ Volunteer Mean 1 2 3 4 5 6 7 8 (SD) 
Induction 4.7 5.0 4.5 6.2 4.7 7.7 7.4 4.6 5.6 (1.3) 
Time (min) 
BIS Stable 4.7 6.8 4.5 12.2 13.7 7.7 7.4 6.5 7.9 (3.3) 
Time (min) 
Recovery NIA 5.5 4.9 4.4 4.9 8.0 7.8 NIA 5.9 (1.6) 
Time (min) 
Wake Ce NIA 2.76 2.76 3.28 2.15 1.12 2.91 NIA 2.5 (0.8) 
(mcg/ml) 
Anaesthesia induction was successful in all subjects. The CLAN system achieved the BIS 
target in 5.6(1.3) minutes (induction time as defined in Section 7.3), and stabilised the BIS at 
62.9(5.4) in 7.9(3.3) minutes (BIS stable time as defined in Section 7.3). After 20 minutes of 
infusion, the subjects breathed 50% N20 for 15 minutes. The addition of N20 did not change 
the BIS trends in subjects. When the two drugs were administered simultaneously, the BIS 
was maintained at 62.7(5.4). Thereafter, the propofol infusion continued for another 15 
minutes without N20 breathed. However, the withdrawal of N20 is associated with the drop 
and oscillation of BIS in some subjects, and the BIS measured during this period was 
62.6(8.4). Following the end of propofol infusion, the BIS value in the 8 subjects reached 90 
or over in 5.9(1.6) minutes (recovery time as defined in Section 7.3). The overall Mean(SD) 
value of BIS in all subjects is 62.7(6.5), which is calculated from the BIS values in all 
subjects after the induction up to the end ofpropofol infusion. 
The individual anaesthesia induction time, the individual BIS stable time, the individual 
recovery time, and the predicted wakening concentration, as defined in Section 7.3, are listed 
in Table 7-6. While Table 7-7 and Table 7-8 show the Mean(SD) values ofBIS and predicted 
effect site concentration Ce in individual volunteers at different periods. 
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Table 7-7 The Mean(SD) values of BIS in volunteers in propofol/ N20 sedation study 
~ 1 2 3 4 5 6 7 8 All lP. 
Period 2 63.7 64.1 64.6 64.0 62.1 60.7 59.5 64.4 62.9 
(3.0) (3.3) (2.3) (3.5) (9.3) (4.5) (6.8) (4.5) (5.4) 
Period 3 60.6 64.4 64.9 65.7 63.8 58.5 60.5 62.7 62.7 
(4.4) (2.2) (1.9) (8.2) (2.0) (6.1) (6.3) (3.6) (5.4) 
Period 4 60.3 63.9 63.4 67.7 60.9 60.8 65.7 58.2 62.6 
(5.2) (2.2) (3.3) (6.2) (7.3) (13.6) (11.4) (6.9) (8.4) 
All Periods 61.6 64.1 64.3 65.8 62.3 60.0 61.9 61.8 62.7 
(4.6) (2.7) (2.7) (6.5) (7.0) (8.9) (8.9) (5.8) (6.5) 
*Penod 2/3/4- mamtenance penod before/dunng/after the mhalatJon ofN20, see Figure 7-14 
Table 7-8 The Mean(SD) values of predicted effect site propofol concentration in individual 
volunteers in propofol/ N20 sedation study 
~ 1 2 3 4 5 6 7 8 All p, 
Period 2 3.6 3.6 3.5 3.7 4.4 2.3 5.4 3.7 3.7 
(0.59) (0.13) (0.1 0) (0.16) (0.47) (0.93) (0.28) (0.29) (0.95) 
Period 3 2.3 3.6 3.8 4.4 3.6 2.1 4.3 3.5 3.4 
(0.31) (0.23) (0.12) (0.68) (0.14) (0.29) (0.78) (0.15) (0.88) 
Period 4 1.6 4.0 3.7 4.6 3.5 1.6 4.4 2.8 3.3 
(0.22) (0.10) (0.10) (0.64) (0.12) (0.52) (1.08) (0.12) (l.l9) 
All Periods 2.5 3.8 3.6 4.3 3.9 2.0 4.7 3.4 3.5 
(0.94) (0.25) (0.16) (0.66) (0.51) (0. 71) (0.94) (0.44) ( 1.03) 
7 .5.4. Discussion 
In this study, the CLAN system was tested on 8 volunteers for propofol sedation with and 
without inhalation of N20. A new set of PID controller gains was used in this study. In 
computer simulation, this set of gains gives roughly the same results on the nine typical 
pseudo patients as presented in Chapter 5. In clinical experiments with the new controller 
gains, the CLAN system is expected to achieve a smoother anaesthesia induction due to the 
smaller Ki, more quickly to re-achieve the BIS target when a subject becomes inadequately 
171 of220 
anaesthetized with less possibility of overshoot because of a bigger Kp and Kd and a smaller 
Ki. However, the induction time is expected to be longer if undershoot is developed. This is 
because less drug will be given by using a smaller integration gain Ki and the increase of 
proportional gain Kp and differential g~in Kd has no effect on increasing the infusion rate 
when BIS drops. These are actually what happened in the clinical experiments, 
The BJS trends for the 8 subjects shown in Figure 7-15 and Figure 7-16 look better than the 
BIS trends preserited in previous study. This is confirmed by the statistical analysis,on the BIS 
data shown in Table 7-7. 
As shown in Table 7-9, the BIS maintained in the 8 subjects in this study is slightly lower 
than that in previous study. This is mainly because of the use of the new set of controller 
gains, which improved the response speed and resulted in fewer occurrences of inadequate 
anaesthesia. The second reason is that no stimulation was given during the entire course of 
infusion except for the audio alarm from the infusion pump when the syringe was nearly 
empty or completely empty. 
Table 7-9 Comparison ofmean(SD) values ofBIS maintained in different periods in this.and 
previous studies 
Mean(SD) BIS Period 2 Period 3 Period 4 All Periods 
This Study 62.9(5.4) 62.7(5.4) 62.6(8.4) 62.7(6.5) 
Prev. Study 63.1(8.2) 66.1(11.4) 63.8(5.3) 63.9(8.7) 
*all values hsted m the table are in Mean(SD). 
lihe use of new controller gains also provided a much smoother induction performance. The 
maximal overshoot developed was a BIS value of 46.9 in subject 6 during anaesthesia 
induction because less drug was given than irt the previous study when BIS target was not yet 
achieved with big positive BIS errors. However, as expected this performance was at the cost 
of a longer time for the CLAN system to achieve the BIS target (5.6(1.3) vs 3.2(1.4) minutes), 
but the time spent by the CLAN system to stabilise the BIS did not differ in the two studies 
(7.9(3.3) vs 7.2(6.0)) and was more consistent in this study (Le., much smaller deviation (SD): 
3.3 vs 6.0) (please refer to liable 7-10). 
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Table 7-10 Induction time, BIS stable time, and recovery time in two studies 
Induction Time BIS Stable Time Recovery Time 
This Study 5.6(1.3) 7.9(3.3) 5.9(1.6) 
Prev. Study 3.2(1.4) 7.2(6.0) 6.4(2.4) 
*all values hsted m the table are m Mean(SD). 
Although the overall control performance has been significantly improved over the previous 
study, BIS oscillation, seen in subject 10 in the previous study, occurred in subject 5 (between 
6.4 and 13.8 minutes after the infusion started) and subject 7 (15 to 28.4 minutes) of this 
study. Inappropriate controller gains and hysteresis could be again the cause of these 
oscillations. This study demonstrates again that there is no single set of controller gains that 
works on all subjects. 
Due to the long infusion time in this study, one syringe of propofol was not enough for some 
subjects. However, the change or refilling of syringes delayed the infusion up to 2 minutes, 
and the infusion pump issues an audio alam1 when the syringe is nearly empty, which 
imposed some stimulation upon the subjects. This was associated with the rise of BIS to 
various degrees in some volunteers (volunteer 2-5, indicated by the marks with "change 
syringe" in Figure 7-15 and arrows in Figure 7-16). 
As with subject 13 in previous study, natural sleep could possibly be developed in subjects 4, 
6, and 7 in this study. To investigate why the large undershoots (marked by arrows 1, 2, 3, 
and 4 in Figure 7-16) were developed in subjects, Table 7-11 lists the no infusion times 
during which the predicted concentration dropped before these undershoots occurred, and the 
predicted effect site concentrations at the time these subjects were aroused. The individual 
times at which they were aroused, recovery times and wakening concentrations of the three 
subjects are also listed in the table for comparison purposes. 
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Table 7-11 Characteristics of the large undershoots developed in subjects 4, 6, and 7 
Recovery Wakening Ce wben subjects Time aroused No infusion 
time (min) concentration* were aroused* (min) period 
Subject 4 4.4 3.28 3.56 23 0.8 
Subject 4 4.4 3.28 3.17 37 9.6 
Subject 6 8.0 1.04 1.02 46.6 17.6 
Subject 7 7.8 2.91 2.53 38 12.6 
.. 
* umt IS mcg/ml 
In subjects 4, 6, and 7, as marked by arrows 1~4 in Figure 7-16, four large undershoots were 
developed. Before the first undershoot (at t=23 minute, Figure 7-16) developed in subject 4, 
the predicted propofol concentration was stably maintained at 3.56 mcg/ml that is slightly 
over the eventual awakening concentration 3.28 mcg/ml. This suggests that the anaesthetic 
level in this subject may have been so low that he could be easily aroused by external 
stimulation such as noises. However before all the other undershoots, due to the long absence 
of infusion (see Ce trends in Figure 7-16 and Table 7-11) the predicted concentrations 
dropped below individual wakening concentrations recorded in recovery. With these drug 
concentrations in the subjects, external stimulation could easily arouse them. The undershoot 
which happened at t=37 minute in subject 4 for example, was initiated by the audio 
stimulation from the pump alarm reminding of change of syringe. 
Before the undershoots (marked by arrows 2-4 in Figure 7-16) developed in subjects 4, 6, and 
7, the BIS had been maintained under the BIS target for 9.6 minutes, 17.6 minutes, and 12.6 
minutes, respectively in the three subjects without drug infusion. These no-infusion times are 
significantly shorter than their recovery times (see Table 7-11), which strongly suggest that 
the subjects had developed natural sleep before they got aroused. 
The addition of N20 did not significantly change the BIS pattern, and it did not break the 
maintenance of the BIS target. However, its withdrawal was associated with moderate 
oscillation of BIS in subject 1, 3, 5, and 8 (see Figure 7-15). These are consistent with 
published findings (Rampil et al., 1998; Barr et al., 1999; Hirota et al., 1999) in which all 
authors claimed that the addition of N20 did not significantly change BIS values during 
propofol sedation. However, Rampil and colleagues (1998) revealed that "N20 (50%) 
increased theta, beta, 40-50 Hz, and 70-110 Hz band powers" and "the abrupt decreases from 
higher to lower (N20) concentrations frequently evoked a profound, transient slowing of 
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(EEG) activity". The change of EEG activity in lower and higher bands of frequencies 
observed by these investigators may well cause changes in BIS values once the inhalation of 
N20 was suddenly stopped. 
Significant inter-variability in subjects was shown by the BIS values during induction of 
anaesthesia in this study. In fact, all subjects except for subject 6 developed various degrees 
of undershoot in response to the same dose (Jlg/kg) of initial bolus. Different amounts of extra 
drug were subsequently given by the CLAN system to achieve the same BIS target. 
Furthermore, different levels of predicted concentrations throughout the infusion process also 
suggest the existence of inter-subject pharmacodynamic variability. The maximal and 
minimal predicted stable concentration maintained were 5.4-5.8mcg/ml in subject 7 and 
2~2.9mcg/ml in subject 6. 
The only problem encountered in this study was the induction of anaesthesia in subject 6. 
Because the syringe was not well seated on the pump, the CLAN system twice failed to give 
the full initial bolus infusion. The CLAN system however eventually gave the full initial 
bolus at the third start in 5 minutes, and successfully achieved the BIS target. This caused an 
overshoot to 48.2 in BIS possibly due to the previous two partial infusions. The infusion 
protocol was therefore extended for another 5 minutes to allow stabilisation. The calculation 
of predicted propofol concentrations in plasma and at effect site was not affected by the 
syringe failure (see Figure 7-17). 
7.6. Propofo/ Sedation in Patients Undergoing Knee Surgery 
7.6.1. Objective 
After the evaluation of the CLAN system on fit volunteers (n=21), the CLAN system was 
subsequently further tested on patients undergoing reconstructive knee surgery under epidural 
anaesthesia. The objective of this test was to examine the control performance of the CLAN 
system on depth of anaesthesia in a surgical environment. Studying patients with an epidural 
in-situ meant that the patients were not dependent on the CLAN system for surgical 
anaesthesia. 
7.6.2. Methods 
A lumber epidural catheter was placed under local anaesthesia either before (n=4) or after 
(n=2) starting sedation, and a regional block established. The BIS target was initially set at 
65(Baker, 2000) and then adjusted at clinical discretion. Closed loop sedation was functioning 
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before the start of surgery and was maintained throughout. The general methods described in 
Section 7.2 applied. 
7.6.3. Results 
Six male patients (ASA status 1-II, age 25-39 years, weight 70-100 kg) have been studied with 
another patient entered into the study without sedation because of a broken cable. Clinically 
satisfactory results were obtained from three patients, however the results from the other three 
were not clinically acceptable due to oscillation in BIS. Table 7-12 gives the individual 
characteristics of these patients. 
Table 7-12 Characteristics of the six patients undergoing knee surgery 
Patient 1 2 3 4 5 6 Mean(SD) 
Gender M M M M M M 
Age (years) 27 25 35 29 31 39 31 (5.2) 
Weight (kg) 85 80 83 100 70 99 86.2 (11.5) 
Height (cm) 190 185 178 188 173 178 182 (6.7) 
Sedation at the initial BIS target was established in 7.8(1.9) minutes, and subsequently the 
BIS target was manually adjusted when necessary to meet clinical requirements for the patient 
undergoing surgery. The BIS error between the measured BIS and BIS targets in the six 
patients after the induction was -3.6(10.9), whilst the predicted effect site propofol 
concentration was maintained at 4.0(2.1) mcg/ml during the same infusion period. The 
recovery time for the patients was I 0.2( 1.2) minutes. 
In the first 4 patients, the changes of patient position and other stimuli before the surgery 
started (e.g., the placement of the lumber epidural catheter, transfer of patient from 
anaesthesia room to surgery room, etc.) were associated with rapid changes of BIS and 
various levels of consciousness. In two patients (patient 2 and 3), during the surgery, when 
stimulation was confined to the leg (i.e. blocked by the epidural), a condition resembling 
natural sleep was possibly developed, and they awakened from a BIS value of 46 or 47 with 
predicted effect site concentration (Ce) of 1.08 mcg/ml or 0.95 mcg/ml, respectively. 
176 of220 
Table 7-13 lists the induction/recovery times and the predicted wakening concentration in 
individual patients. While Table 7-14 lists the measured BIS errors and predicted 
concentrations in the six patients. Figure 7-18 shows the BIS, BIS target, and predicted 
propofol concentrations in plasma and at the effect site in a single patient (patient 2). 
Table 7-13 Induction time, recovery time, and the predicted effect site propofol wakening 
concentration (Ce) of the six patients undergoing knee surgery 
Patient 1 2 3 4 5 6 Mean(SD) 
Induction (min) 9.3 8.3 4.7 8.8 9.4 6.3 7.8(1.9) 
Recovery (min) 10.9 9.0 NI A* 11.5 NI A* 9.3 1 0.2(1.2) 
Wakening Ce (mcg/ml) 1.34 1.23 NIA* 2.82 NI A* 2.25 1.91 (0.76) 
* because the operating theatre had to be made available for the next patient, and the data 
recordings on patient 3 and 5 were terminated before the patients awakened. 
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Figure 7-18 BIS (upper thin line) and its target (upper thick line) and predicted plasma (lower 
thin line) and effect site (lower thick line) propofol concentration in a patient (arrow 1- over-
shoot in anaesthesia induction; arrow 2 - patient unexpectedly awakened from natural sleep) 
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Table 7-14 The means (standard deviations) ofBIS errors and predicted effect site propofol 
concentrations (Ce) in the six patients undergoing knee surgery 
Patient 1 2 3 4 5 6 All 
BIS Error -4.4(15.8) -3.6(7.3) -7.0(12.2) -1.3(7.3) -4.5(7.1) -2.8(1 0.9) -3.6(10.9) 
Ce (mcg/ml) 2.4(1.1) 2.6(0.9) 2.7(1.1) 6.4(1.4) 2.8(1.0) 4.5(1.2) 4.0(2.1) 
As shown in Figure 7-18, two extra boluses were given to this patient after the initial bolus by 
the CLAN system to achieve the sedation target, stable sedation was established after the 
over-sedation (indicated by the arrow marked with '1 '). Between the 45th and 65th minute BIS 
remained below the target for 20 minutes without drug infusion at all due to the apparently 
developed natural sleep, consequently the patient 'awoke'. This resulted in the sharp rise in 
BIS (indicated by the arrow marked with '2') a few seconds later. However, the BIS target 
was achieved again quickly and maintained until the termination of the sedation. 
7 .6.4. Discussion 
In this study, the CLAN system controlled the propofol infusion on real patients m an 
environment different from that in previous studies. In the patients with epidurals in place, all 
painful (nociceptive) input is cut off by the regional anaesthesia, therefore the CLAN system 
is only trying to produce sedation in the patients. In theory, the only difference in drug 
infusion between this situation and that in previous studies without nitrous oxide breathed is 
that the patients were in an operating theatre where not all the other inputs were controllable, 
particularly noise and vibration. A patient having an orthopaedic operation may feel no pain, 
but their ears will hear noise and their sensory system will also detect vibration in parts of the 
body that are not blocked by the epidural. Both of these may cause the patient to demonstrate 
arousal. 
Due to the presence of various stimulations from the operating theatre, the drug delivery 
control performance in this study was worse than that achieved in the fit volunteers in 
previous studies. This can be seen from the standard deviations of BIS errors measured and of 
the predicted effect site propofol concentrations maintained in all patients listed in Table 7-14. 
BIS oscillation still happened in some patients, for example, patient 4 as shown in Figure 
7-19. Inter-patient variability, hysteresis and controller gains remained to be the main causes 
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of the unsatisfactory control performance in these situations. 
Natural sleep, which would cause a large BIS jump when broken by stimulation, possibly 
developed in all patients except for patient 6. At low BIS values, two patients (patient 2 and 
3) opened their eyes due to the break of possible natural sleep, while others demonstrated 
various levels of arousal such as arm or body movement. 
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Figure 7-19 Bispectrallndex (BIS4) and predicted propofol concentrations (Ce, Cp) in 
patient 4 undergoing knee surgery (the patient unexpectedly awoke followed by the BIS jump 
indicated by the arrow) 
Table 7- 15 lists all occurrences of possible natural sleep developed in the patients with the 
predicted effect site concentrations at which the patients were aroused thereafter. It also lists 
the wakening concentration and the recovery time as defined in Section 7.3, and the time 
period over which there was no infusion at all until the patient was awakened. With patients 3 
and 5, the BIS recordings were terminated at the end of surgery before recovery due to the 
tight schedule of the operating theatre. Patient 3 opened his eyes at the predicted 
concentration listed in the table, whilst body movement was observed in patient 5 at the listed 
concentration (predicted). 
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Generally, if natural sleep had been developed when the measured BIS was below the BIS 
target, there would be no drug infusion if the contribution from the natural sleep to the depth 
of anaesthesia could keep the BIS below the target. However, when the drug concentration 
dropped close to or below the concentration at which the patient should have been awakened 
if there were no natural sleep developed, then at this time, the natural sleep developed would 
easily been broken by an external stimulation. In another words, this process is no different 
from the recovery process at the end of an experiment. 
Table 7-15 Identified natural sleep developed in patients undergoing knee surgery 
Recovery time Wakening Ce when subjects No infusion 
(min) concentration* were aroused* period (min) 
Subject 1 10.9 1.34 1.16 11.6 
Subject 1 10.9 1.34 0.76 20.8 
Subject 2 9.0 1.23 1.08 12.9 
Subject 3 NI A** NI A** 0.95 29.2 
Subject 4 11.5 2.82 2.91 5.2 
Subject 5 NI A** NI A** 1.34 14.3 
.. 
*umt m mcg/ml 
** because the operating theatre had to be made available for the next patient, and the data 
recordings on patient 3 and 5 were terminated before the patients awakened .. 
7. 7. Total Intravenous Anaesthesia on Patients Undergoing Back Surgery 
7. 7.1 . Objective 
Total intravenous anaesthesia or general anaesthesia, during which an intravenous hypnotic 
and an intravenous analgesic are infused simultaneously, is popular for surgery due to their 
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property of rapid onset and quick recovery. All previous studies were designed to test the 
closed-loop control ofpropofol infusion under various clinical environments, and in this study 
the CLAN system was further tested for delivery of total intravenous anaesthesia on patients 
undergoing back surgery. 
7.7.2. Methods 
Propofol infusion was controlled by the closed-loop system by on-line monitoring of the 
Bispectral Index as in previous studies, whilst alfentanil infusion was controlled by an open-
loop TCI system. The two drugs were delivered simultaneously. 
To achieve adequate level of anaesthesia in patients for the surgenes under general 
anaesthesia, the BIS target was initially set to 50, while various initial effect site alfentanil 
concentration targets (1 00 ng/ml to 200 ng/ml) were set for individual patients. The choice of 
alfentanil targets and BIS target were based upon clinical research by Vuyk and colleagues 
(1995b) who found out through clinical study and computer simulation that the optimal 
propofol and alfentanil concentrations are 3.5 mcg/ml and 85 ng/ml, respectively (for female 
gynaecology patients). These target settings were found by Vuyk et al. (1995b) to be 
satisfactory both with respect to intra-operative anaesthetic conditions and speed of recovery. 
This is supported by another clinical report from the same investigator. The propofol target 
concentration of 3.5 mcg/ml corresponds to the converted BIS target of 49 by use of the 
population average pharmacodynamic model presented earlier. The BIS target of 50 in 
general anaesthesia is also supported by some other clinical studies (Morley et al., 2000; 
Struys et al., 2001). 
Both the BIS target and the target alfentanil concentrations were adjusted at the clinical 
judgement of the anaesthetist during surgery to meet the dynamic clinical requirements. 
Closed loop controlled hypnosis and open loop controlled analgesia were maintained 
throughout surgery. 
The minimum effect site propofol concentration was set at 2 mcg/ml to all patients and could 
be manually adjusted on-line at clinical discretion. This would reduce the possibility of 
sudden and large BIS rises if natural sleep developed. 
The BIS overshoot threshold value (-2.5) and BIS prediction, as described in Section 6.6.5, 
were used in this study for the CLAN system to resume the infusion earlier when overshoot 
occurred. This mechanism would help prevent large undershoot immediately following an 
overshoot. 
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The BIS algorithm in the Aspect EEG Monitor A1000 was updated from version 3.12 to 
version 3.30. The only change in monitor settings is Bispectral Smoothing, which was 
changed from "off' to "15 seconds", because the "off' option is no longer available and "15 
seconds" is the shortest setting for Bispectral Smoothing. This introduces BIS delay of 15 
seconds. Except for this difference, the other methods described in Section 7.2 apply to this 
study. 
7.7.3. Results 
Nine patients (age 30-68 years, weight 56-98 kg, 7 men and 2 women) entered this study. The 
experiment failed on two of them (patient 5 and 6) due to broken EEG electrode leads, and the 
CLAN system delivered both propofol and alfentanil using open-loop TCI control in these 
two patients. These two patients are therefore excluded from the data analysis. The broken 
EEG electrode leads also affected the BIS values in another two patients during recovery. 
Clinically satisfactory results were obtained during this study. The patient characteristics are 
listed in Table 7-16. 
Table 7-16 Characteristics of patients in the study of total intravenous anaesthesia 
Patient 1 2 3 4 5 6 7 8 9 Mean(SD) 
Gender M F M F M M M M M 
Age (years) 33 41 31 50 49 54 30 53 68 45.4(12.7) 
Weight(kg) 91 93 70 56 89 98 54 82 67 77.8 (16.5) 
Height (cm) 180 157 168 165 183 189 155 173 157 169.7 (12.4) 
The CLAN system quickly induced anaesthesia in patients m 3.04(1.77) minutes, and 
anaesthesia was successfully maintained with a BIS error of -3.5(6.6) between the measured 
BIS and BIS targets in all patients after the induction until the propofol infusion was stopped. 
The negative BIS error indicates that the level of hypnosis maintained is deeper than the 
targets. After the anaesthesia induction, the predicted effect site concentration (Ce) was 
maintained at 4.29(1.28) mcg/ml. The patients became responsive or woke up within 
12.02(2.52) minutes (recovery time) after the termination of infusion, and at which time the 
predicted effect site propofol concentration, or the predicted wakening concentration as 
defined previously, was 1.97(0.6) mcg/ml. The induction time, recovery time, and the 
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wakening concentration are listed in Table 7-17. While the BIS error and predicted effect site 
propofol concentration maintained in individual patients are shown in Table 7-18. 
Table 7-17 Induction time, recovery time, and the predicted wake concentration (Ce) in the 9 
patients under general anaesthesia 
Patient 1 2 3 4 5 6 7 8 9 Mean(SD) 
Induction Time (min) 1.9 1.58 2 5.4 NIA NIA 5.75 2.75 1.9 3.04(1.77) 
Recovery Time (min) 12.75 13 9.75 9.48 NIA NIA 10.91 NI A* 16.2 12.02(2.52) 
Wakening Ce (mcg/ml} 1.79 2.44 2.23 1.35 NIA NIA 2.74 NI A* 1.27 1.97(0.6) 
*data recordmg stopped before the pat1ents became responsive or woke up 
Table 7-18 BIS errors and predicted effect site propofol concentrations in the 9 patients under 
general anaesthesia 
Putie11t 1 2 3 4 5 6 7 8 9 All 
BIS Error -1.1(4.6) -2.4(8.5) -3.2(7.0) -4.8(3.4) NIA NIA -3.9(5.9) -2.4(6.7) -4.7(8.3) -3.5(6.6) 
Ce (mcg/ml) 4.4(0.7) 4.8( 1.1) 4.9(0.9) 2.9(0.6) NIA NIA 5.1 (0.8) 4.9(0.8) 3.0(1.1) 4.3(1.3) 
The same initial bolus (mg!kg), which was calculated from the initial BIS target of 50, was 
given to all patients, and this caused undershoot in 3 patients (such as patient 4 shown in 
Figure 7-20) and overshoot in 2 patients (BIS dropped down to 31.8 or 35.1). However, the 
CLAN system managed to achieve the BIS target and stabilised the BIS. Alfentanil infusion 
was started at the same time as the propofol infusion with various initial targets (see Figure 
7-21). Both BIS target and alfentanil target concentration were changed at clinical discretion. 
In comparison with previous patient study, the induction in this study with presence of 
alfentanil was significantly quicker, and BIS trends were much smoother with less occurrence 
of BIS oscillation throughout surgery. In spite of the synergistic interaction (Vuyk et al., 
1995b) between propofol and alfentanil, the presence or increase/decrease of alfentanil 
concentration did not change the Bispectral Index. Figure 7-20 and Figure 7-21 show the 
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measured BIS trend, predicted propofol and alfentanil concentrations in plasma (Cp) and at 
effect site (Ce) in a single patient (patient 4). 
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Figure 7-21 Predicted alfentanil concentration in plasma (Cp) and at effect site (Ce) in the 
same patient as in Figure 7-20 (patient 4) under total intravenous anaesthesia 
7.7.4. Discussion 
In this study, the CLAN system was working in an entirely different clinical environment. 
This group of patients (and only this group amongst our clinical studies) have continuous 
afferent (i.e. into the brain) sensory input. This ranges from touch through to painful 
stimulation. The painful stimulation is not constant during the entire procedure. It is because 
of this painful stimulation that an analgesic (i.e. alfentanil in this study) is needed. 
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In this study, propofol and alfentanil were infused simultaneously. However, there is 
interaction between the two drugs when used together. The interaction was identified by Vuyk 
and colleagues (I 995b) as synergistic. The presence of alfentanil or any increase of alfentanil 
concentration will non-linearly reduce the requirement of propofol concentration, and the 
decrease in alfentanil concentration will non-linearly increase the requirement of propofol 
concentration. This is true vice versa. They also found out through computer simulation that 
the optimal combination of alfentanil and propofol in general anaesthesia is 3.5 mcg/ml 
propofol concentration and 85 ng/ml alfentanil concentration. This combination would 
produce a satisfactory intra-operative anaesthesia and allow the shortest recovery (in I 0 
minutes for 50% of patients) according to the simulation. However, the presence or increase 
of concentration of one drug does not increase the concentration of the other drug, and vice 
versa. 
The following table (Table 7-19) shows the infusion control performance from the CLAN 
system in all four clinical studies. 
Table 7-19 Control performance of CLAN system in all studies 
Study 1 Study 2 Study 3 Study 4 
Volunteers Volunteers (N10) Knee surgery Back surgery 
(epidural) (alfentanil TCI) 
Induction Time (min) 3.2(1.4) 5.6(1.3) 7.8(1.9) 3.04(1.8) 
Maintenance BIS 63.9(8.7) 62.7(6.5) -3.6(1 0.9)** -3.5(6.6)** 
Maintenance Ce* 3.1(1.2) 3.5(1.0) 4.0(2.1) 4.3(1.3) 
Recovery Time (min) 6.4(2.4) 5.9(1.6) 1 0.2(1.2) 12.02(2.5) 
Wakening Ce* 1.3(0.4) 2.5(0.8) 1.91(0.8) 1.97(0.6) 
.. 
*predicted propofol concentration at effect site, umt 111 mcg/ml **BIS error 
With the presence of alfentanil, the CLAN system achieved the quickest induction of 
anaesthesia without significant overshoot and less BIS oscillation during the induction phase 
and shortly after. This is probably because of the drug interaction and the rapid onset of action 
of alfentanil, which speeded up the induction while the propofol concentration was building 
up. The predicted effect site concentration maintained in this study (4.3(1.3) mcg/ml) is 
higher than any previous studies because lower BIS targets (<=50) or deeper anaesthesia was 
required in surgeries under general anaesthesia. If we assume that the predicted propofol 
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concentration exceeds the measured concentration with a median absolute performance error 
(MD APE) of 26% and a median performance error (MD PE) of 24% (Vuyk et al., l995a), the 
real propofol concentration maintained in patients of this study would have been close to the 
optimal drug combination that gives propofol concentration of 3.5 mcg/ml (and 85 ng/ml for 
alfentanil). Towards the end of surgery, the alfentanil concentration was set to 80-100 ng/ml 
based upon the optimal combination to allow quick recovery. The recovery time 12.02(2.52) 
minutes in patients of this study is consistent with Vuyk and colleagues' simulation result 
(1995b) of 1 0 minutes when using optimal combination of propofol and alfentanil 
concentrations. 
Although stronger and non-constant stimuli were present, there is a significant improvement 
in the control performance on BIS in this study over the previous patient study (-3.5(6.6) 
versus -3.6(10.9)). Unlike the previous patient study where all painful stimulation was cut off 
by the regional anaesthesia, the patients in this study received a (variable) nociceptive input. 
A BIS rise in response to stimulation can be seen in the first and especially the third study. 
However, big changes in BIS were never seen in this study because of the maintenance of a 
deeper level of hypnosis (BIS target of 50), the presence of alfentanil, and improved CLAN 
system response speed. IselinChaves and colleagues (1998) reported that the absolute change 
of BIS after a painful stimulus was significantly decreased by both an increase in the 
concentration of propofol and the presence of alfentanil. Their finding was supported by this 
study in which there is no evidence of any significant BIS response to painful stimulation. 
When the requirement of propofol concentration for a certain level of anaesthetic depth is 
reduced due to the presence of alfentanil, the time needed to build such a reduced propofol 
concentration will be shorter. This actually increases the response speed of the CLAN system. 
Before the start of this study, the CLAN system was modified to allow earlier response to any 
sudden BIS rise even when BIS value is under the target. This was implemented by the 
combined use of BIS prediction and BIS overshoot threshold value (-2.5), as described in 
Section 6.6.5. 
This method was only used for detecting the time for the BIS to reach the overshoot threshold 
BIS value under the BIS target so that the CLAN system will turn on the infusion one cycle (5 
seconds) earlier when BIS changes up from under the target. 
By predicting the next BIS with a threshold BIS value, the CLAN system is able to respond to 
stimulation earlier, thus it potentially reduces the effect of hysteresis on infusion control. 
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However, as a result of this, the BIS will be maintained slightly under the target for the most 
of the infusion time as can be seen in this study. This is why the mean value of BIS in this 
study is 3.5 under the target. The use of this method and the presence of strong stimulation 
effectively engaged the infusion control throughout surgery and successfully avoided long 
time absence of infusion as seen in patients of previous studies. 
When the BIS is maintained below or well below the BIS target and a painful stimulation 
happens, the patient could become responsive and consequently BIS would rise. As soon as 
the predicted BIS is above the threshold value the CLAN system resumes propofol infusion, 
or increases the infusion rate if the infusion has already started (when BIS is maintained 
between the target and the threshold value). The increase ofpropofol concentration will bring 
the patient into a deeper level of hypnosis, and it also reduces the requirement of alfentanil 
concentration that in return enhances the analgesic effect with unchanged alfentanil 
concentration. This way the BIS change in response to a painful stimulation is suppressed, 
and the sign of this stimulation is therefore buried into the normal BIS pattern of small 
oscillation. 
In patient 4 (see Figure 7-20) for example, the measured BIS was maintained below the target 
almost throughout the surgery, and the propofol infusion was actively engaged due to the use 
of the BIS overshoot threshold value of -2.5, the BIS prediction mechanism, and the 
minimum effect site propofol concentration (2 mcg/ml). Due to the improvement of the 
CLAN system, no sudden big BIS jump was observed or recorded in any patients in this 
study. 
Without the episodes of light anaesthesia, the CLAN system achieved the best result of all 
four clinical studies. The problem from the controller gains coping with the inter-patient 
variability did not show up because of this. 
The quality of the electrode lead caused concern in this study. The CLAN system exited the 
infusion control in patient 5 and 6 because of the bad condition of leads from which bad 
quality of EEG signal was measured and this caused the wrong calculation of BIS in the 
anaesthesia monitor. This happened again on patient 8 and 9 as the patients awoke with body 
movement after the termination of infusion. 
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8. Discussions, Future Work and Conclusion 
8. 1. Discussions 
Anaesthesia monitoring plays an important role in the operating theatre for surgery and in the 
intensive care unit. Traditionally, anaesthetists deliver anaesthetic drugs manually using their 
experience and clinical signs. Automation of anaesthesia monitoring would minimise the 
possibility of excessive dosing. Although TCI automates the drug administration, experienced 
anaesthetists are still required to adjust the target concentration. Closed-loop anaesthesia is 
superior to TCI technology and could lead to better patient care by intelligently controlling 
drug administration based on on-line monitoring of anaesthesia, and allowing prompt 
identification of and response to perturbations that might go unnoticed by a clinician. 
This project has set out to investigate closed-loop anaesthesia for better patient care, and to 
develop a safe and reliable closed-loop anaesthesia system that could be used as a research 
tool in both intensive care unit and operating theatre. 
The main contributions of the project include the development of a generic mathematic model 
of closed-loop anaesthesia, closed-loop controlled anaesthesia induction, system supervision 
techniques, and the development of a closed-loop anaesthesia system. 
I. A generic mathematic model of closed-loop controlled anaesthesia which consists of 
the following sub-components: 
• PID Controller component model 
• Pharmacokinetic (PK) component model 
• Phannacodynamic (PD) component model 
• Patient component model 
The mathematical model, which had not been reported at the time it was developed, 
can serve as a generalised tool for investigating closed loop anaesthesia. The model is 
modular and its sub-components can be readily updated or replaced. The mathematical 
model is developed as generally as possible and so can be used for various purposes. 
In this project, it was used for the investigation of the control strategy, for controller 
gain tuning, and for the investigations of patient variability in pharmacokinetics and 
pharmacodynamics. 
188 of220 
By replacing the controller model, it can also be used for investigating other control 
strategies (e.g. fuzzy logic control and adaptive control) and evaluating their 
perfonnance and tuning controller parameters. In future, the phannacokinetic, 
pharmacodynamic, and patient models can be updated ifthere is significant advance in 
clinical understanding of CLAN. For example, in the project, the pharmacodynamic 
model specifies the relationship between propofol concentration and the drug effect 
(depth of anaesthesia) measured by Bispectral Index. However, other feedback signals 
that measure depth of anaesthesia could easily be accommodated by replacing the 
concentration-effect relationship algorithm. The patient component model allows 
testing of a closed-loop anaesthesia system with any control strategy on as many 
virtual patients as necessary and can be easily updated with more accurate 
phannacokinetic parameters. 
Due to the generalisation of the component model interface, the mathematical model 
provides an important entry point for investigation, design, implementation, and test of 
variety of closed-loop anaesthesia control systems using different control strategies 
and various feedback signals that measure depth of anaesthesia. 
This work has resulted in a journal paper published in 200l(Sneyd, 2001). 
2. Closed-loop controlled anaesthesia induction 
Anaesthesia induction is a significant problem in anaesthesia monitoring because of 
inter-patient variability. Ideally, anaesthesia induction should have a rapid onset 
without overshoot for all patients. Traditionally, anaesthetists induce anaesthesia by 
giving a bolus infusion based on experience and pre-calculation of the bolus size, 
which is often at the cost of overshoot. However, multiple-bolus infusion schemes 
have been adopted for anaesthesia induction by some closed-loop anaesthesia control 
systems by increasing the open-loop target concentration step-by-step. In the CLAN 
system in this project, a closed-loop anaesthesia induction technique is developed. The 
CLAN system monitors the drug effect in individual patients and intelligently decides 
whether another bolus infusion is necessary during the next cycle and calculates the 
size of the bolus objectively based on the desired drug effect and that measured. 
3. Controller compensation technique 
A closed-loop anaesthesia control system is a safety critical feedback control system. 
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It reqmres fast response with mtmmum overshoot in patients with dynamic 
characteristics. The feedback signal is self-fluctuating with dynamic length of delay. 
Furthermore, there is no way to take infused drug out of the patient. These properties 
make a closed-loop anaesthesia system a non-linear dynamic system with delayed 
feedback signal. 
To tackle problems inherent in closed-loop anaesthesia, a controller compensation (or 
supervision) technique, which is independent of controller type, was developed. This 
compensation technique or supervision system provides an intelligent solution for the 
problems caused by non-linearity, dynamics (such as varying hysteresis), and 
feedback delay. This technique also supports patient safety by monitoring the drug 
effect and infusion rate. Various digital signal processing algorithms have been 
developed for this mechanism. 
4. Development of the CLAN system for total intravenous anaesthesia 
The CLAN system developed is the first research system in this project that is capable 
of delivering both a hypnotics and an analgesic agent simultaneously, and the control 
strategy investigated in this project has never been previously reported. The CLAN 
system physically consists of two anaesthesia pumps, an EEG monitor, and a personal 
computer. Functionally, the system is composed of a PID controller, two TCI systems, 
a system control unit or a supervision system, and a user interface. The CLAN system 
was tested with a population of 78125 virtual patients based on the published data, and 
evaluated on healthy volunteers (n=21) and patients (n=IS) undergoing surgery in 
various clinical environments. The anaesthesia quality maintained by the CLAN 
system is clinically satisfactory. 
This CLAN system provides a platform for further investigations in closed-loop 
anaesthesia, patient variability in pharmacokinetics and pharmacodynamics, drug 
interaction, as well as leading towards systems for routine clinical use. Other control 
strategies such as fuzzy logic controller, neural network controller, or any other 
adaptive controllers can be easily evaluated on this platform. 
This work has resulted in three conference abstracts (Dong et al., 1999a, 1999b, 1998). 
8.2. Limitations and Future Work 
The research on closed-loop anaesthesia is at a very early stage, and this investigation is a 
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new approach to the solution of this problem. The long-term objective of this project is to 
provide a basis for the development of a commercial CLAN system for total intravenous 
anaesthesia. To achieve this goal, there are a number of limitations to be addressed and 
overcome in the current investigation. 
These limitations are discussed below together with proposals for future work on which a 
more advanced CLAN system could be based. 
• Lack of an adaptive controller. As demonstrated by the computer simulations using 
the CLAN model and shown by the volunteer/patient studies, the same dose of initial 
bolus resulted in a wide range of drug concentration and effect in individual subjects. 
This patient variability would largely affect the drug infusion rate calculation. Clearly, 
for those who are more sensitive to a drug (i.e., same amount of drug results in higher 
drug concentration or more drug effect in them than in others, or vice versa), less drug 
should be infused in achieving and maintaining the target. This means that a smaller 
set of controller gains should be used. Therefore, an adaptive drug sensitivity model, 
which assesses and quantifies the drug sensitivity in individual subjects, should be 
developed in the future research. This sensitivity model should be dynamically 
updated throughout the drug infusion as it may change over time, and the controller 
gains should be adaptively adjusted against the individual drug sensitivity. 
• Lack of dynamic hysteresis analysis in individual patients. Hysteresis of drug 
distribution is an important factor in drug infusion. The variations of drug effect peak 
time are clearly shown by the anaesthesia induction both in the investigation via 
computer simulation and in the clinical experiments. When inadequate anaesthesia, 
which is usually caused by stimulation, occurs, the controller usually gives a series of 
boluses. However it is unknown when drug infusion should be turned off without this 
information. For this reason, a BIS undershoot is frequently followed by a BIS 
overshoot in clinical experiments. In the future, a mechanism to detect this hysteresis 
in individual subjects should be developed. The quantification of individual hysteresis 
also helps the built-in pharmacokinetic model make a more precise estimation in effect 
site drug concentration. 
• Lack of a stimulation level model. Another important factor that affects the drug 
infusion rate calculation is the stimulation level. Intuitively, higher stimulation level 
causes lighter anaesthesia level and hence more drug is required to re-achieve the drug 
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effect target. Practically, any occurrence of inadequate anaesthesia could be 
considered as the existence of stimulation with varying levels. Therefore a model that 
describes how much extra drug should be infused according to the stimulation level 
should be developed in the future. 
• Lack of analgesic effect monitoring. Currently, a TCI system is used in this 
investigation to deliver analgesics due to the lack of an analgesic effect monitor. A 
closed-loop control system should be developed as soon as such a monitor is available. 
• Incomplete drug interaction investigation. In this project, the interaction has only 
been investigated between propofol and alfentanil or nitrous oxide because of the time 
schedule. However, to achieve the commercial product goal in the long term, more 
combinations of drugs should be investigated. 
• Incomplete validation. The prototype CLAN system has only been evaluated on 
healthy volunteers and ASA 1111 patients. This does not cover all categories of 
patients, and therefore further validation is needed on a wider range of patients. A 
database holding all clinical data is highly recommended in favour of further 
investigations on patient variability (in both pharmacokinetics and 
pharmacodynamics) and drug interaction in the future. 
• Lack of a graphical user interface. A friendly graphical user interface is essential for 
an interactive commercial product. The current user interface is based on DOS, and is 
only for research purposes. Graphical displays of variable histories are essential. 
These variables include drug concentrations in plasma and effect site and their targets, 
the drug effect (BIS in this investigation) and its target, drug infusion rate, and the 
amount of drug infused. 
• More control strategies need to be investigated. This investigation uses a PID 
control strategy because of limited project time schedule and the simplicity and 
efficiency of PID controllers. However, the drug infusion process is highly complex 
and it contains too much uncertainty at this stage because of the limitations in the 
understanding of pharmacokinetics and pharmacodynamics, which result in 
incomplete modelling and substantial modelling errors. Fuzzy logic and neural 
network training, which are useful to solve the problems from incomplete modelling 
and uncertain dynamics, are good candidate control strategies for further investigation 
of closed-loop anaesthesia. 
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8.3. Conclusion 
Closed-loop anaesthesia has been investigated in this project. Much of the work and effort 
over the course ofthis programme of work has gone into developing the mathematical CLAN 
model, investigating the problems in closed-loop anaesthesia by using the CLAN model, 
developing digital signal processing techniques to tackle the inherent problems (for example, 
the non-linear characteristics of the system, incomplete PK/PD modelling or uncertainty), and 
in developing a CLAN system delivering total intravenous anaesthesia. A working prototype 
has been developed with comprehensive patient safety protection mechanism. A robust test of 
the mathematical CLAN model has been carried out on 78125 virtual patients modelled by 
using published data, and the prototype system has been evaluated in typical clinical settings 
on 21 healthy volunteers and 15 patients undergoing surgery. 
The novelty in this investigation is in the mathematical modelling of closed-loop anaesthesia 
process, the investigation of the control strategy of combining a PID controller with a 
pharmacokinetic model, the closed-loop anaesthesia induction scheme, system supervision 
scheme, and in providing a single integrated platform that is capable of delivering both 
hypnotic and analgesic agents simultaneously. 
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Appendix A Data Format Transmitted by A-1 000 EEG Monitor 
A. 1 Processed EEG Data Packet and Variables 
Table A-8-1 Artifact flags transmitted by A-1 000 via raw EEG port 
I Bit# I Signal I Description I 
0 (unused) 
1 Out Of Range Each sample is checked for values out of range ( limit is +1 mV 
and -1 mV). 
2 Bad Slope The slew rate of the signal is too high. 
3 (unused) 
4 Throw Away A previous artifact has caused this second to be artifacted. 
5 Suppressed The standard deviation for the entire second is below a 
minimum value. 
6 Start Up The monitor has just started up. For the first few seconds there 
is an artifact. 
7 Serial Bit Error There is a checksum error in the EEG Data from the IPU. 
8 Total Power When the smoothed power in the band from 0.5- 30 Hz goes 
Too Small below 1 t.N rms, then spectral variables are considered to be 
noise. 
9 Motion A sudden change has occurred in the power of the band from 1 
to 10Hz. 
10 Glitch A sudden change has occurred in the power of the band from 
20 to 45Hz. 
11 Positive The raw eeg has been out of range in the positive direction for 
Lead off 5 seconds. 
Clipping 
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12 Negative The raw eeg has been out of range in the negative direction for 
Leadoff 5 seconds. 
Clipping 
13 Positive The positive lead is disconnected from either the DSC or the 
Lead off patient. 
14 Negative The negative lead is disconnected from either the DSC or the 
Leadoff patient. 
15 Clipping The raw eeg data has been out of range during the last 
second, and the data has been clipped at the largest positive 
or negative value. 
16 Framing Error The current frame of data from the DSC is bad. This signal is 
polled at a 16Khz rate. 
17 DSC Busy The DSC cannot receive commands. 
18 No DSC The DSC is not interrupting the IPU. 
Interrupt 
19 DSC Interface The interface between the DSC and monitor is malfunctioning. 
Error 
20 DSC Power The voltage regulators on the DSC are malfunctioning. 
Regulation 
Fault 
21 DSC Not The DSC is disconnected from the monitor, or is not receiving 
Present power from the monitor. 
22 DSC The DSC is drawing too much current. 
Overcurrent 
23 PLL Not The phase lock loop is not locked. 
Locked 
24 No DSC This signal indicates that a status nibble from the DSC was 
Status requested but was not received. 
25 Blocking The DSC is in Blocking mode. 
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26 Negative The DSC is checking the impedance of the negative lead. 
Impedance 
Check 
27 Start Up The DSC is in the process of turning on. 
28 Software Error Error detected in the serial interface between FPU and IPU, 
error detected In timing from DSC, or error detected in 
processing overrun 
29 Positive The DSC is checking the impedance of the positive lead. 
Impedance 
Check 
30 (unused) 
31 (unused) 
Table A-8-2 Processed variables transmitted by A-1000 via raw EEG port 
vanable Name Description Range 
Bispectral Signal The percentage of good epochs and 0.0- 100.0% 
Quality (SQI) suppressed epochs in the last 120 (61.5 
seconds) that could be used in the 
Bispectrallndex calculation. 
Power Spectrum Signal The percentage of good epochs in the last 0.0- 100.0% 
Quality (PSQI) spectral smoothing period. 
Suppression Ratio The percentage of good seconds in the last 0.0- 100.0% 
Signal Quality 63 seconds 
(BSRSQI) 
Asymmetry Signal The percentage of good epochs in the last 0.0- 100.0% 
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Quality (ASYSQI) spectral smoothing period. 
Absolute Delta Power A measure of the power in the Delta 40.0 - 100.0 
(ADELTA) frequency range (0.5 to 3. 75 Hz). dB 
Absolute Theta Power A measure of the power in the Theta 40.0 - 100.0 
(A THETA) frequency range (4.0 to 7.75 Hz). dB 
Absolute Alpha Power A measure of the power in the Alpha 40.0 - 100.0 
(AALPHA) frequency range (8.0 to 13.5 Hz). dB 
Absolute Beta Power A measure of the power in the Beta 40.0 - 100.0 
(ABET A) frequency range (13.75 to 30.0 Hz). dB 
Total Power (TOTPOW) A measure of the absolute total power in the 40.0 - 100.0 
frequency range from 0.5 to 30.0 Hz. dB 
User Band 1 Power A measure of the absolute power in the 40.0 - 100.0 
(PBI) frequency range defined by the User Band dB 
1. 
User Band 2 Power A measure of the absolute power in the 40.0 - 100.0 
(PBII) frequency range defined by the User Band dB 
2. 
Relative Delta Power The percentage of the Total Power which 0.0- 100.0% 
(RDELTA) lies in the Delta frequency range. 
Relative Theta Power The percentage of the Total Power which 0.0- 100.0% 
(RTHETA) lies in the Theta frequency range. 
Relative Alpha Power The percentage of the Total Power which 0.0- 100.0% 
(RALPHA) lies in the Alpha frequency range. 
Relative Beta Power The percentage of the Total Power which 0.0-100.0% 
(RBETA) lies in the Beta frequency range. 
User Band Ratio The ratio formed by User Band 1 Power 0.0- 100.0% 
(PBRAT) divided by User Band 2 Power, reported as 
a percentage. 
Suppression Ratio (SR) The percentage of epochs in the past 63 0.0- 100.0% 
197 of220 
seconds in which the EEG signal is 
considered suppressed. 
Spectral Edge The frequency at which 95% of the total 0.50 - 30.00 
Frequency (SEF) power lies below it. Hz 
Median Frequency The frequency at which 50% of the total 0.50 - 30.00 
(MEDFRQ) power lies below it. Hz 
Asymmetry Value The ratio of the total power in channel 1 (or 0.0- 100.0% 
(ASYM) channel 3) to the sum of the total powers of 
channels 1&2 (or channels 3&4). 
Bispectrallndex (B30U) This variable gives a bispectral index. 0.0- 100.0 
Bispectral Index (B31 U, This variable gives a bispectral index. 0.0- 100.0 
displayed as BIS) 
Bispectral Index (B31 F) This variable gives a bispectral index. 0.0- 100.0 
EMG Band 1 The absolute power in the 70 - 300 Hz 0.0 - 100.0 
(EMGLOW) range. dB 
EMG Band 2 (EMGHI) The absolute power in the 70 - 11 0 Hz 0.0 - 100.0 
range. dB 
The processed EEG variables are transmitted in ASCII format in the format and order shown 
below followed by a sample data record. The value of a variable is sent by using 8 ASCII 
characters separated by a vertical bar 'I'. 
Time I Update 
ISpSmoothiBiSmoothiLoFilteriNotFiltriHiFilteriSpecArtfiBisArtf I 
ADELTA IATHETA IAALPHA IABETA ITOTPOW IPBI IPBII IRDELTA IRTHETA 
IRALPHA I 
RBETA IPBRAT ISR ISEF IMEDFRQ IASYM IB30U IB31U IB31F 
IEMGHI I 
EMGLOW ISQI IASYSQI IPSQI IBSRSQI IARTF IADELTA IATHETA IAALPHA 
IABETA I 
TOTPOW IPBI IPBII IRDELTA IRTHETA IRALPHA IRBETA IPBRAT ISR ISEF 
I 
MEDFRQ IASYM IB30U IB31U IB31F IEMGHI IEMGLOW ISO! I ASYSQI I PSQI 
I 
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BSRSQI 
IRDELTA 
RTHETA 
I 
B31F 
IATHETA 
AALPHA 
IPBRAT 
SR 
I 
ASYSQI 
I 
PBII 
I 
B30U 
I 
ADELTA 
IRALPHA 
RBETA 
IEMGHI 
EMGLOW 
IARTF 
I 
IRALPHA 
IEMGHI 
I 
IABETA 
I 
ISEF 
IPSQI 
IRDELTA 
IB31U 
IATHETA 
I 
IPBRAT 
I lsor 
IADELTA 
IRBETA 
IEMGLOW 
ITOTPOW 
IMEDFRQ 
IBSRSQI 
IRTHETA 
IB31F 
IAALPHA 
ISR 
IASYSQI 
A sample data record: 
01/30/1998 11:37:01 
IATHETA 
IPBRAT 
ISQI 
IPBI 
IASYM 
IARTF 
IRALPHA 
IEMGHI 
IABETA 
ISEF 
IPSQI 
IAALPHA 
ISR 
IASYSQI 
I PBII 
IB30U 
IADELTA 
IRBETA 
IEMGLOW 
ITOTPOW 
IMEDFRQ 
IBSRSQI 
IABETA 
ISEF 
IPSQI 
IRDELTA 
IB31U 
IATHETA 
IPBRAT 
ISQI 
IPBI 
IASYM 
IARTF 
ITOTPOW 
IMEDFRQ 
IBSRSQI 
IRTHETA 
IB31F 
IAALPHA 
ISR 
IASYSQI 
IPBII 
IB30U 
c:::CR><LF> 
IPBI 
IASYM 
IARTF 
IRALPHA 
IEMGHI 
IABETA 
ISEF 
IPSQI 
IRDELTA 
IB31U 
I PBII 
IB30U 
IADELTA 
IRBETA 
IEMGLOW 
ITOTPOW 
IMEDFRQ 
IBSRSQI 
IRTHETA 
IB31F 
10s 
60.85 
3.1 
86.14 
OFF OFF 2.00 Hz SO Hz 
63.27 
3.00 
30 Hz FFFFF9FF FFFFFFFF 
57.96 
1.3 
0.0 
53.31 
6430.6 
0.0 
62.85 57.86 50.55 
2.3 0.1 6430.6 
588.94 0.0 0.0 
0.00 0.00 0.00 
0.0 200.0 6430.6 
587.09 0.0 0.0 
0.00 
0.0 
587.34 
61.85 
2.7 
587.54 
0.00 
0.0 
587.22 
0.00 0.00 
200.0 6430.6 
0.0 0.0 
57.91 51.93 
0.7 6430.6 
0. 0 0. 0 
0.00 0.00 
200.0 6430.6 
0. 0 0.0 
48.22 
11.00 
0.0 
47.95 
9.00 
0.0 
0.00 
30.00 
0.0 
44.67 63.43 57.3 
43.9 6430.6 6430.6 
0.0 OFA49000 
64.34 34.30 
2.50 43.9 
0.0 OFA49000 
0.00 0.00 
30.00 50.0 
0.0 OFA49100 
64.35 
6430.6 
0.00 
6430.6 
71.0 
6430.6 
0.0 
6430.6 
29.5 
6430.6 
10.1 
586.33 
22.5 4.2 
6430.6 588.81 
0. 0 0. 0 
6430.6 585.80 
0.00 0.00 
30.00 30.00 
0.00 0.00 0.0 0.0 0.0 
50.0 6430.6 6430.6 6430.6 587.44 
0.0 0. 0 OFA4 9100 
48.09 63.80 
10.00 2.75 
39.48 63.89 64.2 26.0 7.1 
43.9 6430.6 6430.6 6430.6 587.57 
0.0 0.0 OFA49000 
0.00 0.00 0.00 0.00 0.0 0.0 0.0 
30.00 30.00 50.0 6430.6 6430.6 6430.6 586.62 
0.0 0.0 OFA49100 
ERROR IOl/30/1998 11:37:01IDSC Disconnected (EOl) 
ERROR IOl/30/1998 11:37:0liPoor Signal Quality (E43) 
IMPEDNCEIOl/30/1998 11:37:011- 8001- 13001- Ol- 0 
199of220 
IB31U 
ISQI 
IPBI 
IASYM 
IARTF 
A.2 Raw EEG Data Packet 
The raw EEG data packet is transmitted sequentially in binary format, and the order of data 
transmission is in the sequence described in Table A-8-3. 
Table A-8-3 Raw EEG packet- 128 samples/second 
Header (byte) = Ox ab 
Type (byte) = 2 
Sequence Number (16 bits) 
Raw EEG data, 4 channels interleaved 
Checksum (16 bits) 
There are 4 data channels in total. The data in each channel is from the measurement of EEG 
waveform from a dedicated electrode lead attached to patients. The data from the four 
channels are interleaved when transmitted, i.e., in the order ofChl->Ch2->Ch3->Ch4->Chl. 
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Appendix B Clinical Data Archiving 
B. 1 File Structure 
There is a directory structure for storing the clinical data collected from the patient studies. 
The data include raw EEG data, processed EEG variables, extracted BIS data, calculated drug 
concentration in plasma and at effect site, infusion rates, and volume of drug infused at each 
interval (5 seconds). To avoid over large of the data files, the incoming data are split into 
sections and stored in files under the dedicated directories according to the type of the data. 
Each raw EEG data file contains only five minutes data, each processed EEG data file 
contains the data of fifteen minutes while BIS file contains two hours data because of the low 
data rate. A data archive directory structure has been built for this purpose, which is shown 
below: 
Patient 1 
(yymrndd) 
Base Directory 
Patient 2 
(yymmdd) 
Figure B-8-1 Data archiving structure 
Patient n 
(yymmdd) 
The base directory is the one in which the system executable resides. The data of a specific 
patient are stored in a dedicated directory. The patient directory name is made up of the year 
(yy), month (mm), and date (dd) of the study. Each patient directory consists of 5 
subdirectories storing raw EEG data, processed EEG data, BIS data, drug related data (such as 
drug concentration, infusion rate, etc.), and the programs used for the study. If the programs 
directory is empty, it indicates that the last version of the programs were used. The name of 
individual BIS, raw EEG, processed EEG data file uses the naming convention of 
mrnddhhmm.ext which is similar to the naming of the patient directory. The extension name 
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for BIS data file is .bis, for raw EEG data is .raw, while .pro for processed EEG data. 
The file Log.txt and Personal.txt under the patient directory contain the patient information. 
While Log.txt contains the public data and any event occurs during the study, the Personal.txt 
contains the private data of the patient and is not allowed to be public accessible. 
Note: Each raw EEG data packet is stamped by the data logger with the time of receipt at the 
head. 
Table B-1 Trial names and directory names of the clinical experimental data 
Trial Names Triall 01 Tria1102 Tria1103 Trial104 Triall05 Trial106 
DirNames 980122.101 980130.102 980206.103 980214.104 980226.105 980226.106 
Trial Names Tria1107 Tria1108 Trial I 09 Trial110 Trial111 Triall12 
DirNames 980227.107 980323.108 980402.109 980417.110 980420.111 980423.112 
Trial Names Tria1113 Tria1201 Trial202 Trial203 Tria1204 Trial205 
DirNames 980423.113 980731.201 980904.202 980911.203 980918.204 981002.205 
8.2 File Locations 
The full clinical trial data are stored both on PC and network server in both the University and 
Derriford Hospital with a hard copy stored in a CDROM. Following are the path of the 
archiving: 
University of Plymouth: 
D:\TCI\Trials (PC, Apricot LS550) 
/lisbon/staff/chao/CLAN Data (server) 
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,. 
. ' 
11!Jerriforcl Hqspit11I: 
C:\I'c:l\;r'rials (P(i:;, Compaq 1l!>esktop, serial numberA3J.78) 
/Phtser:ver04/Dongc/CLAN !Data/ (ser\iet)1 
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Appendix C Run-Time Command File 
The CLAN system developed has a long list of command line options to initialise the system, 
such as selection of a specific drug, type of anaesthesia pump, syringe size, patient data, 
system paran1eters, and so forth. In order to avoid the on-line input of these data in which 
some of them are fixed in this investigation, a command file cmd_file.txt is designed and used 
for this purpose. The typical options available in the command file is shown below (options 
are in bold font type and the value of the options are in regular font type: 
START SETTING 
•basic_settings: 
Graseby user username delta 5 quick delete 
direct_control 0 working_mode 5 fixed model 
*patient data: 
file filename subject patient_name initials x 
height 180 weight 70 gender male age 50 
hospital_number xxxxxxxx DOB xx/xx/xxxx 
•simulation data: 
*debug 
1 
•io_display 
PKPD 1 t_peak 
0.207 
2.3 
kl3 
V1 0.159 
klO 0.152 kl2 
k21 0. 092 k31 
start simu time 
- -
0.0048 
20 
keO 
0.04 
0.25 
end simu time 
- -
target_change_timel 1200 target_cbange_time2 
second_target 50 
•simulation_patient_control: 
use converted BIS 
- -
third_target 
0 
pseudo_bis_from_file 0 
•targets: 
target effect *plasma 
BIS_target 65 
upper_limit 1.5 
*PID_gains: 
kp_ic 0.0024 ki ic 
END SETTING 
propofol gepts 
desired initial bolus 
- -lower limit -2.5 
0.00001 kd ic 
-2.22 
0.169 
3000 
2400 
65 
max_cp 10.0 
The command file includes five parts, which are basic_settings, patient_ data, simulation_data, 
targets, and PID_gains. The valid command starts from the unique word START_SETTING, 
and ends with the unique word END_SETTING. The words in bold type are commands, and 
the rest of them are parameters needed by the commands. 
The meanings of the commands are listed below, where [TCI] is followed, the command is 
inherited from ST ANPUMP: 
AlOOO_Ver : followed by 330 or 312 for BIS algorithm version 3.30 or 3.12 
Graseby: if this command appears in the command file, the system will run with two 
pumps, otherwise no pump involves. No parameter is followed after this command. [TCI] 
user: followed by the name of the user. [TCI] 
delta: followed by the system update cycle, or the sampling period. [TCI] 
quick: speed up the initialisation. [TCI] 
delete: if the study file name already exists, delete the old file. [TCI] 
debug: enable the display of debug information in the run time. [TCI] 
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io_display: enable the display of I/0 status. [TCI] 
direct_control: 1 for non-model based PID control (not implemented) 
0 for indirect PID control via a PKPD model. 
working_mode: the parameter followed is now always 5. 
fixed model : 1 - use fixed PKPD model 
0 - use adaptive PKPD model (not implemented) 
file: followed by the study file name [TCI] 
subject: followed by the patient name [TCI] 
initials followed by the initials of the patient [TCI] 
height followed by the height of the patient [TCI] 
weight followed by the height of the patient [TCI] 
gender followed by the gender of the patient [TCI] 
age : followed by the age of the patient [TCI] 
hospital number : followed by the hospital number of the patient (optional) 
DOB : followed by the date of birth of the patient [TCI] 
PKPD : 1-9, user defined PKPD parameter sets for propofol, refer to the code in 
drug.c. if PKPD=10, the following PKPD parameter set specified in V1, k10, k12, k13, 
k21, k31, keO will be used for the simulation. 
start simu time : the start time of infusion in simulation 
end simu time : the end time of infusion in simulation 
target_change_timel: the time of the first change of the BIS target 
target change time2 : the time of the second change of the BIS target 
second-target-: the second target applied at the first BIS target change time 
third_target : the third target applied at the second BIS target change time 
use converted BIS : 1(0) - the BIS converted from Ce will (not) be used 
pse~do_bis_fr~m_file : 1(0) - the BIS read from an external file will (not) be used 
BIS_target : the initial BIS target 
target : use target controlled infusion instead of bolus infusion 
propofol : followed by the name of the propofol PKPD parameter set 
propofol_effect : target on effect site for propofol 
propofol_plasma : target on plasma for propofol 
alfentanil : followed by the name of the alfentanil PKPD parameter set 
alfentanil_effect : target on effect site for alfentanil 
alfentanil_plasma : target on plasma for alfentanil 
propofol target: the effect site drug concentration to be used for calculating the 
initial bolus. If the concentration is positive, then the system will give a bolus 
based on this value, otherwise the bolus will be given based on the initial 
BIS target. 
alfentanil_target 
max_ propofol _ce 
min_propofol_ce : 
max alfentanil ce 
- -
: followed by the alfentanil target concentration at effect site 
the maximum propofol effect site concentration allowed 
the minimum propofol effect site concentration to be maintained 
: the maximum alfentanil effect site concentration allowed 
min alfentanil ce : the minimum alfentanil effect site concentration to be maintained 
- -
upper_limit : the threshold value of BIS to toggle the propofol target on effect site 
lower limit : the threshold value of BIS to restart the PID control from overshoot 
kp_ic 
ki ic 
kd ic 
PID gain Kp 
PID gain Ki 
PID gain Kd 
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Appendix D CLAN System Hardware Settings 
There is a distinct difference in the settings of CLAN system hardware components between 
that used for propofol sedation studies (two volunteer studies and the study with patients 
undergoing knee surgery) and that used for the total intravenous anaesthesia study with 
patients undergoing back surgery. 
BIS algorithm v3.12 in Aspect A-1000 Monitor was used for the first three studies, while it 
was updated to BIS v3.30 for the last study. 
Hardware settings for the first three studies (propofol sedation): 
Aspect A-1000 monitor settings 
• EEG channels : two channels bipolar 
• Channel 1 :positive (Fp1), negative (F7) 
• Channel 2 : positive (Fp2), negative (F8) 
• Reference (ground) : Fpz 
• Spectral smoothing : OFF 
• Bispectral smoothing : OFF 
• EEG Filtering : Low- 2 Hz, High-30Hz 
• EEG sweep speed : 25 mm/s 
• EEG scale : 25 uv/div 
• Electrode lead-off detection : on 
• Audible alarm : off 
• BIS algorithm : v3 .12 
• EEG variable update rate : 5 seconds 
Communication ports 
• COMl :processed EEG variables in ASCII format 
• COM2 : raw EEG data in binary format 
• COM3: N/C 
• COM4 : Graseby anaesthesia pump for propofol 
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Hardware settings for the last study (total intravenous anaesthesia): 
Aspect A-1000 monitor settings 
• EEG channels : two channels bipolar 
• Channel 1 :positive (Fpl), negative (F7) 
• Channel 2 : positive (Fp2), negative (F8) 
• Reference (ground) : Fpz 
• Spectral smoothing : OFF 
• Bispectral smoothing : 15 seconds 
• EEG Filtering : Low- 2 Hz, High- 70Hz 
• EEG sweep speed : 25 mm/s 
• EEG scale : 25 uv/div 
• Electrode lead-off detection : ON 
• Audible alarm : OFF 
• BIS algorithm : v3.30 
• EEG variable update rate : 5 seconds 
Communication ports 
• COMl : Graseby anaesthesia pump for alfentanil 
• COM2 : processed EEG variables in ASCII format 
• COM3 : raw EEG data in binary format 
• COM4 : Graseby anaesthesia pump for propofol 
207 of220 
Appendix E User Interface 
E. 1 Screen Messages 
A Sample Run Time Screen Shot 
Department of Anaesthesia Derriford Hospital Plymouth 
Graseby 3400 
Drug: Propofol Parameters: Gepts 
7110/1998 Day 01 15:20:00 Elapsed Time: 3min 40sec Aspect Time: 15:20:09 
Pump Status: OK 
Patient : J:Peters 
Effect site level of 0.50 expected in 14.7 minutes 
data not saved drive C: 128MB left 
Channel!: 
Lead(+) Lead(-) ADELTA ATHETA AA:LPHA ABETA TOTPOW SEF MEDFRQ EMGHI 
EM GLOW 
off 
77.64 
Channel2: 
0.0 0.0 0.0 0.0 0.0 30.0 30.0 80.15 
Lead(+) Lead(-) ADELTA ATHETA AALPHA ABETA TOTPOW SEF MEDFRQ EMGHI 
EM GLOW 
off 
77.64' 
Location 
Feedback 
0.0 
Units 
0.0 0.0 
Predicted 
0.0 0.0 
Target CHI CH2 Cl-15 
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Plasma mcg/ml 
Good BIS 
Effect Site mcg/mi 
0.00001 
Bispectral Index 
65.0 
2.2261 2.226I 
2.2272 
65.00 65.00 
Infusion Rate: 5.16 ml/hour, 86.00 ug!kg/min 
1.964 ml 
Fl: Change BIS target 
F2: Change lower threshold value(-2.5) 
63.0 67.0 65.0 
Total Infused: 
F8: Open-Loop Control 
F9: Pause infusion 
F3: Change syringe FI 0: Terminate infusion at end of study 
Fll: Change gains(0.0024, Ie-05, 0.18) FI2: Change max_Ce(IOmcg/ml) 
>I I 0: I 0: I 0 000 Program start(Press "F5 to toggle data save and event record) 
"F I: last event "F2: next event "F3: even No 
"F4: debug 
"F5: save "F6: make comment "F7: 
redraw screen 
E.2 Command Menu 
The interactive user interface of the system enables the user to start, pause, resume, and end 
the drug infusion at any time without losing data. Some system parameters can be modified 
on-line from the command menu. If BIS value is not available the system will automatically 
switch from closed-loop control to open-loop control, however, if the BIS value is not correct 
then the user is allowed to force the system to run in open-loop control. Target change can be 
made in both the closed-loop mode and the open-loop mode. Following is a list of the on-line 
commands available to the user: 
Fl :change target BIS (closed-loop) or target concentration (open-loop) 
F2 : toggle closed-loop and open-loop control 
F3 : change syringe (either propofol or alfentanil) 
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F4 : start the infusion/change parameters (PID gains, threshold values, maximum and minimum propofol or 
alfentanil concentration) 
FS : pause/resume drug infusion (either propofol or alfentanil) 
F6: exit 
"Fl: view last event logged 
"F2: view next event logged 
"F3: view a specified event 
"F4: display debug information 
"FS: toggle data saving and event logging 
"F6: make an event/comment or cancel the event/comment being made 
"F7: redraw the screen 
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Appendix F List of Programs Developed 
F. 1 C Programs 
The software of the CLAN system is written in C and runs in DOS. The following is a list of 
the C programs developed with description. For more details, please refer to the actual code. 
stan2.c: this is a largely modified version ofshareware STANPUMP main program. 
Update of two PKPD models (propofol and alfentanil), calculation of infusion 
rates for the two drugs, most of the security control are implemented in this 
program. 
cmd2.c: part ofSTANPUMP, largely modified. Load the system variables from the 
command file. 
async2.c: part ofSTANPUMP, modified. Part of pump driver 
drugs2.c: definitions of various PKPD models for a number of drugs. 
cube.c: part ofSTANPUMP, no modification. Solve characteristic equation. 
drivers2.c: part ofSTANPUMP, modified. Part of pump driver. 
gr_34002.c: part ofSTANPUMP, modified. Graseby 3400 pump driver. 
keyboard.c: part of ST ANPUMP, no modification. Keyboard handler. 
control.c : implementation of the PID controller and some rules. 
tci.c : data logger main program 
aspect.c: definitions of variables and functions used by the data logger 
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aspcfg.c : general functions used by the data logger 
ascproeeg.c : functions for processed EEG data collection from processed EEG port 
binproeeg.c : functions for processed EEG data collection from raw EEG port 
raweeg.c : functions for collecting raw EEG data 
kbdbandler.c : keyboard handler for data logger 
All above programs are in d:\clan\simo\ at the university site, and c:\dongc\simo\ in the 
hospital. 
EEG2SMR : c program to convert the raw or processed EEG data file into .smr file format 
which can be read by Spike 2 for Windows for post analysis. (d:\clan\eeg2smr\) 
NB: l. The programs listed above are for both the real system that can be used in a clinical 
setting, and the real time simulation system without using any pumps. If compile and build 
the project in IDE with Rea!Time=true in TCipub.h, then a system that could be used with 
patient will be generated, otherwise a simulation system will be built. 
2. All C programs were written for Borland C++ compiler, and were compiled and built 
in Borland C++ 5.0 or 5.02 IDE. To compile and build the CLAN system, the Greenleaf 
Comm Library is needed. For a Borland IDE project with target of standard DOS huge 
memory model, the gclh.lib should be included in the project. This library file is under 
\gcl520\B50\. For more details about this, please refer to the Greenleaf Comm Library 
manual. 
3. There is a stand-alone version of data logger in d:\clan\aspect\ that runs with A-1000 to 
collect data only. 
4. Also, a closed-loop controlled propofol only infusion system can be found in d:\clan\tci 
(university), c:\tci (hospital), and the CDROM under \clan\tci\. This is the previous version of 
the system with which three patient studies including 27 healthy volunteers/patients have been 
done. 
F.2 MA TLAB Programs 
Matlab programs are for off-line simulation of the CLAN system, all Matlab programs are 
located in d:/clan/simu/matlab/ on the PC or the same path in CDROM. 
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The following is a list of the matlab programs: 
Clan.m: the implementation of the CLAN system with TCI in Matlab. 
• 
Clanloop.m : a special version of Clan.m that runs the system for a specified number of 
times. Each time, the system runs with a different PKPD model. 
Clanplot.m : plot the results obtained from Clanloop.m 
MeanSD.m : calculate the means and standard deviations on the data obtained from 
Clan loop. m 
TCI.m: an open-loop controlled simulation system, or implementation ofTCI CONTROL in 
Mat lab 
New_keO.m : a function to correct keO value with given peak time, called by Clan.m and 
TCI.m 
Beforaft.m : a function perfom1ing numerical searching in determining the peak time, called 
by new_keO.m 
Findpeak.m: a function to find the time of peak effect after drug has been given, called by 
Clan.m and TCI.m 
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Tabk 2 Loss rates ofpropofol from tissue samples 
Tissue 
Bolus: non-spleen 
spleen 
Infusion: all tissues 
Log (cone) per day 
Mean 
-0.001273 
0.000342 
-0.000119 
SE 
0.000161 
0.000263 
0.000150 
631P 
Loss rate (%per day) 
Half life 
Estimate 95%CI (days) 
0.293 0.22 to 0.37 236 
-0.079 -0.20 to 0.04 -881 
0.027 -0.04 to 0.10 2525 
Cone, concentration in J.Lg g-1; CIJ confidence interval. 
to the tissue concentration measurements w determine the fitted 
concentration at "day 0" - except that zero loss rate was used 
instead of the two non-significant loss rates. In the infusion experi-
ments, the day 0 concentrations were divided by the lined arterial 
concenuation at the time of cardiac arrest to yield tissue/blood 
partition coefficients. 
One possible mechattism of loss is evaporation. If that were the 
case, half life should be proportional to the solubility of propofol in 
the tissues; but there was nothing exceptional about spleen in 
tenns of concentration in the bolus experiments or partition coef-
ficient in the infusion experiments. Also it seems inconceivable 
lhat solubility in tissues in the infusion experiments was 10 times 
that in the bolus experiments. Another possibility is degradation of 
the propofol. There is wide overlap of concentrations of propofol 
between the three conditions in table 2, but the amount of its vehi-
cle, Intralipid, would be much greater in the infusion experiments, 
and somewhat greater in spleen than other tissues because of the 
very high blood content of spleen. Could Intralipid have some 
kind of preservative action? Comments and alternative explana-
tions will be welcomed. 
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Closed loop computer controlled sedation with 
propofol 
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Automated control systems are widely used in critical applica-
tions; however, their use in medical care is relatively unusual. We 
have developed a system for automatic control of sedation and 
tested it in seven human volunteers. 
Bifrontal raw electroencephalogram (EEG) and derivatives 
including the bispectral index (BIS V3.12} were recorded and 
-10 -5 0 5 10 15 
lime (mini 
logged using an Aspect A I 000 monitor and a personal computer 
with custom wrinen software (C Borland). A proportional integral 
derivative (PID) controller and a four-compartment pharmacoki-
netidpharmacodynamic (PKIPD) model automatically adjusted 
target effect site propofol concentration by controlling an infusion 
pump (Graseby 3400) to maintain a constant value of B!S. After a 
10 minute baseline EEG recording without sedation, the BIS tar-
get was set to 65 for a period of 25 minutes, after which sedation 
was discontinued. "Open loop" target controlled infusion was 
used for the first 2.3 minutes. The initial target effect site propofol 
concentration (Ce) was calculated from the BIS target using 
the following formula adapted from Doi and colleagues': 
BIS= -12.837Ce+93.582. 
Subsequently the PID controller adjusted the effect site target 
automatically-that is, a "closed loop." After 15 minutes of seda-
tion subjects were stimulated with a nerve stimulator applied to 
the wrist (30 mA for 2 min followed by 40 mA for 3 min). 
Satisfactory sedation was achieved in all subjects (fig 1). 
Anainmen! of the BIS target was rapid but three subjects were 
initially oversedated (minimum BIS values during minutes 0-5 for 
these subjects were 48.3, 34.9, and 41.5). The measured BIS in 
seven subjects between 2.3 and IS minutes ("closed loop" control, 
no stimulation) was 65.2 (5.8) (mean (SD)), and between 15 and 
20 minutes (during stimulation), 66.3 (6.8). 
Our system automatically established and maintained sedation 
in volunteers. Clinical application will require further evaluation in 
patients. 
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A comparison of vasoactivity between levobupivacaine 
and bupivacaine 
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Stereoisomerism and drug concentration both influence the 
vasoactive properties of local anaesthetic agents. Determination of 
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Figure 1 Bispectral index (BIS), prerlicted plasma propofol concentration (Cp), and effect site propofol concentration 
(Ce) in a single subject. The period of stimulation is indicated by a bar. 
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fig 4 Bispectral index (BIS) (top curve), predicted plasma concentration (bottom thick curve) and predicted effect-site propofol concentration (bottom 
thin curve) in a single subject. Nitrous oxide was inhaled during the period indicated by the bar. 
before and after intubation were derived, enabling 
measurement of Pa amplitude. Analysis of variance and 
Student's 1 test were used to compare the log-transfonned 
data from these two periods for the saline, esmolol and 
alfentanil groups. Haemodynamic variables measured 
I min before and I and 5 min after intubation were 
subjected to similar statistical analysis but without log 
transformation. 
The results are summarized in Table 3. Both esmolol and 
alfentanil blocked the AER response to intubation to the 
extent that the AER changes were not significantly different 
from zero. This has been reported previously for alfentanil 2 
and may be explained by its analgesic effects. The 
attenuation produced by esmolol is in keeping with an 
anaesthetic sparing effect 1 and a central mechanism for this 
effect has to be considered. 
Keywords: monitoring, evoked potenlials; pharmacology, 
esmolol; sympathetic nervous system, esmolol; analgesics 
opioid, remifentanil; cardiovascular system, effects 
References 
I Johansen JW, Flaishon R, Sebel PS, et al. Anes!hesiology 1997; 86: 
364-71 
l Shinner G, Sharpe RM, Shannon C, Thorn ton C, Do re CJ, Brunner 
MD. Br J Anaeslh 1997; 79: 137--8P 
Does nitrous oxide affect closed-loop 
anaesthetic propofol? 
C. Dong1*, J. Kehoe1*, E. C. lfeachor1•, C. D. Reeve 1* 
and J. R. Sneyd2 
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We have described previously closed-loop infusion of 
propofol using the bispectral index (BIS) and a feedback 
control system. 1 Nitrous oxide is used commonly as a 
supplement to propofol infusion to provide analgesia and 
additional hypnosis. We have evaluated introduction of 
nitrous oxide during closed-loop anaesthesia with propofol. 
We studied eight volunteers (five males; aged 29-41 yr; 
weight 62-97 kg). An Aspect A I 000 monitor recorded the 
raw EEG from bipolar leads (Fpi/Fp7 and Fp2/F8). BIS 
(V3.2) was obtained in real-time by the closed-loop control 
system running on a personal computer. Compared with the 
previous system, 1 the proportional integral derivative (PID) 
controller gains and supervision rule-base have been 
improved. Target concentration of the built-in PKIPD model 
was regulated by the controller while the target site (effect 
site or plasma) was regulated by the supervision rule-base. 
After a 5-min baseline EEG recording, the BIS target 
was set constantly to 65 during the 50-min closed-loop 
propofol infusion. Subjects breathed 50% nitrous oxide 
between the 20th and 35th minutes. 
Anaesthesia was achieved in all subjects. Two subjects 
were anaesthetized during induction with minimum BIS 
values of 42.4 and 46.9. After some initial instability, stable 
anaesthesia was achieved after a mean time of 7.6 (so 3.5) 
min. Mean measured BIS between the time of establishment 
of stable anaesthesia and 20 min (propofol only) was 62.9 
(3.7); between 20 and 35 min (propofol and nitrous oxide), 
62.6 (5.4); and between 35 and 50 min (propofol only), 
62.6 (8.4). Addition of nitrous oxide did not prevent 
maintenance of the anaesthesia target, but its withdrawal 
was associated with moderate oscillation of BIS in three 
subjects (Fig. 4). 
Our closed-loop system maintained anaesthesia during 
and after addition of nitrous oxide in volunteer subjects 
who were not subjected to painful stimulation. 
Keywords: sedation; anaesthetics i.v., propofol; anaesthetics 
gases, nitrous oxide; monitoring, electroencephalography 
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Fig 5 Bispectral index (BIS) (top thin curve) nnd its target (top thick curve), and predicted plasma (bottom lhin curve) and effect-site (bottom thick 
curve) propofol concentrations in a single subject. After initial over-sedation (arrow I), the closed-loop system estnblishcd stable sedation. Between 
45 and 65 m in, BIS remained below lhe target and the controller allowed plasma propofol concentrntions to decrease. The patient then 'awoke' (arrow 2). 
We have reported previously computer-controlled closed-
loop propofol sedation ofvolunteers. 1 We have subsequently 
evaluated this system in patients undergoing reconstructive 
knee surgery during epidural anaesthesia. A lumbar epidural 
catheter was placed under local anaesthesia either before 
(11=4) or after (11=2) starting sedation, and a regional block 
established. The BIS target was initially set at 65 and then 
adjusted at clinical discretion. Closed-loop sedation was 
maintained throughout surgery. 
We studied six male patients (ASA 1-11, aged 25-39 yr, 
weight 70-100 kg). One other patient was entered into the 
study but sedation was not commenced because of technical 
difficulties (broken cable). Sedation at the initial BIS target 
was established in a mean time of 7.8 (so 1.9) min. 
Subsequently, the error between measured and target BlS 
in the six patients after induction was -3.4 (10.5). Changes 
in patient position and other stimuli during placement of 
the lumbar epidural catheter in the first four patients were 
associated with rapid changes in BIS and variable levels 
of consciousness. In two patients, during surgery, when 
stimulation was confined to the leg (i.e. blocked by the 
epidural), measured BIS remained slightly deeper than 
target. The controller therefore gradually reduced the target 
propofol concentration until the patient suddenly 
'awakened' (Fig. 5). 
Although the closed-loop system was initially able to 
induce and maintain sedation, the response of the 
proportional integral derivative (PlO) controller to 
persistent small errors caused progressive withdrawal of 
the sedative agent which gave clinically unsatisfactory 
sedation in two patients. We hypothesize that this may 
have been caused by establishment of natural sleep. 
Keywords: sedation; anaesthetics i. v., propofol; anaesthetics 
gases, nitrous oxide; surgery, orthopaedic 
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Table 4 Times to reach 90% desaturntion (S~) using the METI system 
compared with those predicted by the model of Farmery and Roe. 1 The METI 
system was consistently slower than the model of Fannery and Roe 
FRC (ml) Fio, Time (or S&o2 1o reach 90% (s) 
MET I 1-,annery 
1530 0.21 90 48 
2700 0.21 145 64 
4000 0.21 195 79 
1530 1.0 240 161 
2700 1.0 420 310 
4000 1.0 590 430 
Desaturation modelling in the 'human 
patient' simulator at the Bristol Medical 
Simulation Centre 
J. W. J. Bloor* and B. Williams• 
Bris/01 University Medical School. Bristol, UK 
The Bristol Medical Simulation Centre uses a manikin 
and simulation software developed by Medical Education 
Technologies, Inc (MET I). We investigated how realistically 
the MET! system simulates normal physiology and chose 
to study one of the most fundamental emergencies in 
medicine-loss of airway and consequent interruption of 
the oxygen supply. We used the data-logging facility of 
MET! to record the time course of decrease in arterial 
oxygen partial pressure (Pao2) and oxyhaemoglobin 
saturation (Sao2) after software imposition of I 00% 
neuromuscular block. We did this at various settings of 
functional residual capacity (FRC) and fractional inspired 
concentration of oxygen (Flo2), at a fixed oxygen 
consumption (i1 02) of 250 ml min-1 and pulmonary venous 
admixture ('shunt', Qs!Qt) of 2%. We compared times to 
90% S~ with those predicted by the model of Farrnery 
and Roe. The MET! system was consistently slower than 
the model of Farrnery and Roe (Table 4 ). 
On further examination, the corresponding time courses 
of decreases in Pa02 were more closely aligned. Therefore, 
we examined for inconsistencies in the behaviour of the 
oxygen-haemoglobin dissociation curve using published 
standards.' 3 We plotted the decrease in MET! values of 
Sa02 with Pao, at different values of steady state pH and 
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We are developing a closed-loop system for intravenous anaesthesia in human. 
Using published pharmacokinetic data for the intravenous anaesthetic agent, 
propofol, we have generated a population of"virtual patients" and simulated 
their response to induction and maintenance of intravenous anaesthesia using a 
feedback system based on an electroencephalogram (EEG) derivative. Our 
simulations suggested that the proposed system would accommodate patients 
with widely varying pharmacokinetic characteristics. The system was 
subsequently tested in human and successfully induced and maintained 
anaesthesia in seven volunteers. 
KEYWORDS: anaesthesia; Bispectral Index; closed loop system; computer controlled 
anaesthesia; EEG; modelling; pharmacokinetics; pharmacodynamics; simulation; 
virtual patients. 
In contrast to fields such as aviation, anaesthesia currently enjoys low levels of 
automation (Sharma et al., 1993; Glen, 1998). When an intravenous drug is used to 
induce and maintain anaesthesia, the doctor administering anaesthesia must estimate 
the initial dose and subsequently make an appropriate adjustment to the drug infusion 
rate in order to reflect the gradual accumulation of the drug within the body. 
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Recently, the introduction of Target Controlled Infusion (TCI) has made it easier to 
achieve relatively stable blood concentrations but the anaesthetist must still decide 
whether the patient's level of anaesthesia is sufficient and make adjustments as 
necessary (Glen, 1998). Electronic monitoring of the electroencephalogram (EEG) 
offers a selection of processed EEG derivatives which may reflect the patient's 
underlying state of anaesthesia. We are developing a closed-loop system for computer 
controlled anaesthesia in human using an EEG derivative, the Bispectral Index, as a 
feed back signal. Our work so far has involved extensive computer simulations using 
"virtual patients" and successful tests on volunteers after ethical approval. 
We are grateful to Graseby Medical Ltd for the loan of an infusion pump and 
Dr Steven Shafer for some source C code from ST ANPUMP which formed a basis for 
the work. We are also indebted to the volunteers who made it possible to test system. 
1. Feedback signal 
The Bispectral Index (BIS) is a commercially developed EEG derivative optimised 
to produce a linear, monotonic index of hypnosis (depth of sleep/anaesthesia) (Doi et 
al., 1997; Leslie et al, 1995). The Bispectral Index (BIS) is a real-time EEG derivative 
generated by a proprietary algorithm developed by Aspect Medical Systems, Inc., and 
is a composite, numerical index ranging from 0 to 100 showing hypnotic 
states/sedation levels. 
Before the calculation ofBIS, the EEG segments with artifacts and suppressed 
EEG are identified and rejected, thereafter the index is calculated by combining the 
EEG features selected from a set of candidate bispectral and power spectral variables. 
While conventional spectrum analysis represents the power of frequency components 
of the EEG waveform, the bispectral analysis quantifies the inter-frequency 
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relationship. The bispectral index provides a measure of the effects of anaesthetics 
and other pharmacological agents on the hypnotic state of the brain. It was reported 
that the BIS both correlated well with the level of responsiveness and provided an 
excellent prediction of the loss of consciousness, and that BIS is linearly correlated 
with the blood concentration of propofol and the magnitude of the cerebral metabolic 
reduction caused by propofol and isoflurane anaesthesia (Doi et al., 1997; Leslie et al, 
1995). This suggests that a physiologic link exists between the EEG and cerebral 
metabolism during anesthesia that is mathematically quantifiable. The bispectral 
index has been prospectively validated with a large clinical database (Doi et al., 1997; 
Leslie et al, 1995). 
We have developed a closed-loop system in which raw EEG is collected from 
the patient, processed to produce the derivative Bispectral Index which is then fed to 
an anaesthesia control system which incorporates a Proportional Integral Derivative 
(PID) controller with additional rules which calculates an appropriate target drug 
concentration for the patient and adjusts the rate of infusion of the anaesthetic agent 
by controlling a clinical infusion pump. We have used published data on the 
distribution within the body and brain response to a commonly used anaesthetic agent, 
propofol, and simulated a large population of"virtual patients" (Leslie et al, 1995; 
Gepts et al, 1987). This has allowed us to evaluate how our closed-loop system might 
perform when deployed on a range of individual patients. 
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2. Methods 
2.1 Pharmacokinetics and Pharmacodynamics 
In modem medical practice, anaesthesia is usually induced by an intravenous 
injection of an anaesthetic agent (hypnotic). It may then be maintained by a 
continuous infusion of the same drug. The rise and fall in blood concentration of a 
commonly used anaesthetic agent, propofol, following a single dose is illustrated in 
Figure 1. The decline in blood anaesthetic concentration following a single dose may 
be described as some other series of exponentials (see Equation 1) (Egan, 1996). 
n 
Dp(t) = LA;e_,~,, 
i=l 
CpcALctt) = l(t) * Dp(t) (1) 
Where Dp(t) is the disposition function of the drug in the body after a bolus infusion, 
exponents -1-; are the inverse of the half-lives(half-life = 0.693/A-), coefficients A; are 
the relative contributions of each half-life to overall drug disposition, and the integer n 
is the number of exponentials. If the infusion rate over time is I(t), then the plasma 
drug concentration over time is CpcALc(t). The operator* denotes the convolution 
algorithm. 
These equations may be used to describe the body in terms of a series of 
connecting compartments between which the drug (initially administered into the 
blood) equilibrates by a series of micro rate-constants 
(Figure 2). 
Page 5 
In medical anaesthetic practice, it is common experience that there is a delay 
between the administration of drug and the peak effect. This may be confirmed by 
electronic monitoring of the electroencephalogram (EEG). When blood concentration 
and brain effect are simultaneously measured, this latency of drug action may be 
clearly seen (Figure 3). When drug concentration and EEG measured brain effect are 
plotted against each other, a hysteresis loop is demonstrated (Figure 4) and the 
mathematical model of drug distribution may be extended to include an additional 
compartment known as the effect site which reflects the latency between peak blood 
concentration and drug action (Levy, 1998; Holford and Sheiner, 1981 ). 
2.2 Target Controlled Infusion (TCI) 
A clinical application of phannacokinetic models such as Equation 1 has been 
developed by solving the equations necessary to calculate the changing quantities of 
drug which must be administered across time to achieve stable blood concentrations. 
The initial bolus injection and subsequent changes in infusion rate necessary to 
achieve and maintain a stable clinical concentration of the anaesthetic drug, propofol, 
are illustrated in Figure 5. 
Simulations such as these have advanced our understanding of drug 
distribution and effect, however, they reflect the average response of a population of 
patients and do not accommodate inter-patient variability. Figure 6 illustrates the 
simulated response of 9 patients with slightly different pharmacokinetic characteristics 
to whom a standard scheme of drug infusion has been applied. We see that 
application ofthis standard infusion scheme results in different drug 
concentration/time profiles in each patient and this variability must be considered if 
we are to use an automatic system to induce and maintain clinical anaesthesia. 
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2.3 Closed-loop Anaesthesia 
In a closed-loop anaesthesia system, an indication ofthe individual patient's 
"depth of anaesthesia" is derived from the electroencephalogram (EEG) and an EEG 
derivative such as the Bispectral Index (BIS) is fed to a central controller. The 
controller may control the drug infusion directly or, alternatively, use a process of 
pharmacokinetic (drug distribution) or pharmacodynamic (drug effect) modelling as 
described above to improve the system's control of drug infusion to the patient. We 
have implemented closed-loop intravenous anaesthesia using a standard control theory 
with a proportional integral derivative (PID) controller which quantifies the error 
between the measured Bispectral Index and a pre-set target. This, with the addition of 
some additional rules, is used to adjust the target concentration of drug to the 
individual patient to which is then implemented using a modified target controlled 
drug infusion system. 
2.4 Design Consideration and Constraints: 
The control system was designed and optimized based upon the published 
pharmacokinetic/dynamic data which were obtained from a certain range of patients 
(Gepts et al., 1987; Vuyk et al, 1995), outside this population it would result in a 
larger induction overshoot or a longer time to achieve stable level of anaesthesia. The 
basic assumption of the control system is that the pharmacokinetics and 
pharmacodynamics are linear. 
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2.4.1 Choice of control strategy 
A control strategy combining a PID controller with a reference model is used 
in the simulation. Usually, PID control is effective for a process containing some 
unknown dynamics like the one under investigation, and can give satisfactory results. 
The reference model provides a general guide for the PID control, especially for the 
size of the induction bolus. The use of a reference model will reduce the risk of a large 
and sudden increase in infusion rate (this will be spread over a period of time if the 
physical limit on maximum infusion rate applies) as the adjustment from the PID 
controller is only an offset to the guess from the reference model, and the adjustment 
is therefore small and safe to the patients. If the feedback signal is absent or other 
emergent events occurred, the reference model can automatically take over the control 
to force the system to run in TCI mode until everything returns to the normal status. 
Finally, referring to the literature this control strategy has not been investigated. 
2.4.2 Validation of the underlying model 
The PID controller has achieved huge success in industrial process control and 
the reference model has also been successfully used in TCI (Glen, 1998). The use of 
the reference model will provide safer control on drug infusion while PID controller 
gives the infusion system ability to dynamically respond to the real time measurement 
of anaesthetic depth of patients. 
3. Simulation 
Before implementing closed-loop anaesthesia in practice, we simulated the 
individual components of our proposed system and tested its response to a population 
of"virtual" patients with different pharmacokinetic and pharmacodynamic 
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characteristics. Figure 7 illustrates the sequential changes in the Bispectral Index that 
might be programmed for a particular patient and illustrates how our population of 
virtual patients might respond when anaesthetised. 
4. Clinical Testing of Closed-loop Anaesthesia 
We have subsequently used our closed-loop system to anaesthetise human 
volunteers and this is illustrated in Figure 8. 
5. Conclusion 
Mathematical modelling of blood concentrations and EEG derivatives after 
drug administration to human permit the elaboration of mathematical models. 
Implementation of these models has allowed the clinical development of Target 
Controlled Anaesthesia which is now commercially available. We have developed 
this technique further by using standard industrial control theory to adjust drug 
administration in response to an EEG derivative, the Bispectral Index measured from 
each individual patient. Because the characteristics of individual patients are variable, 
we simulated the response of our system to a wide range of individual patients prior to 
successful testing of the closed-loop system in human. 
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Legends for Figures 
Figure 1 
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Changes in plasma concentration of an intravenous anaesthetic drug, propofol which 
is infused for a period of one minute (black bar). Note that the concentration of the 
drug rapidly reaches a peak and then gradually decays in a poly-exponential manner. 
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Figure 2 
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A three compartment mathematical model describing the distribution and elimination 
of the anaesthetic drug, propofol. The drug is administered to a central compartment 
V1 which equilibrates with two other compartments V2 and V3. The transfer of drug 
between compartments is described by micro rate-constants k 12 etc. The drug is 
eliminated from the central compartment at a rate determined by k10. 
Figure 3 
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Following a single dose of the human anaesthetic agent, propofol, there is a delay 
between peak concentration of the drug in the blood and the peak effect on the brain. 
Blood concentration of the intravenous anaesthetic agent, propofol, following a single 
dose is illustrated by the thin line. An electroencephalogram (EEG) derived measured 
brain effect is indicated by the heavy line. Note the delay between the two peaks. 
Figure 4 
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10 12 
The plasma concentration and brain effect data from Figure 3 can be plotted against 
each other to form a hysteresis loop. The passage of time is indicated by arrows. Note 
that concentration initially arises rapidly and well in advance of the onset of drug 
action. 
Figure 5 
4 1200 
3 ~\ 1000 
800 
concentration 
of propofol 2 
mcg/ml 
600 rate of drug /,~~'--------------+ infusion ml/hr 400 
,,I 
I 200 
0 -¥1--.._.~~~~~~~~~~ 0 
0 2 4 6 
minutes 
8 10 
Page 15 
Implementation of a complex infusion scheme designed to achieve a stable drug effect 
in man. In order to achieve the desired drug effect (lower thin line), the rate of drug 
infusion is changed every few seconds (thick line). Note that the rate of drug infusion 
is initially very rapid i.e. a bolus of the drug is given, the pump then switches off and 
re-starts 2 minutes later at a much lower rate. This infusion scheme gives a high 
initial concentration of drug in the plasma (upper thin line) which produces an 
increasing brain effect (lower thin line). A stable brain effect is achieved within 2.5 
minutes. 
Figure 6 
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minutes 
lllustration of inter-patient variability. The infusion scheme developed in Figure 5 has 
been implemented in 9 virtual patients with different pharmacokinetic characteristics. 
Notice that the same infusion scheme produces differing drug effect/time profiles in 
individual patients. 
Figure 7 
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The traces are the simulated response of 3125 individual virtual patients anaesthetised 
by a closed loop anaesthesia system. The system is set to depress the Bispectral Index 
(BIS), a measure of consciousness from a baseline (conscious) level of 100 to a 
lightly anaesthetised level of 65 from 0-20 minutes, to a deeper level of 50 between 20 
and 40 minutes, back to 65 between 40 and 60 minutes when anaesthesia is 
discontinued and the virtual patient allowed to recover. Note that there is some initial 
instability however the responses of the virtual patients are tightly grouped suggesting 
that if the system has been con·ectly modelled there is a low risk of excessive 
responses or gross instability in man. 
Figure 8 
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40 45 
Anaesthesia of a single hwnan volunteer using a bispectral index (BIS) derivative of 
the electroencephalogram (EEG) and a Proportional Integral Derivative (PID) 
controller with additional rules. The system has successfully induced and maintained 
light anaesthesia between the I 01h and 451h minutes with a target Bispectral Index 
(BIS) of65 . 
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